var title_f36_18_37152="Dx rx syphilis algorithm I";
var content_f36_18_37152=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F79954&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F79954&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 557px\">",
"   <div class=\"ttl\">",
"    Algorithm for diagnosis and treatment of syphilis-I",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 537px; height: 412px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Patient with no history of syphilis presents with ulcer or with symptoms and/or signs of secondary syphilis. Patient has no symptoms or signs suggesting neurologic disease or ophthalmic disease.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Rompalo, AM. Neurosyphilis. In: Johnson R, Griffin J, McArthur J (Eds.) Current Therapy and Neurology Disease. Mosby, Inc. New York, NY. 2001. Copyright &copy; 2001 Elsevier.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_18_37152=[""].join("\n");
var outline_f36_18_37152=null;
var title_f36_18_37153="Spread out Bragg peak";
var content_f36_18_37153=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F53348&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F53348&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 472px\">",
"   <div class=\"ttl\">",
"    Spread out Bragg peak",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 452px; height: 418px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A characteristic spread-out Bragg peak (SOBP) depth-dose distribution along the beam central axis, together with the depth-dose distributions of the contributing pristine Bragg peaks. The SOBP is specified in terms of its range, measured at the distal 90 percent dose position and which is approximately 1 mm less than the range (160 mm here) of the most distal pristine Bragg peak, and its modulation width (100 mm here and indicated by the horizontal dash-dot line) specified as the width between the distal and proximal 90 percent dose values (indicated by the vertical dash-dot lines). The depth-dose distribution is characterized by an entrance dose region that rises from a nonzero entrance dose to the near uniform 100 percent region (bounded by the &plusmn;2 percent dashed lines) which extends up to the range of the most distal pristine Bragg peak. The composite pristine Bragg peaks (13 in this example) have specific relative intensities such that, in summation, they yield the observed uniform 100 percent dose region.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Kooy HM, Trofimov A, Engelsman M, Smith AR. Principles of Systems and Optimization. In: Proton and Charged Particle Radiotherapy, DeLaney TF, Kooy HM (eds.). Philadelphia: Lippincott Williams &amp; Wilkins, 2008. Copyright &copy; 2008 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_18_37153=[""].join("\n");
var outline_f36_18_37153=null;
var title_f36_18_37154="TEE aortic valve";
var content_f36_18_37154=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F69646&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F69646&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 567px\">",
"   <div class=\"ttl\">",
"    Aortic valve on transesophageal echocardiogram",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 547px; height: 405px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Panel A: Horizontal (0) imaging shows the aortic valve (AoV during systole with the leaflets widely opened. Panel B: Short axis view of the normal trileaflet aortic valve at 37&ordm; transducer rotation during systole. Panel C: With the same transducer position, the short axis view during diastole is seen and the right (RCC), left (LCC), and non-coronary cusps (NCC) are well delineated.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Warren Manning, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_18_37154=[""].join("\n");
var outline_f36_18_37154=null;
var title_f36_18_37155="Dermatosis papulosa nigra";
var content_f36_18_37155=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F52430&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F52430&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Dermatosis papulosa nigra",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 400px; height: 371px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The lesions of this common inherited condition appear as small, pigmented papules on the face that resemble seborrheic keratoses. This condition is most commonly seen in black individuals.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Goodheart, HP. Goodheart's Photoguide of Common Skin Disorders, 2nd Edition, Lippincott Williams &amp; Wilkins, Philadelphia 2003. Copyright &copy; 2003 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_18_37155=[""].join("\n");
var outline_f36_18_37155=null;
var title_f36_18_37156="Vaccines for children age 7 to 18 years";
var content_f36_18_37156=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Vaccines for children age 7 to 18 years (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?36/18/37156/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/18/37156/contributors\" id=\"au462\">",
"       Amy B Middleman, MD, MPH, MS Ed",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?36/18/37156/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/18/37156/contributors\" id=\"se4794\">",
"       Teresa K Duryea, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?36/18/37156/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/18/37156/contributors\" id=\"de5754\">",
"       Mary M Torchia, MD",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"mobipreview.htm?36/18/37156?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      INTRODUCTION",
"     </span>",
"    </p>",
"    <p>",
"     In the United States, there are several vaccines that are routinely recommended for children and adolescents between the ages of 7 and 18 years. These include vaccines for Neisseria meningitidis (meningococcus), tetanus-diphtheria-acellular pertussis, varicella, and human papillomavirus. The recommended schedule is available through the",
"     <a class=\"external\" href=\"file://www.cdc.gov/vaccines/who/teens/downloads/parent-version-schedule-7-18yrs.pdf\">",
"      Centers for Disease Control and Prevention",
"     </a>",
"     . Some children will also need a second dose of varicella vaccine if two doses are not given before age seven and influenza vaccine is recommended annually.",
"    </p>",
"    <p>",
"     A separate topic review is available that discusses how vaccines work, the risks and benefits of vaccines, and common concerns regarding vaccine safety. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?17/42/18084?source=see_link\">",
"      \"Patient information: Why does my child need vaccines? (Beyond the Basics)\"",
"     </a>",
"     .) A topic review is also available that discusses vaccines for infants and children age 0 to 6 years. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?41/36/42566?source=see_link\">",
"      \"Patient information: Vaccines for infants and children age 0 to 6 years (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     Topic reviews that discuss immunizations for adults and immunizations for travel are reviewed separately. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?38/25/39318?source=see_link\">",
"      \"Patient information: Adult vaccines (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?20/44/21187?source=see_link\">",
"      \"Patient information: Vaccines for travel (The Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      INFLUENZA",
"     </span>",
"    </p>",
"    <p>",
"     Commonly known as flu, influenza is a highly contagious viral infection that occurs in outbreaks worldwide, usually during the winter in the United States. Young children and those with certain underlying medical conditions are at increased risk for severe or complicated influenza infection. Immunizing all children (and adults) can help decrease this risk. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?34/12/35013?source=see_link\">",
"      \"Patient information: Influenza symptoms and treatment (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H3\">",
"     <span class=\"h2\">",
"      Timing and dose",
"     </span>",
"     &nbsp;&mdash;&nbsp;There are two types of influenza vaccines. One is injected either into muscle (intramuscularly) or skin (intradermally). The other is given as a nasal spray. The intramuscular injection can be given to adults and children 6 months and older, the intradermal injection can be given to adults 18 to 64 years of age, and the intranasal spray can only be given to people between 2 and 49 years of age. People who have a weakened immune system or who have chronic heart, lung, kidney, or metabolic disease should not use the intranasal spray since it contains live virus that has been weakened. In very rare situations, household contacts of those who have",
"     <strong>",
"      severely",
"     </strong>",
"     weakened immune systems should also not receive the intranasal spray.",
"    </p>",
"    <p>",
"     The influenza viruses change every year, which means that a reformulated vaccine must be given every year (in the fall). In the first year that a child (younger than age 9 years) receives the vaccine, two doses are recommended; the second dose is given at least one month after the first. The influenza vaccine does not prevent illnesses such as the common cold or strep throat.",
"    </p>",
"    <p>",
"     The vaccine is recommended for all children between 6 months and older, particularly those who:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Have chronic medical conditions (eg, lung or heart disease, diabetes, kidney disease, weakened immune conditions, nervous system disorders)",
"      </li>",
"      <li>",
"       Live with a person who is at high risk for complications of influenza (eg, someone with chronic lung disease)",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H4\">",
"     <span class=\"h2\">",
"      Influenza vaccine precautions",
"     </span>",
"     &nbsp;&mdash;&nbsp;Both forms of the influenza vaccine are prepared with chicken eggs. Allergic reactions to influenza vaccine are rare. A severe (life-threatening) allergy to egg proteins may be a reason not to receive the vaccine; the vaccine may be given under supervision of an allergist. (See",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/5/43097?source=see_link\">",
"      \"Allergic reactions to vaccines\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5\">",
"     <span class=\"h3\">",
"      Injectable influenza vaccine precautions",
"     </span>",
"     &nbsp;&mdash;&nbsp;Vaccination may be delayed in children with moderate to severe illness until their symptoms have resolved. However, the vaccine does not need to be delayed in children with mild illnesses.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H446751531\">",
"     <span class=\"h3\">",
"      Injectable influenza vaccine side effects",
"     </span>",
"     &nbsp;&mdash;&nbsp;The most common side effect of the injectable vaccine is redness and soreness at the injection site. A low-grade fever may develop after vaccination. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?36/23/37235?source=see_link\">",
"      \"Patient information: Fever in children (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6\">",
"     <span class=\"h3\">",
"      Nasal spray influenza vaccine precautions",
"     </span>",
"     &nbsp;&mdash;&nbsp;The nasal spray form of influenza vaccine is not recommended for children who take aspirin daily or those with a weakened immune system, asthma, and other conditions (eg, chronic lung or heart problems, pregnancy, chronic metabolic disease, kidney dysfunction, and blood disorders), or a history of Guillain-Barr&eacute; syndrome. It may be necessary to delay the nasal vaccine or to use the injectable vaccine in children or adolescents with nasal congestion.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7\">",
"     <span class=\"h2\">",
"      Influenza vaccine effectiveness",
"     </span>",
"     &nbsp;&mdash;&nbsp;The injectable influenza vaccine protects between 60 and 65 percent of healthy children from developing laboratory-confirmed influenza infection. The nasal spray vaccine protects approximately 70 to 80 percent of healthy children from developing laboratory-confirmed influenza infection.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H8\">",
"     <span class=\"h1\">",
"      MENINGOCOCCAL",
"     </span>",
"    </p>",
"    <p>",
"     Neisseria meningitidis (meningococcus) is a bacterium that can cause meningitis and meningococcemia. Meningitis is an inflammation of the tissues surrounding the brain and spinal cord that causes symptoms of a stiff and painful neck. Meningococcus is the most common cause of bacterial meningitis in the United States. Meningococcemia is a serious infection of the bloodstream that can begin with dramatic rash and fever and lead to shock and death (",
"     <a class=\"graphic graphic_picture graphicRef52107 \" href=\"mobipreview.htm?30/28/31168\">",
"      picture 1",
"     </a>",
"     ). Meningitis and meningococcemia may occur separately or together.",
"    </p>",
"    <p>",
"     In the United States, approximately 1000 to 3000 cases of meningococcal disease occur each year. Large-scale epidemics occur in Africa, parts of Asia, South America, and the countries of the former Soviet Union.",
"    </p>",
"    <p>",
"     Meningococcus first infects the lining of the nose and pharynx (wind pipe) and is transmitted from person to person by respiratory secretions (eg, from coughing, sneezing). Meningococcal infection is contagious and can spread quickly to close contacts of a person who is infected. This includes household members and anyone who kisses or shares toothbrushes or eating utensils.",
"    </p>",
"    <p>",
"     Meningococcal disease can be treated in most people. However, the illness is frequently mistaken for a common viral illness (eg, cold) during the early stages, delaying diagnosis. Meningococcal disease often progresses quickly to serious illness or death. Serious long-term complications can occur, even in people who are treated promptly. Up to 15 percent of people who become infected die as a result of their infection. In survivors, 10 to 20 percent of patients have long-term complications, including hearing loss, nerve or brain damage,",
"     <span class=\"nowrap\">",
"      finger/toe",
"     </span>",
"     amputation, or skin scarring.",
"    </p>",
"    <p>",
"     The meningococcal vaccines only protect against four of the five common subtypes of meningococcus affecting humans. It is possible to become infected with meningococcus despite having received one of these vaccines, although the risk is significantly lower than in someone who is unvaccinated. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?1/48/1796?source=see_link\">",
"      \"Patient information: Meningitis in children (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H9\">",
"     <span class=\"h2\">",
"      Timing and dose",
"     </span>",
"     &nbsp;&mdash;&nbsp;Expert groups recommend the meningococcal vaccine for all children age 11 or 12 years and a booster dose at age 16 years. Adolescents who receive the first dose of meningococcal vaccine between 13 and 15 years should receive a booster dose between 16 and 18 years of age. Those who receive the first dose after age 16 years do not need a booster dose.",
"    </p>",
"    <p>",
"     Meningococcal vaccine is also recommended for children aged 2 to 10 years who are at increased risk for meningococcal disease. The initial vaccination series consists of two doses; the schedule for a subsequent booster dose for these children depends upon their age at first immunization and whether they remain at increased risk for disease.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H10\">",
"     <span class=\"h2\">",
"      Meningococcal vaccine side effects",
"     </span>",
"     &nbsp;&mdash;&nbsp;Approximately 70 percent of people have a local reaction (eg, tenderness, redness) at the injection site.",
"    </p>",
"    <p>",
"     There is no thimerosal or mercury in the meningococcal vaccine, and there is no risk of becoming infected with meningococcus as a result of the vaccine.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11\">",
"     <span class=\"h2\">",
"      Meningococcal vaccine benefit",
"     </span>",
"     &nbsp;&mdash;&nbsp;The meningococcal vaccine provides protective levels of antibody in 82 to 97 percent of those who are vaccinated (depending upon the particular strain of meningococcus).",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H12\">",
"     <span class=\"h1\">",
"      TETANUS AND DIPHTHERIA, WITH OR WITHOUT ACELLULAR PERTUSSIS",
"     </span>",
"    </p>",
"    <p>",
"     Diphtheria is a highly contagious disease. It is usually transmitted via droplet particles that are coughed or sneezed into the air. It can cause a thick covering in the back of the throat that can lead to breathing problems or heart failure.",
"    </p>",
"    <p>",
"     Tetanus is another very serious infection that is caused by the bacterial toxin of Clostridium tetani bacterium. The bacteria reside in soil and the intestinal tracts of certain mammals. The bacteria can enter the body through an open wound, multiply, and produce a toxin that can affect nerves controlling muscle activity. A common symptom of tetanus infection is stiffness of the jaw muscles (\"lockjaw\").",
"    </p>",
"    <p>",
"     Tetanus and diphtheria disease are rare in the United States because of the high numbers of people who have been immunized. However, the consequences of untreated tetanus or diphtheria can be very serious.",
"    </p>",
"    <p>",
"     Pertussis, or whooping cough, is an upper respiratory illness caused by the toxin of Bordetella pertussis bacteria. The organism is highly contagious, spreads easily and can cause serious illness, especially in infants.",
"    </p>",
"    <p>",
"     The number of people infected with pertussis is rising to epidemic levels, especially in adolescents, despite widespread vaccination. The Centers for Disease Control and Prevention (CDC) reported over 25,000 cases of whooping cough in the United States in 2005 [",
"     <a class=\"abstract\" href=\"mobipreview.htm?36/18/37156/abstract/1\">",
"      1",
"     </a>",
"     ]. Since pertussis is significantly underreported, the number of people actually infected with pertussis each year in the United States is likely closer to 1 to 3 million.",
"    </p>",
"    <p>",
"     Pertussis was added to the traditional Td booster for teenagers and adults because the vaccine's protection decreases after 5 to 8 years. Protection also decreases after being infected with pertussis. Thus, the vaccine is recommended even for people who have had the disease.",
"    </p>",
"    <p>",
"     There are several forms of combined diphtheria, tetanus, and pertussis vaccines:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       The DTaP, or diphtheria tetanus acellular pertussis vaccine, is used for routine immunization of children younger than 7 years of age.",
"      </li>",
"      <li>",
"       The Tdap, or tetanus, reduced diphtheria, acellular pertussis vaccine, is recommended as a routine one-time dose for children at 11 to 12 years and for adolescents 13 to 18 years who were not previously immunized. The vaccine is also recommended as a one-time dose for adults and as one of the series of catch-up doses of tetanus and diphtheria toxoid (Td) vaccines for children between 7 and 10 years of age who are incompletely vaccinated against tetanus, diphtheria, or pertussis. (See",
"       <a class=\"medical medical_patient\" href=\"mobipreview.htm?38/25/39318?source=see_link\">",
"        \"Patient information: Adult vaccines (Beyond the Basics)\"",
"       </a>",
"       .)",
"      </li>",
"      <li>",
"       The Td, or tetanus and reduced diphtheria vaccine (without pertussis), is recommended for adolescents and adults who require tetanus vaccine and have already received one dose of Tdap.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H13\">",
"     <span class=\"h2\">",
"      Timing and dose",
"     </span>",
"     &nbsp;&mdash;&nbsp;A single tetanus-containing booster vaccine is recommended for children and adolescents at age 11 to 12 years; Tdap is recommended unless there is an allergy to one of the vaccine components.",
"    </p>",
"    <p>",
"     If an adolescent has an injury that requires a tetanus shot, Tdap may be given instead of Td, provided that the adolescent has not received Tdap previously. Currently, only one dose of Tdap is recommended in a lifetime. Subsequent booster doses of Td are recommended every 10 years throughout life. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?38/25/39318?source=see_link\">",
"      \"Patient information: Adult vaccines (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H14\">",
"     <span class=\"h2\">",
"      Tdap vaccine side effects",
"     </span>",
"     &nbsp;&mdash;&nbsp;The most common side effect of the Tdap vaccine is pain at the injection site.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H15\">",
"     <span class=\"h2\">",
"      Tdap vaccine effectiveness",
"     </span>",
"     &nbsp;&mdash;&nbsp;Tdap is a very effective vaccine that provides protection against laboratory-confirmed pertussis infection in about 90 percent of adolescents and adults.",
"    </p>",
"    <p>",
"     The vaccine provides 95 percent protection from diphtheria, and nearly 100 percent from tetanus. Because protection can fade over time, booster vaccines for tetanus and diphtheria are needed at least every 10 years. (See",
"     <a class=\"local\" href=\"#H13\">",
"      'Timing and dose'",
"     </a>",
"     above.)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H16\">",
"     <span class=\"h1\">",
"      HUMAN PAPILLOMAVIRUS",
"     </span>",
"    </p>",
"    <p>",
"     Human papillomavirus (HPV) is a virus that is spread by direct skin-to-skin contact, including sexual intercourse, oral sex, anal sex, or any other contact involving the genital area (eg, hand to genital contact). The risk of HPV exposure increases with the number of sexual partners. It is estimated that more than 50 percent of sexually active persons become infected with HPV at least once in their lifetime [",
"     <a class=\"abstract\" href=\"mobipreview.htm?36/18/37156/abstract/2\">",
"      2",
"     </a>",
"     ].",
"    </p>",
"    <p>",
"     Over 100 different types of HPV have been identified, approximately 40 of which are known to infect the anogenital region and 15 of which are known to cause cancer. Researchers have labeled the HPV types as being high or low risk for cervical cancer. HPV types 6 and 11 can cause warts and are low-risk types because they rarely cause cervical or other cancers. Types 16 and 18 are high-risk types and cause most cases of cervical and other types of cancer.",
"    </p>",
"    <p>",
"     A vaccine against HPV is available for males and females. The vaccine is discussed in greater detail separately. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?37/45/38610?source=see_link\">",
"      \"Patient information: Human papillomavirus (HPV) vaccine (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H547446115\">",
"     <span class=\"h2\">",
"      Timing and dose",
"     </span>",
"     &nbsp;&mdash;&nbsp;The HPV vaccination series is recommended for all youth (males and females) at 11 to 12 years of age. The vaccine can be given as young as 9 years of age. The vaccine is also recommended for the following groups if they have not previously received the vaccination series:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Females 13 to 26 years of age",
"      </li>",
"      <li>",
"       Males 13 to 21 years of age",
"      </li>",
"      <li>",
"       Males (age 13 to 26 years) who have sex with males &nbsp;",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     The vaccination series consists of three shots. The second shot is ideally given 1 to 2 months after the first, and the third shot is given 6 months after the first. If the second and third shots are delayed for any reason, it is not necessary to restart the vaccination series.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H547446108\">",
"     <span class=\"h2\">",
"      HPV vaccine side effects",
"     </span>",
"     &nbsp;&mdash;&nbsp;There are no serious adverse events associated with the HPV vaccination series. The most common side effects are pain at the injection site.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H547446101\">",
"     <span class=\"h2\">",
"      HPV vaccine effectiveness",
"     </span>",
"     &nbsp;&mdash;&nbsp;The HPV vaccine is 93 to 98 percent effective in preventing HPV infections and cervical precancers caused by HPV in females. It is also very effective in preventing genital warts in females and males. It is 75 percent effective in preventing anal precancer among males who have sex with males. The duration of protection is at least 7 to 10 years.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H17\">",
"     <span class=\"h1\">",
"      VARICELLA (CHICKENPOX) VACCINE",
"     </span>",
"    </p>",
"    <p>",
"     Varicella is a highly contagious viral illness caused by infection with the varicella zoster virus (VZV). The disease causes fever, sore throat, and a distinctive, itchy rash with fluid-filled blisters that later form scabs. Complications of chickenpox can include bacterial infections of the skin, pneumonia, or, less commonly, inflammation of the brain. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?2/40/2691?source=see_link\">",
"      \"Patient information: Chickenpox prevention and treatment (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     A vaccine to prevent chickenpox is recommended for all children. Two doses of varicella vaccine are recommended for children 0 to 6 years of age; the first is usually given at 1 year of age and the second at 4 to 6 years. A second dose is recommended if a child is older than 7 years and was not previously given two doses of vaccine.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H18\">",
"     <span class=\"h1\">",
"      OTHER VACCINES",
"     </span>",
"    </p>",
"    <p>",
"     Children who are 7 to 18 years may need vaccines other than those mentioned above if they have missed any of the recommended vaccines for children age 0 to 6 years. This may include hepatitis A, hepatitis B, varicella, polio, or measles, mumps, and rubella vaccines. The recommended schedule is available through the",
"     <a class=\"external\" href=\"file://www.cdc.gov/vaccines/who/teens/downloads/parent-version-schedule-7-18yrs.pdf\">",
"      Centers for Disease Control and Prevention",
"     </a>",
"     . Detailed information about these vaccines is available separately. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?41/36/42566?source=see_link\">",
"      \"Patient information: Vaccines for infants and children age 0 to 6 years (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     Children who are age 7 to 18 years may need additional vaccines if they are at high risk for certain infections, such as pneumococcal infection. Influenza vaccine is recommended once per year for all children over age 6 months. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?38/12/39105?source=see_link\">",
"      \"Patient information: Influenza prevention (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H19\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your child's healthcare provider is the best source of information for questions and concerns related to your child's medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H191\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H3358420\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?18/7/18547?source=see_link\">",
"      Patient information: Vaccines for children age 7 to 18 years (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?11/48/12035?source=see_link\">",
"      Patient information: Vaccines (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?3/43/3763?source=see_link\">",
"      Patient information: Meningitis in children (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?27/22/28003?source=see_link\">",
"      Patient information: Vaccines for babies and children age 0 to 6 years (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?20/44/21187?source=see_link\">",
"      Patient information: Vaccines for travel (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?23/4/23619?source=see_link\">",
"      Patient information: Vaccines for adults (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?35/38/36450?source=see_link\">",
"      Patient information: Whooping cough (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?4/8/4227?source=see_link\">",
"      Patient information: Sickle cell anemia (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?32/61/33746?source=see_link\">",
"      Patient information: Tdap vaccine (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?22/12/22723?source=see_link\">",
"      Patient information: When your child has sickle cell disease (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H3358542\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?37/45/38610?source=see_link\">",
"      Patient information: Human papillomavirus (HPV) vaccine (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?17/42/18084?source=see_link\">",
"      Patient information: Why does my child need vaccines? (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?41/36/42566?source=see_link\">",
"      Patient information: Vaccines for infants and children age 0 to 6 years (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?38/25/39318?source=see_link\">",
"      Patient information: Adult vaccines (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?34/12/35013?source=see_link\">",
"      Patient information: Influenza symptoms and treatment (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?36/23/37235?source=see_link\">",
"      Patient information: Fever in children (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?1/48/1796?source=see_link\">",
"      Patient information: Meningitis in children (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?2/40/2691?source=see_link\">",
"      Patient information: Chickenpox prevention and treatment (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?38/12/39105?source=see_link\">",
"      Patient information: Influenza prevention (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?20/44/21187?source=see_link\">",
"      Patient information: Vaccines for travel (The Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H21\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/5/43097?source=see_link\">",
"      Allergic reactions to vaccines",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/10/13480?source=see_link\">",
"      Clinical trials of human papillomavirus vaccines",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/32/23050?source=see_link\">",
"      Meningococcal vaccines",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/17/19738?source=see_link\">",
"      Recommendations for the use of human papillomavirus vaccines",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/56/39818?source=see_link\">",
"      Standard immunizations for children and adolescents",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Centers for Disease Control and Prevention (CDC)",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;Toll-free: (800) 311-3435",
"     <br/>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.cdc.gov/\">",
"      www.cdc.gov/",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/healthtopics.html\">",
"      www.nlm.nih.gov/medlineplus/healthtopics.html",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Institute of Allergy and Infectious Diseases",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.niaid.nih.gov/\">",
"      www.niaid.nih.gov/",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Network for Immunization Information",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.immunizationinfo.org/\">",
"      www.immunizationinfo.org/",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"mobipreview.htm?36/18/37156/abstract/1-3\">",
"      1-3",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 3, 2013.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"mobipreview.htm?36/18/37156?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/18/37156/abstract/1\">",
"      Kretsinger K, Broder KR, Cortese MM, et al. Preventing tetanus, diphtheria, and pertussis among adults: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine recommendations of the Advisory Committee on Immunization Practices (ACIP) and recommendation of ACIP, supported by the Healthcare Infection Control Practices Advisory Committee (HICPAC), for use of Tdap among health-care personnel. MMWR Recomm Rep 2006; 55:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/18/37156/abstract/2\">",
"      Workowski KA, Berman S, Centers for Disease Control and Prevention (CDC). Sexually transmitted diseases treatment guidelines, 2010. MMWR Recomm Rep 2010; 59:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/18/37156/abstract/3\">",
"      ACIP Childhood/Adolescent Immunization Work Group, Akinsanya-Beysolow I, Jenkins R, et al. Advisory Committee on Immunization Practices (ACIP) recommended immunization schedule for persons aged 0 through 18 years--United States, 2013. MMWR Surveill Summ 2013; 62 Suppl 1:2.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f36_18_37156=[""].join("\n");
var outline_f36_18_37156=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           INTRODUCTION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           INFLUENZA",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H8\">",
"           MENINGOCOCCAL",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H12\">",
"           TETANUS AND DIPHTHERIA, WITH OR WITHOUT ACELLULAR PERTUSSIS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H16\">",
"           HUMAN PAPILLOMAVIRUS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H17\">",
"           VARICELLA (CHICKENPOX) VACCINE",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H18\">",
"           OTHER VACCINES",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H19\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          PICTURES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?30/28/31168\" title=\"picture 1\">",
"           Acute meningococcemia",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f36_18_37157="Probenecid: Drug information";
var content_f36_18_37157=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Probenecid: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?35/57/36756?source=see_link\">",
"    see \"Probenecid: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?11/7/11382?source=see_link\">",
"    see \"Probenecid: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F213409\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Benuryl&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F213442\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Uricosuric Agent",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F213413\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Hyperuricemia with gout:",
"     </b>",
"     Oral: 250 mg twice daily for 1 week; may increase to 500 mg twice daily; if needed, may increase to a maximum of 2 g/day (increase dosage in 500 mg increments every 4 weeks). If serum uric acid levels are within normal limits and gout attacks have been absent for 6 months, daily dosage may be reduced  by 500 mg every 6 months.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Prolong penicillin serum levels:",
"     </b>",
"     Oral: 500 mg 4 times/day.",
"     <b>",
"      Note:",
"     </b>",
"     Dosing per manufacturer, see indication-specific dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Gonorrhea, uncomplicated infections of cervix, urethra, and rectum:",
"     </b>",
"     Oral: 1 g once with cefoxitin 2 g I.M. (CDC, 2010)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Pelvic inflammatory disease (unlabeled use):",
"     </b>",
"     Oral: 1 g once with cefoxitin 2 g I.M. plus doxycycline (CDC, 2010)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Neurosyphilis (unlabeled use):",
"     </b>",
"     Oral: 500 mg 4 times/day with procaine penicillin 2.4 million units/day I.M for 10-14 days (CDC, 2010).",
"     <b>",
"      Note:",
"     </b>",
"     Penicillin G aqueous I.V. is the preferred agent.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F213428\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?11/7/11382?source=see_link\">",
"      see \"Probenecid: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Contraindicated in children &lt;2 years of age.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Prolong penicillin serum levels:",
"     </b>",
"     Oral: Children 2-14 years: Initial: 25 mg/kg, then 40 mg/kg/day in 4 divided doses (maximum: 500 mg/dose)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Treatment of gonorrhea:",
"     </b>",
"     &gt;50 kg: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F213414\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F213415\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute: Avoid use.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F213388\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 500 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F213373\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F213392\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer with food or antacids to minimize GI effects.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F213391\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of hyperuricemia associated with gout or gouty arthritis; prolongation and elevation of beta-lactam plasma levels (eg, uncomplicated gonococcal infection)",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F13108712\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Prolongation and elevation of beta-lactam plasma levels (eg, neurosyphilis, pelvic inflammatory disease)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F213449\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Probenecid may be confused with Procanbid",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F213440\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Flushing",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Dizziness, fever, headache",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Alopecia, dermatitis, pruritus, rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Anorexia, dyspepsia, gastroesophageal reflux, nausea, sore gums, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Hematuria, polyuria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Anemia, aplastic anemia, hemolytic anemia (in G6PD deficiency), leukopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Hepatic necrosis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Costovertebral pain, gouty arthritis (acute)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: Nephrotic syndrome, renal colic",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Anaphylaxis, hypersensitivity",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F213395\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to probenecid or any component of the formulation; small- or large-dose aspirin therapy; blood dyscrasias; uric acid kidney stones; children &lt;2 years of age; initiation during an acute gout attack",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F213377\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Allergic reaction: Has been associated with rare, severe hypersensitivity reactions, including anaphylaxis.  Discontinue therapy if reaction occurs.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Gout: May cause exacerbation of acute gouty attack.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; G6PD deficiency: Use caution in patients with G6PD deficiency; may increase risk for hemolytic anemia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Peptic ulcer disease: Use with caution in patients with peptic ulcer disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Monotherapy may not be effective in patients with a creatinine clearance &lt;30 mL/minute.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Methotrexate: Probenecid may increase the serum concentration of methotrexate.  Avoid concomitant use of probenecid and methotrexate if possible. If used together, consider lower methotrexate doses and monitor for  methotrexate toxicity.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Penicillin: Use of probenecid with penicillin in patients with renal insufficiency is not recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Salicylates: Salicylates may diminish the therapeutic effect of probenecid; this effect may be more pronounced with high, chronic doses, however, the manufacturer recommends the use of an alternative analgesic even in place of small doses of aspirin.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F213438\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2C19 (weak), UGT1A6",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F213382\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetaminophen: Probenecid may increase the serum concentration of Acetaminophen. Probenecid may also limit the formation of at least one major non-toxic metabolite, possibly increasing the potential for formation of the toxic NAPQI metabolite.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cefotaxime: Probenecid may increase the serum concentration of Cefotaxime.  Management: Avoid cefotaxime doses greater than 6 g/day with concurrent probenecid.  Any patients receiving this combination should be monitored closely for evidence of cefotaxime toxicity.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cephalosporins: Probenecid may increase the serum concentration of Cephalosporins.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dapsone (Systemic): Probenecid may increase the serum concentration of Dapsone (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferiprone: UGT1A6 Inhibitors may increase the serum concentration of Deferiprone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Doripenem: Probenecid may increase the serum concentration of Doripenem. This effect is due to probenecid's ability to decrease the active tubular secretion of doripenem.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ertapenem: Probenecid may increase the serum concentration of Ertapenem.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ganciclovir-Valganciclovir: Probenecid may increase the serum concentration of Ganciclovir-Valganciclovir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gemifloxacin: Probenecid may decrease the excretion of Gemifloxacin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Imipenem: Probenecid may increase the serum concentration of Imipenem.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketoprofen: Probenecid may increase the serum concentration of Ketoprofen.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketorolac (Nasal): Probenecid may increase the serum concentration of Ketorolac (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketorolac (Systemic): Probenecid may increase the serum concentration of Ketorolac (Systemic).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: Probenecid may enhance the adverse/toxic effect of Loop Diuretics. Probenecid may diminish the diuretic effect of Loop Diuretics. Probenecid may increase the serum concentration of Loop Diuretics.  Management: Monitor for decreased diuretic effects or increased adverse effects of loop diuretics with concomitant use of probenecid. Bumetanide prescribing information recommends against concomitant use of probenecid.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     LORazepam: Probenecid may increase the serum concentration of LORazepam.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Meropenem: Probenecid may increase the serum concentration of Meropenem.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrexate: Probenecid may increase the serum concentration of Methotrexate.  Management: Avoid concomitant use of probenecid and methotrexate if possible.  If used together, consider lower methotrexate doses and monitor for evidence of methotrexate toxicity.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mycophenolate: Probenecid may increase the serum concentration of Mycophenolate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nitrofurantoin: Probenecid may increase the serum concentration of Nitrofurantoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: Probenecid may increase the serum concentration of Nonsteroidal Anti-Inflammatory Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oseltamivir: Probenecid may increase serum concentrations of the active metabolite(s) of Oseltamivir.  Management: Consider a change in therapy when using oseltamivir together with probenecid; reduced oseltamivir dose may be necessary.  Increase monitoring for adverse events, such as thrombocytopenia.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pegloticase: Probenecid may enhance the adverse/toxic effect of Pegloticase. Specifically, Probenecid may blunt increases in serum urate that would signal an elevated risk of anaphylaxis and infusion reactions.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Penicillins: Probenecid may increase the serum concentration of Penicillins.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PRALAtrexate: Probenecid may increase the serum concentration of PRALAtrexate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinolone Antibiotics: Probenecid may increase the serum concentration of Quinolone Antibiotics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: May diminish the therapeutic effect of Probenecid.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Benzoate: Probenecid may increase the serum concentration of Sodium Benzoate. Specifically, probenecid may inhibit the renal transport of the hippuric acid metabolite of sodium benzoate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Phenylacetate: Probenecid may increase the serum concentration of Sodium Phenylacetate. Specifically, probenecid may inhibit the renal transport of the phenylacetylglutamine metabolite of sodium phenylacetate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sulfonylureas: Probenecid may decrease the protein binding of Sulfonylureas. Probenecid may increase the serum concentration of Sulfonylureas.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Theophylline Derivatives: Probenecid may increase the serum concentration of Theophylline Derivatives.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Aminophylline; Theophylline.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zidovudine: Probenecid may decrease the metabolism of Zidovudine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13108713\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Probenecid crosses the placenta; adverse fetal events have not been reported.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F213418\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk; based on a single case report, very small amounts of probenecid have been detected in breast milk",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F213398\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Drug may cause GI upset; take with food if GI upset. Drink plenty of fluids.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F213397\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Probenecid Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500 mg (100): $98.33",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F213386\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Uric acid, renal function, CBC",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F13108716\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Uric acid, serum: An increase occurs during childhood",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Males: 3.4-7 mg/dL or slightly more",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Females: 2.4-6 mg/dL or slightly more",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Target: &lt;6 mg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Values &gt;7 mg/dL are sometimes arbitrarily regarded as hyperuricemia, but there is no sharp line between normals and the serum uric acid of those with clinical gout. Normal ranges cannot be adjusted for purine ingestion, but high-purine diet increases uric acid. Uric acid may be increased with body size, exercise, and stress.",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F213399\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Benacid (TH);",
"     </li>",
"     <li>",
"      Bencid (IN, TH);",
"     </li>",
"     <li>",
"      Benecid Valdecasas (MX);",
"     </li>",
"     <li>",
"      Benemid (GB, GR, IE, NL);",
"     </li>",
"     <li>",
"      Benemide (FR);",
"     </li>",
"     <li>",
"      Benuryl (IL);",
"     </li>",
"     <li>",
"      Gonocilin (BR);",
"     </li>",
"     <li>",
"      Pro-Cid (AU);",
"     </li>",
"     <li>",
"      Probecid (FI, NO, SE);",
"     </li>",
"     <li>",
"      Probecilin (BR);",
"     </li>",
"     <li>",
"      Probenecid Weimer (DE);",
"     </li>",
"     <li>",
"      Probenecid &rdquo;Dak&rdquo; (DK);",
"     </li>",
"     <li>",
"      Probenecid &rdquo;Medic&rdquo; (DK);",
"     </li>",
"     <li>",
"      Procid (TW);",
"     </li>",
"     <li>",
"      Pronid (TW);",
"     </li>",
"     <li>",
"      Santuril (CH)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F213376\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Competitively inhibits the reabsorption of uric acid at the proximal convoluted tubule, thereby promoting its excretion and reducing serum uric acid levels; increases plasma levels of weak organic acids (penicillins, cephalosporins, or other beta-lactam antibiotics) by competitively inhibiting their renal tubular secretion",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F213394\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Effect on penicillin levels: 2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Rapid and complete",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination (dose dependent): Normal renal function: 6-12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum: 2-4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Jordan KM, Cameron JS, Snaith M, et al, &ldquo;British Society for Rheumatology and British Health Professionals in Rheumatology Guideline for the Management of Gout,&rdquo;",
"      <i>",
"       Rheumatology (Oxford)",
"      </i>",
"      2007, 46(8):1372-4. Available at file://rheumatology.oxfordjournals.org/content/suppl/2008/02/21/kem056a.DC1/kem056b.pdf",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/18/37157/abstract-text/17522099/pubmed\" id=\"17522099\" target=\"_blank\">",
"        17522099",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), \"Sexually Transmitted Diseases Treatment Guidelines, 2010,\"",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2010, 59(RR-12):1-110.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/18/37157/abstract-text/21160459/pubmed\" id=\"21160459\" target=\"_blank\">",
"        21160459",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ilett KF, Hackett LP, Ingle B, et al, &ldquo;Transfer of Probenecid and Cephalexin into Breast Milk,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 2006, 40(5):986-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/18/37157/abstract-text/16551765/pubmed\" id=\"16551765\" target=\"_blank\">",
"        16551765",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9812 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-89.32.226.102-C9EBEEE8B0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_18_37157=[""].join("\n");
var outline_f36_18_37157=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213409\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213442\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213413\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213428\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213414\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213415\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213388\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213373\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213392\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213391\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13108712\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213449\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213440\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213395\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213377\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213438\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213382\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13108713\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213418\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213398\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213397\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213386\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13108716\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213399\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213376\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213394\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9812\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9812|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?35/57/36756?source=related_link\">",
"      Probenecid: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?11/7/11382?source=related_link\">",
"      Probenecid: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_18_37158="Hashimotos thyroiditis";
var content_f36_18_37158=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F57542&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F57542&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Hashimoto's thyroiditis: Findings on surgical histology",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 237px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Surgical specimen from a patient with Hashimoto's thyroiditis. Some areas show normal appearing follicles with minimal lymphocytic infiltrates, while other areas have complete destruction of follicles with a dense lymphocytic infiltrate, in which the lymphocytes form germinal centers.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_18_37158=[""].join("\n");
var outline_f36_18_37158=null;
var title_f36_18_37159="Treatment of Staphylococcus aureus bacteremia in children";
var content_f36_18_37159=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of Staphylococcus aureus bacteremia in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/18/37159/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/18/37159/contributors\">",
"     Sheldon L Kaplan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/18/37159/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/18/37159/contributors\">",
"     Morven S Edwards, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/18/37159/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/18/37159/contributors\">",
"     Mary M Torchia, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?36/18/37159/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 26, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <em>",
"     Staphylococcus aureus",
"    </em>",
"    is a leading cause of both community-acquired and hospital-acquired bacteremia. Normal children usually have",
"    <em>",
"     S. aureus",
"    </em>",
"    bacteremia (SAB) in association with a focus of infection such as osteomyelitis or pneumonia. Observational studies indicate that bone and joint infections are the most common source of community-acquired SAB in children, accounting for approximately 60 percent of cases, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/18/37159/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. In comparison, bacteremia alone is most common in patients with a central line in place. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/61/28632?source=see_link\">",
"     \"Epidemiology of and risk factors for Staphylococcus aureus bacteremia in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Infective endocarditis (IE), especially in community-acquired SAB, is much less frequent in children than in adults (1.4 percent in children compared with up to 30 percent in adults) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/18/37159/abstract/2\">",
"     2",
"    </a>",
"    ]. Similarly, although less well studied, mortality rates associated with SAB are much lower in children. In the above surveys, the mortality rates were 3.2 and 1.4 percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/18/37159/abstract/1,2\">",
"     1,2",
"    </a>",
"    ], compared with 20 to 40 percent reported in adults. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/1/26649?source=see_link\">",
"     \"Complications of Staphylococcus aureus bacteremia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ANTIBIOTIC SELECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Until 2000, the standard approach to the empiric treatment of suspected",
"    <em>",
"     S. aureus",
"    </em>",
"    bacteremia (SAB) in children with community-acquired infections was a beta-lactam antibiotic, such as",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?25/57/26519?source=see_link\">",
"     nafcillin",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?0/59/950?source=see_link\">",
"     oxacillin",
"    </a>",
"    , or",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?9/36/9797?source=see_link\">",
"     cefazolin",
"    </a>",
"    . However, with the changes in antimicrobial susceptibility of community-acquired isolates in many communities, the empiric selection of antibiotics has been modified.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Antibiotic resistance",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <em>",
"     S. aureus",
"    </em>",
"    isolates have developed resistance to methicillin, macrolides,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/56/34688?source=see_link\">",
"     clindamycin",
"    </a>",
"    , and, in rare cases,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?22/58/23465?source=see_link\">",
"     vancomycin",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/13/15575?source=see_link\">",
"     \"Microbiology of methicillin-resistant Staphylococcus aureus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Methicillin",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a number of locations in the United States and worldwide, an increasing proportion of",
"    <em>",
"     S. aureus",
"    </em>",
"    isolates associated with community-acquired infections are methicillin-resistant (MRSA). At Texas Children's Hospital, for example, MRSA has accounted for more than 75 percent of community-acquired",
"    <em>",
"     S. aureus",
"    </em>",
"    isolates since 2004 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/18/37159/abstract/3-5\">",
"     3-5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/21/30042?source=see_link&amp;anchor=H12#H12\">",
"     \"Epidemiology and clinical spectrum of methicillin-resistant Staphylococcus aureus infections in children\", section on 'Epidemiology and risk factors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most community-associated MRSA isolates remain susceptible to",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/56/34688?source=see_link\">",
"     clindamycin",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?40/23/41336?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    (TMP-SMX), unlike most nosocomial MRSA isolates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/18/37159/abstract/3,4\">",
"     3,4",
"    </a>",
"    ], although the differences in antibiotic resistance patterns are less clear as the dominant community MRSA clone, USA300, becomes an important nosocomial pathogen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/18/37159/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. This difference probably reflects differences in genotype between community-acquired and nosocomial MRSA isolates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/18/37159/abstract/4,8\">",
"     4,8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/13/15575?source=see_link\">",
"     \"Microbiology of methicillin-resistant Staphylococcus aureus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Macrolides and clindamycin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Macrolide resistance occurs by two different mechanisms in",
"    <em>",
"     S. aureus",
"    </em>",
"    . The most common mechanism among community-acquired",
"    <em>",
"     S. aureus",
"    </em>",
"    isolates in the United States is an efflux pump encoded by the mefA gene that affects only 14- and 15-membered macrolides and does not lead to resistance to lincosamide antibiotics such as",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/56/34688?source=see_link\">",
"     clindamycin",
"    </a>",
"    or streptogramin-B.",
"   </p>",
"   <p>",
"    The second mechanism of resistance, which has been primarily seen with nosocomial infection but now is present in up to 5 to 30 percent of MRSA isolates associated with community-onset infection in children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/18/37159/abstract/5,9\">",
"     5,9",
"    </a>",
"    ], is through alteration of the target ribosomal RNA encoded by erm genes, resulting in resistance to macrolides, lincosamides, and streptogramin-B (MLS(B) phenotype). The MLS(B) phenotype can be expressed either constitutively, in which case the isolate is resistant to",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?37/11/38064?source=see_link\">",
"     erythromycin",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/56/34688?source=see_link\">",
"     clindamycin",
"    </a>",
"    from the outset, or inducibly, following exposure to erythromycin or clindamycin. These latter isolates are resistant to macrolides but appear susceptible to clindamycin in vitro. However, exposure of the organism to a macrolide or clindamycin will induce clindamycin resistance.",
"   </p>",
"   <p>",
"    There is evidence that inducible resistance can happen in patients. As a result,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/56/34688?source=see_link\">",
"     clindamycin",
"    </a>",
"    should be avoided in the treatment of patients with serious infections caused by",
"    <em>",
"     S. aureus",
"    </em>",
"    isolates with the inducible MLS(B) form of resistance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/18/37159/abstract/10-12\">",
"     10-12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/6/29802?source=see_link&amp;anchor=H5#H5\">",
"     \"Treatment of invasive methicillin-resistant Staphylococcus aureus infection in children\", section on 'Inducible resistance'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Macrolide resistance can be detected in the clinical microbiology laboratory using the routine disk susceptibility tests for",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?37/11/38064?source=see_link\">",
"     erythromycin",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/56/34688?source=see_link\">",
"     clindamycin",
"    </a>",
"    &nbsp;(",
"    <a class=\"graphic graphic_picture graphicRef54213 \" href=\"mobipreview.htm?30/31/31217\">",
"     picture 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/18/37159/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. Isolates with the efflux mechanism of macrolide resistance demonstrate complete inhibition around the clindamycin disk. Isolates with constitutive MLS(B) resistance are fully resistant to both erythromycin and clindamycin. Isolates with the inducible MLS(B) phenotype are fully resistant to erythromycin but have a zone of inhibition around the clindamycin disk that is blunted in the area between the two disks-\"D\" zone. Isolates with the inducible form of MLS(B) resistance should be considered resistant to clindamycin.",
"   </p>",
"   <p>",
"    Clinicians must remain vigilant for the emergence of",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/56/34688?source=see_link\">",
"     clindamycin",
"    </a>",
"    resistance among community-associated MRSA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/18/37159/abstract/15,16\">",
"     15,16",
"    </a>",
"    ], as more clindamycin is being used for treating these infections in children.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Empiric therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In areas of the world where community-associated MRSA isolates are not a concern, empiric therapy for suspected SAB includes intravenous",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?25/57/26519?source=see_link\">",
"     nafcillin",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?0/59/950?source=see_link\">",
"     oxacillin",
"    </a>",
"    , or",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?9/36/9797?source=see_link\">",
"     cefazolin",
"    </a>",
"    . These are the antibiotics of choice when treating bacteremia caused by methicillin-susceptible",
"    <em>",
"     S. aureus",
"    </em>",
"    (MSSA). Some physicians prefer cefazolin because of a reduced rate of phlebitis, neutropenia, and liver enzyme elevation compared with nafcillin or oxacillin. The dose of nafcillin or oxacillin in children is 150 to 200",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day in four or six divided doses. The dose of cefazolin is 100",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day in three divided doses.",
"   </p>",
"   <p>",
"    In communities where MRSA accounts for more than 10 percent of the community",
"    <em>",
"     S. aureus",
"    </em>",
"    isolates, patients should receive an antibiotic effective against these isolates. More than 90 percent of community-associated MRSA isolates are susceptible to",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/56/34688?source=see_link\">",
"     clindamycin",
"    </a>",
"    in most reports.",
"   </p>",
"   <p>",
"    For suspected MRSA bacteremia in the child with serious infection (eg, osteomyelitis, septic arthritis, pneumonia with empyema) who is not critically ill, empiric",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?22/58/23465?source=see_link\">",
"     vancomycin",
"    </a>",
"    (60",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day in four divided doses) should be administered [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/18/37159/abstract/16-18\">",
"     16-18",
"    </a>",
"    ]. For life-threatening infections (eg, septic shock or acute infective endocarditis), vancomycin",
"    <strong>",
"     plus",
"    </strong>",
"    either",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?0/59/950?source=see_link\">",
"     oxacillin",
"    </a>",
"    or",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?25/57/26519?source=see_link\">",
"     nafcillin",
"    </a>",
"    should be included in empiric therapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/6/29802?source=see_link&amp;anchor=H13#H13\">",
"     \"Treatment of invasive methicillin-resistant Staphylococcus aureus infection in children\", section on 'For critically ill'",
"    </a>",
"    .) The value of targeting vancomycin trough levels to between 15 and 20",
"    <span class=\"nowrap\">",
"     mcg/mL",
"    </span>",
"    for serious MRSA infections in children is unclear [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/18/37159/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. Nevertheless, maintaining vancomycin trough levels in this range for life-threatening infections in children with normal renal function who have ongoing MRSA bacteremia is suggested [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/18/37159/abstract/18\">",
"     18",
"    </a>",
"    ]. Once MRSA bacteremia is cleared, this trough range is no longer targeted. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/6/29802?source=see_link&amp;anchor=H20#H20\">",
"     \"Treatment of invasive methicillin-resistant Staphylococcus aureus infection in children\", section on 'MRSA infections'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?0/59/950?source=see_link\">",
"     Oxacillin",
"    </a>",
"    or",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?25/57/26519?source=see_link\">",
"     nafcillin",
"    </a>",
"    is recommended along with",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?22/58/23465?source=see_link\">",
"     vancomycin",
"    </a>",
"    because beta-lactam antistaphylococcal antibiotics are more rapidly bactericidal than is vancomycin against MSSA. One study from Spain among adults with MSSA pneumonia found that mortality was greater for those patients treated with vancomycin compared with those treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/45/31446?source=see_link\">",
"     cloxacillin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/18/37159/abstract/20\">",
"     20",
"    </a>",
"    ]. In another study of 294 consecutive patients with SAB at a single institution, vancomycin therapy was associated with a higher risk of relapse confirmed by pulsed-field gel electrophoresis (odds ratio = 4.1, 95% CI 1.5-11.6) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/18/37159/abstract/21\">",
"     21",
"    </a>",
"    ]. Similar data are not available in children. There are no data from controlled trials to indicate that combination therapy with",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?36/48/37632?source=see_link\">",
"     gentamicin",
"    </a>",
"    or",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?16/52/17225?source=see_link\">",
"     rifampin",
"    </a>",
"    for potential synergy is beneficial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/18/37159/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Once susceptibilities have been determined, the antimicrobial regimen can be modified. If MRSA is not isolated within 72 to 96 hours after antibiotics are initiated, the",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?22/58/23465?source=see_link\">",
"     vancomycin",
"    </a>",
"    can be discontinued. This approach requires that physicians be aggressive in obtaining appropriate cultures in addition to blood cultures. Aspiration or surgical incision and drainage of bone or joint infections should be performed within 48 hours of starting antibiotic treatment. For SAB associated with musculoskeletal infections or pneumonia, once SAB is cleared,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/56/34688?source=see_link\">",
"     clindamycin",
"    </a>",
"    can be administered to complete therapy of infections caused by clindamycin-susceptible isolates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/18/37159/abstract/18\">",
"     18",
"    </a>",
"    ]. Clindamycin is bacteriostatic for",
"    <em>",
"     S. aureus",
"    </em>",
"    and thus is not routinely recommended for the treatment of SAB.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Alternative drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Alternative agents for treating SAB include",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?21/52/22345?source=see_link\">",
"     linezolid",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?38/39/39542?source=see_link\">",
"     daptomycin",
"    </a>",
"    , and possibly, TMP-SMX. The use of these agents in the treatment of invasive methicillin-resistant",
"    <em>",
"     S. aureus",
"    </em>",
"    infections, including bacteremia is discussed separately (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/6/29802?source=see_link&amp;anchor=H2#H2\">",
"     \"Treatment of invasive methicillin-resistant Staphylococcus aureus infection in children\", section on 'Antimicrobial agents'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     DURATION OF THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The duration of therapy for",
"    <em>",
"     S. aureus",
"    </em>",
"    bacteremia (SAB) varies as follows depending upon the presence of a central catheter or associated infection:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Parenteral therapy for 10 days generally is adequate for uncomplicated SAB in children.",
"     </li>",
"     <li>",
"      Two weeks of treatment are recommended for catheter-related SAB [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/18/37159/abstract/23\">",
"       23",
"      </a>",
"      ]. If a central line is removed and bacteremia clears promptly, no further studies usually are necessary, unless clinically indicated.",
"     </li>",
"     <li>",
"      <em>",
"       S. aureus",
"      </em>",
"      infective endocarditis is treated parenterally for a minimum of four to six weeks. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?27/15/27896?source=see_link&amp;anchor=H15#H15\">",
"       \"Infective endocarditis in children\", section on 'Treatment'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The duration of treatment for osteomyelitis, septic arthritis, or skin and soft tissue infections associated with SAB is dependent upon the associated infection. At least three weeks is recommended for treating acute osteomyelitis or septic arthritis, although this is not all administered parenterally. Children often are treated for four to six weeks and until the erythrocyte sedimentation rate is &lt;25 to 30",
"      <span class=\"nowrap\">",
"       mm/hour.",
"      </span>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?24/9/24730?source=see_link&amp;anchor=H22#H22\">",
"       \"Treatment of hematogenous osteomyelitis in children\", section on 'Duration and efficacy of therapy'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?27/33/28186?source=see_link&amp;anchor=H18#H18\">",
"       \"Bacterial arthritis: Treatment and outcome in infants and children\", section on 'Total duration'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     FOLLOW-UP TESTING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Blood cultures should be repeated every 24 to 48 hours until they are sterile. Positive cultures persisting beyond 48 to 72 hours should prompt evaluations for unidentified foci of infection, such as septic thrombophlebitis, infective endocarditis, or undrained abscess.",
"   </p>",
"   <p>",
"    A complete blood count and transaminases should be monitored weekly for patients receiving beta-lactam antibiotics. If neutropenia occurs, it typically develops after the first 10 days of therapy. Neutropenia can also be associated with",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?22/58/23465?source=see_link\">",
"     vancomycin",
"    </a>",
"    treatment. Elevated aspartate aminotransferase (AST) or alanine aminotransferase (ALT) concentrations also are common but usually are less than five times normal, and the patient is not symptomatic. Hypersensitivity rashes may be severe enough to require discontinuation of the beta-lactam antibiotic, although similar rashes may be encountered with",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/56/34688?source=see_link\">",
"     clindamycin",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     INTRAVASCULAR CATHETER REMOVAL",
"    </span>",
"    &nbsp;&mdash;&nbsp;A central catheter optimally is removed in a child with",
"    <em>",
"     S. aureus",
"    </em>",
"    bacteremia (SAB) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/18/37159/abstract/23\">",
"     23",
"    </a>",
"    ]. In a study of catheter-related",
"    <em>",
"     S. aureus",
"    </em>",
"    blood stream infection, catheter removal &gt;4 days after infection or failure to remove the catheter, prolonged SAB &gt;4 days, or thrombocytopenia at presentation each were independent predictors of complications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/18/37159/abstract/24\">",
"     24",
"    </a>",
"    ]. However, practically, many experts would agree to an attempt to clear the infection in select children without first removing the catheter. In some children who have undergone multiple line placements and require a central line for survival, an alternative site for catheter placement may be very limited. Furthermore, any replacement usually requires general anesthesia. Thus, in selected non-neonatal pediatric patients, treatment with the catheter in place may be continued if the child is not septic or in shock, responds promptly to medical therapy with a defervescence in fever and clearance of bacteremia, and has no evidence of an infected thrombus or distant sites of infection. Depending upon the type of catheter and the underlying illness of the child, treatment with the central line in place may be successful in more than 50 percent of children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/18/37159/abstract/25\">",
"     25",
"    </a>",
"    ]. If the catheter remains in place, it is recommended to treat both systemically and with antibiotic lock therapy for three weeks after the SAB has been cleared [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/18/37159/abstract/23\">",
"     23",
"    </a>",
"    ]. However, if the blood cultures remain positive for more than three to five days or the child becomes more ill, the catheter should be removed immediately [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/18/37159/abstract/26\">",
"     26",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/20/7498?source=see_link&amp;anchor=H7#H7\">",
"     \"Treatment of intravascular catheter-related infections\", section on 'Children'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     ECHOCARDIOGRAPHY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Unlike adults, it is not clear if routine echocardiography is necessary in children with",
"    <em>",
"     S. aureus",
"    </em>",
"    bacteremia (SAB). In one study, clinically silent",
"    <em>",
"     S. aureus",
"    </em>",
"    infective endocarditis was found in 11 percent of 36 hospitalized bacteremic children who underwent echocardiographic examination [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/18/37159/abstract/27\">",
"     27",
"    </a>",
"    ]. However, in a prospective series of 125 children with SAB, 19 underwent transthoracic echocardiography and none had abnormal findings [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/18/37159/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Many case series describe the successful treatment of children with SAB and associated infections, especially musculoskeletal infections, without an echocardiogram or prolonged parenteral therapy. SAB with osteomyelitis, for example, often is treated with a few days of parenteral antibiotics until the child is afebrile and improving, followed by an oral agent when appropriate. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/9/24730?source=see_link&amp;anchor=H15#H15\">",
"     \"Treatment of hematogenous osteomyelitis in children\", section on 'Sequential antibiotic therapy'",
"    </a>",
"    .) Recurrence of bacteremia in such cases is very rare in children.",
"   </p>",
"   <p>",
"    The Infectious Disease Society of America clinical practice guideline recommends echocardiography in children with congenital heart disease, bacteremia more than two to three days&rsquo; duration, or other clinical findings suggestive of endocarditis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/18/37159/abstract/18\">",
"     18",
"    </a>",
"    ]. Transesophageal echocardiography generally is not performed in children because of the size of the probes, as well as the need for sedation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     ORAL THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;As stated above, oral therapy often is administered to complete treatment of musculoskeletal infections in children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/18/37159/abstract/28\">",
"     28",
"    </a>",
"    ]. For methicillin-susceptible isolates, older children may tolerate",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?16/61/17363?source=see_link\">",
"     dicloxacillin",
"    </a>",
"    at 75 to 100",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day dosed every six hours. However, younger children do not readily ingest the dicloxacillin suspension. In general, the",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?30/5/30804?source=see_link\">",
"     cephalexin",
"    </a>",
"    suspension (75 to 100",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day in three or four divided doses) is preferred in the younger age groups.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/56/34688?source=see_link\">",
"     Clindamycin",
"    </a>",
"    (30 to 40",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day in three divided doses) is an alternative for children with hypersensitivity to beta-lactam antibiotics or for completing treatment for infection caused by methicillin-resistant",
"    <em>",
"     S. aureus",
"    </em>",
"    fully susceptible to clindamycin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/18/37159/abstract/17\">",
"     17",
"    </a>",
"    ].",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?21/52/22345?source=see_link\">",
"     Linezolid",
"    </a>",
"    is a second alternative but is more expensive than clindamycin and may be associated with bone marrow depression if administered for more than two weeks. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/6/29802?source=see_link&amp;anchor=H2#H2\">",
"     \"Treatment of invasive methicillin-resistant Staphylococcus aureus infection in children\", section on 'Antimicrobial agents'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?32/50/33569?source=see_link\">",
"       \"Patient information: Sepsis in adults (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <em>",
"       Staphylococcus aureus",
"      </em>",
"      is a leading cause of both community-acquired and hospital-acquired bacteremia. Normal children usually have",
"      <em>",
"       S. aureus",
"      </em>",
"      bacteremia (SAB) in association with a focus of infection such as osteomyelitis or pneumonia. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <em>",
"       S. aureus",
"      </em>",
"      isolates have developed resistance to methicillin and macrolides,",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/56/34688?source=see_link\">",
"       clindamycin",
"      </a>",
"      , and, in rare cases,",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?22/58/23465?source=see_link\">",
"       vancomycin",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Antibiotic resistance'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Intravenous",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?25/57/26519?source=see_link\">",
"       nafcillin",
"      </a>",
"      ,",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?0/59/950?source=see_link\">",
"       oxacillin",
"      </a>",
"      , or",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?9/36/9797?source=see_link\">",
"       cefazolin",
"      </a>",
"      are the antibiotics of choice when treating bacteremia caused by methicillin-susceptible",
"      <em>",
"       S. aureus",
"      </em>",
"      (MSSA). (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Empiric therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In communities where methicillin-resistant",
"      <em>",
"       S. aureus",
"      </em>",
"      (MRSA) accounts for more than 10 percent of the community",
"      <em>",
"       S. aureus",
"      </em>",
"      isolates, empiric therapy should include coverage for MRSA.",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?22/58/23465?source=see_link\">",
"       Vancomycin",
"      </a>",
"      should be included in the empiric regimen for children with life-threatening infections, such as septic shock or infective endocarditis. Some experts recommend that",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?0/59/950?source=see_link\">",
"       oxacillin",
"      </a>",
"      or",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?25/57/26519?source=see_link\">",
"       nafcillin",
"      </a>",
"      be administered along with vancomycin because these agents are more rapidly bactericidal than is vancomycin against MSSA. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Empiric therapy'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?29/6/29802?source=see_link&amp;anchor=H13#H13\">",
"       \"Treatment of invasive methicillin-resistant Staphylococcus aureus infection in children\", section on 'For critically ill'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Once susceptibilities have been determined, the antimicrobial regimen can be modified. If MRSA is not isolated within 72 to 96 hours after antibiotics are initiated, the",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?22/58/23465?source=see_link\">",
"       vancomycin",
"      </a>",
"      can be discontinued. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Empiric therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Alternative agents for treating MRSA SAB include",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?21/52/22345?source=see_link\">",
"       linezolid",
"      </a>",
"      ,",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?38/39/39542?source=see_link\">",
"       daptomycin",
"      </a>",
"      (not for patients with associated pneumonia), and, possibly,",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?40/23/41336?source=see_link\">",
"       trimethoprim-sulfamethoxazole",
"      </a>",
"      .",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/56/34688?source=see_link\">",
"       Clindamycin",
"      </a>",
"      or linezolid can be used to complete therapy of infections associated with SAB, once MRSA bacteremia has resolved. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Alternative drugs'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Parenteral therapy for 10 days generally is adequate for uncomplicated",
"      <em>",
"       S. aureus",
"      </em>",
"      bacteremia in children; 14 days are recommended for",
"      <em>",
"       S. aureus",
"      </em>",
"      central catheter-related bacteremia when the catheter is removed and following clearing of the SAB. The duration of treatment for",
"      <em>",
"       S. aureus",
"      </em>",
"      bacteremia associated with infective endocarditis, osteomyelitis, septic arthritis, or skin and soft tissue infection is dependent upon the associated infection. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Duration of therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Blood cultures should be repeated every 24 to 48 hours until they are sterile. Positive cultures persisting beyond 72 hours should prompt evaluations for unidentified foci of infection, such as septic thrombophlebitis, infective endocarditis, or undrained abscess. A complete blood count should be monitored weekly for patients receiving beta-lactam antibiotics. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Follow-up testing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Echocardiography is recommended in children with SAB who have underlying congenital heart disease, bacteremia more than two to three days&rsquo; duration, or other clinical findings suggestive of endocarditis. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Echocardiography'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/18/37159/abstract/1\">",
"      Hill PC, Wong CG, Voss LM, et al. Prospective study of 125 cases of Staphylococcus aureus bacteremia in children in New Zealand. Pediatr Infect Dis J 2001; 20:868.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/18/37159/abstract/2\">",
"      Suryati BA, Watson M. Staphylococcus aureus bacteraemia in children: a 5-year retrospective review. J Paediatr Child Health 2002; 38:290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/18/37159/abstract/3\">",
"      Sattler CA, Mason EO Jr, Kaplan SL. Prospective comparison of risk factors and demographic and clinical characteristics of community-acquired, methicillin-resistant versus methicillin-susceptible Staphylococcus aureus infection in children. Pediatr Infect Dis J 2002; 21:910.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/18/37159/abstract/4\">",
"      Naimi TS, LeDell KH, Boxrud DJ, et al. Epidemiology and clonality of community-acquired methicillin-resistant Staphylococcus aureus in Minnesota, 1996-1998. Clin Infect Dis 2001; 33:990.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/18/37159/abstract/5\">",
"      Kaplan SL, Hulten KG, Gonzalez BE, et al. Three-year surveillance of community-acquired Staphylococcus aureus infections in children. Clin Infect Dis 2005; 40:1785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/18/37159/abstract/6\">",
"      Gonzalez BE, Rueda AM, Shelburne SA 3rd, et al. Community-associated strains of methicillin-resistant Staphylococccus aureus as the cause of healthcare-associated infection. Infect Control Hosp Epidemiol 2006; 27:1051.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/18/37159/abstract/7\">",
"      Seybold U, Kourbatova EV, Johnson JG, et al. Emergence of community-associated methicillin-resistant Staphylococcus aureus USA300 genotype as a major cause of health care-associated blood stream infections. Clin Infect Dis 2006; 42:647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/18/37159/abstract/8\">",
"      Ma XX, Ito T, Tiensasitorn C, et al. Novel type of staphylococcal cassette chromosome mec identified in community-acquired methicillin-resistant Staphylococcus aureus strains. Antimicrob Agents Chemother 2002; 46:1147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/18/37159/abstract/9\">",
"      Szczesiul JM, Shermock KM, Murtaza UI, Siberry GK. No decrease in clindamycin susceptibility despite increased use of clindamycin for pediatric community-associated methicillin-resistant Staphylococcus aureus skin infections. Pediatr Infect Dis J 2007; 26:852.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/18/37159/abstract/10\">",
"      McGehee RF R, Barre FF, Finland M. Resistance of Staphylococcus aureus to lincomycin, clinimycin, and erythromycin. Antimicrob Agents Chemother (Bethesda) 1968; 8:392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/18/37159/abstract/11\">",
"      Panagea S, Perry JD, Gould FK. Should clindamycin be used as treatment of patients with infections caused by erythromycin-resistant staphylococci? J Antimicrob Chemother 1999; 44:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/18/37159/abstract/12\">",
"      Drinkovic D, Fuller ER, Shore KP, et al. Clindamycin treatment of Staphylococcus aureus expressing inducible clindamycin resistance. J Antimicrob Chemother 2001; 48:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/18/37159/abstract/13\">",
"      Jenssen WD, Thakker-Varia S, Dubin DT, Weinstein MP. Prevalence of macrolides-lincosamides-streptogramin B resistance and erm gene classes among clinical strains of staphylococci and streptococci. Antimicrob Agents Chemother 1987; 31:883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/18/37159/abstract/14\">",
"      Fiebelkorn KR, Crawford SA, McElmeel ML, Jorgensen JH. Practical disk diffusion method for detection of inducible clindamycin resistance in Staphylococcus aureus and coagulase-negative staphylococci. J Clin Microbiol 2003; 41:4740.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/18/37159/abstract/15\">",
"      Siberry GK, Tekle T, Carroll K, Dick J. Failure of clindamycin treatment of methicillin-resistant Staphylococcus aureus expressing inducible clindamycin resistance in vitro. Clin Infect Dis 2003; 37:1257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/18/37159/abstract/16\">",
"      Frank AL, Marcinak JF, Mangat PD, et al. Clindamycin treatment of methicillin-resistant Staphylococcus aureus infections in children. Pediatr Infect Dis J 2002; 21:530.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/18/37159/abstract/17\">",
"      Mart&iacute;nez-Aguilar G, Hammerman WA, Mason EO Jr, Kaplan SL. Clindamycin treatment of invasive infections caused by community-acquired, methicillin-resistant and methicillin-susceptible Staphylococcus aureus in children. Pediatr Infect Dis J 2003; 22:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/18/37159/abstract/18\">",
"      Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 2011; 52:e18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/18/37159/abstract/19\">",
"      Frymoyer A, Hersh AL, Benet LZ, Guglielmo BJ. Current recommended dosing of vancomycin for children with invasive methicillin-resistant Staphylococcus aureus infections is inadequate. Pediatr Infect Dis J 2009; 28:398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/18/37159/abstract/20\">",
"      Gonz&aacute;lez C, Rubio M, Romero-Vivas J, et al. Bacteremic pneumonia due to Staphylococcus aureus: A comparison of disease caused by methicillin-resistant and methicillin-susceptible organisms. Clin Infect Dis 1999; 29:1171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/18/37159/abstract/21\">",
"      Fowler VG Jr, Kong LK, Corey GR, et al. Recurrent Staphylococcus aureus bacteremia: pulsed-field gel electrophoresis findings in 29 patients. J Infect Dis 1999; 179:1157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/18/37159/abstract/22\">",
"      Perlroth J, Kuo M, Tan J, et al. Adjunctive use of rifampin for the treatment of Staphylococcus aureus infections: a systematic review of the literature. Arch Intern Med 2008; 168:805.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/18/37159/abstract/23\">",
"      Mermel LA, Allon M, Bouza E, et al. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 Update by the Infectious Diseases Society of America. Clin Infect Dis 2009; 49:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/18/37159/abstract/24\">",
"      Carrillo-Marquez MA, Hulten KG, Mason EO, Kaplan SL. Clinical and molecular epidemiology of Staphylococcus aureus catheter-related bacteremia in children. Pediatr Infect Dis J 2010; 29:410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/18/37159/abstract/25\">",
"      Rubin LG, Shih S, Shende A, et al. Cure of implantable venous port-associated bloodstream infections in pediatric hematology-oncology patients without catheter removal. Clin Infect Dis 1999; 29:102.",
"     </a>",
"    </li>",
"    <li>",
"     American Academy of Pediatrics. Staphylococcal infections. In: Red Book: 2012 Report of the Committee on Infectious Diseases, 29th, Pickering LK.  (Ed), American Academy of Pediatrics, Elk Grove Village, IL 2012. p.653.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/18/37159/abstract/27\">",
"      Friedland IR, du Plessis J, Cilliers A. Cardiac complications in children with Staphylococcus aureus bacteremia. J Pediatr 1995; 127:746.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/18/37159/abstract/28\">",
"      Tetzlaff TR, McCracken GH Jr, Nelson JD. Oral antibiotic therapy for skeletal infections of children. II. Therapy of osteomyelitis and suppurative arthritis. J Pediatr 1978; 92:485.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5967 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-122.72.76.133-5682FA82D5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_18_37159=[""].join("\n");
var outline_f36_18_37159=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H16\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ANTIBIOTIC SELECTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Antibiotic resistance",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Methicillin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Macrolides and clindamycin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Empiric therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Alternative drugs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      DURATION OF THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      FOLLOW-UP TESTING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      INTRAVASCULAR CATHETER REMOVAL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      ECHOCARDIOGRAPHY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      ORAL THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/5967\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5967|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?30/31/31217\" title=\"picture 1\">",
"      MRSA susceptibility testing",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/33/28186?source=related_link\">",
"      Bacterial arthritis: Treatment and outcome in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/1/26649?source=related_link\">",
"      Complications of Staphylococcus aureus bacteremia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/21/30042?source=related_link\">",
"      Epidemiology and clinical spectrum of methicillin-resistant Staphylococcus aureus infections in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/61/28632?source=related_link\">",
"      Epidemiology of and risk factors for Staphylococcus aureus bacteremia in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/15/27896?source=related_link\">",
"      Infective endocarditis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/13/15575?source=related_link\">",
"      Microbiology of methicillin-resistant Staphylococcus aureus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?32/50/33569?source=related_link\">",
"      Patient information: Sepsis in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/9/24730?source=related_link\">",
"      Treatment of hematogenous osteomyelitis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/20/7498?source=related_link\">",
"      Treatment of intravascular catheter-related infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/6/29802?source=related_link\">",
"      Treatment of invasive methicillin-resistant Staphylococcus aureus infection in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_18_37160="Interferon-gamma release assays for diagnosis of latent tuberculosis infection";
var content_f36_18_37160=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Interferon-gamma release assays for diagnosis of latent tuberculosis infection",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/18/37160/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/18/37160/contributors\">",
"     Madhukar Pai, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/18/37160/contributors\">",
"     Dick Menzies, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/18/37160/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/18/37160/contributors\">",
"     C Fordham von Reyn, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/18/37160/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/18/37160/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?36/18/37160/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 11, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H365757202\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The development of interferon-gamma release assays (IGRAs) is an important advance in the diagnosis of latent tuberculosis infection (LTBI). IGRAs are in vitro blood tests of cell-mediated immune response; they measure T cell release of interferon-gamma (IFN-gamma) following stimulation by antigens unique to Mycobacterium tuberculosis.",
"   </p>",
"   <p>",
"    The goal of testing for LTBI is to identify individuals who are at increased risk for the development of tuberculosis and therefore who would benefit from treatment of latent TB infection. Only those who would benefit from treatment should be tested, so a decision to test presupposes a decision to treat if the test is positive.",
"   </p>",
"   <p>",
"    A large number of studies have evaluated IGRAs, and these have been summarized in systematic reviews and guidelines [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/18/37160/abstract/1-12\">",
"     1-12",
"    </a>",
"    ]. Issues related to the assays and their use will be reviewed here. Other issues related to diagnosis of LTBI are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/10/20648?source=see_link\">",
"     \"Diagnosis of latent tuberculosis infection in HIV-negative adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/46/12009?source=see_link\">",
"     \"Diagnosis of latent tuberculosis infection in HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4851314\">",
"    <span class=\"h1\">",
"     OVERVIEW OF IGRAs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Interferon-gamma release assays (IGRAs) are diagnostic tools for latent tuberculosis infection (LTBI). They are surrogate markers of Mycobacterium tuberculosis infection and indicate a cellular immune response to M. tuberculosis. IGRAs cannot distinguish between latent infection and active tuberculosis (TB) disease, and should not be used for diagnosis of active TB, which is a microbiological diagnosis. A positive IGRA result may not necessarily indicate active TB, and a negative IGRA result may not rule out active TB [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/18/37160/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/56/9098?source=see_link\">",
"     \"Diagnosis of pulmonary tuberculosis in HIV-negative patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Because IGRAs are not affected by Bacille Calmette-Gu&eacute;rin (BCG) vaccination status, IGRAs are useful for evaluation of LTBI in BCG-vaccinated individuals, particularly in settings where BCG vaccination is administered after infancy or multiple (booster) BCG vaccinations are given. In contrast, the specificity of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/35/15924?source=see_link\">",
"     tuberculin skin test",
"    </a>",
"    (TST) varies depending on timing of BCG and whether repeated (booster) vaccinations are given. A World Atlas of BCG Policies and Practices (www.bcgatlas.org) has been compiled to help clinicians and public health practitioners review variations in BCG policies and their impact on TST, and determine the populations for which IGRAs may be more specific than the TST [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/18/37160/abstract/14\">",
"     14",
"    </a>",
"    ]. Further, although based on limited evidence, IGRAs appear to be unaffected by most infections with environmental nontuberculous mycobacteria (NTM), which can cause false-positive TSTs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/18/37160/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Two NTM that affect humans, Mycobacterium marinum and Mycobacterium kansasii, contain gene sequences that encode for ESAT-6 or CFP-10, antigens used in the new IGRAs. Infection with either of these NTM has been shown to produce positive results in IGRAs using these antigens, as with the TST [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/18/37160/abstract/16-18\">",
"     16-18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    IGRA results can be available in 24 to 48 hours (although it can take longer, in routine practice, because of batching of samples) and, in contrast to TST, do not require a follow-up visit for reading of results. Interpretation of IGRAs is more objective, while TST interpretation is affected by inter- and intra-reader variation. Baseline two-step testing is not required for repeated IGRA testing because IGRA testing does not boost subsequent IGRA test results.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4850554\">",
"    <span class=\"h2\">",
"     Assay antigens",
"    </span>",
"    &nbsp;&mdash;&nbsp;M. tuberculosis-specific antigens include early secreted antigenic target 6 (ESAT-6) and culture filtrate protein 10 (CFP-10). These are encoded by genes located within the region of difference 1 (RD1) segment of the M. tuberculosis genome. They are more specific for M. tuberculosis than purified protein derivative (PPD) because they are not shared with any BCG vaccine strains or most species of nontuberculous mycobacteria other than M. marinum, M. kansasii, M. szulgai, and M. flavescens [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/18/37160/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4850561\">",
"    <span class=\"h2\">",
"     Types of assays",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two IGRAs are available in many countries: the QuantiFERON-TB Gold In-Tube (QFT-GIT) assay (Cellestis Limited, Carnegie, Australia) (which has replaced the second-generation Quantiferon-TB Gold [QFT-G] assay), and the T-SPOT.TB assay (Oxford Immunotec, Abingdon, United Kingdom). Both tests are approved by the United States Food and Drug Administration (FDA) and are also available in Canada, Europe, and many other countries.",
"   </p>",
"   <p>",
"    The QFT-GIT assay is an ELISA-based, whole-blood test that uses peptides from three TB antigens (ESAT-6, CFP-10, and TB7.7) in an in-tube format. The result is reported as quantification of IFN-gamma in international units (IU) per mL. An individual is considered positive for M. tuberculosis infection if the IFN-gamma response to TB antigens is above the test cut-off (after subtracting the background IFN-gamma response in the negative control).",
"   </p>",
"   <p>",
"    The T-SPOT.TB is an enzyme-linked immunospot (ELISPOT) assay performed on separated and counted peripheral blood mononuclear cells (PBMCs); it uses ESAT-6 and CFP-10 peptides. The result is reported as number of IFN-gamma producing T cells (spot forming cells). An individual is considered positive for M. tuberculosis infection if the spot counts in the TB antigen wells exceed a specific threshold relative to the control wells.",
"   </p>",
"   <p>",
"    The TST may boost subsequent IGRA results [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/18/37160/abstract/3\">",
"     3",
"    </a>",
"    ]. The effect appears to be more apparent in those individuals who were already IGRA-positive (ie, previously sensitized to M. tuberculosis or possibly other mycobacteria). The effect seems apparent after the first few days following TST and appears to wane after three months, but this requires further confirmation. Therefore, if an IGRA test is needed to confirm a TST result, it has been suggested that blood be drawn for IGRA within three days of TST placement (ie, at the time of the TST reading).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4851487\">",
"    <span class=\"h2\">",
"     Sensitivity and specificity",
"    </span>",
"    &nbsp;&mdash;&nbsp;IGRAs have specificity &gt;95 percent for diagnosis of latent TB infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/18/37160/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. The sensitivity for T-SPOT.TB appears to be higher than for QFT-GIT or TST (approximately 90, 80, and 80 percent, respectively) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/18/37160/abstract/2\">",
"     2",
"    </a>",
"    ]. The higher sensitivity of T-SPOT.TB may be useful for evaluating individuals with immunosuppressive conditions.",
"   </p>",
"   <p>",
"    TST specificity is high in populations not vaccinated with BCG (97 percent). Among populations where BCG is administered, it is much lower although variable (approximately 60 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/18/37160/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    IGRA sensitivity is diminished by HIV infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/18/37160/abstract/9\">",
"     9",
"    </a>",
"    ]. Lower CD4 counts have been associated with higher rates of indeterminate IGRA results; this is especially the case with QFT-GIT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/18/37160/abstract/9\">",
"     9",
"    </a>",
"    ]. TSPOT appeared to be less affected by immunosuppression than QFT-GIT, likely because the testing procedure requires that an adequate number of peripheral blood mononuclear cells are placed in each test well, even if the overall peripheral blood lymphocyte count is low [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/18/37160/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For the diagnosis of active TB, IGRA sensitivity and specificity are poor, particularly in high TB incidence settings [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/18/37160/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. Specificity is poor because these populations will have high prevalence of LTBI, and the immune based tests cannot distinguish between active disease and latent infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/18/37160/abstract/12\">",
"     12",
"    </a>",
"    ]. Sensitivity is reduced because of the temporary anergy of the acute illness. Therefore, IGRAs should not be used for diagnosis of active TB.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H454305591\">",
"    <span class=\"h2\">",
"     Prediction of active disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neither IGRAs nor the TST have high accuracy for the prediction of active TB, although use of IGRAs in some populations might reduce the number of people considered for preventive treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/18/37160/abstract/19-21\">",
"     19-21",
"    </a>",
"    ]. Several longitudinal studies show that incidence rates of active TB, even in IGRA positive individuals in high TB burden countries, are low, suggesting that a vast majority (&gt;95 percent) of IGRA-positive individuals do not progress to TB disease during follow-up [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/18/37160/abstract/21-26\">",
"     21-26",
"    </a>",
"    ]. This is similar to the TST. Thus, further research is needed to identify biomarkers that are highly predictive and can identify latently infected individuals who are at highest risk of disease progression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/18/37160/abstract/19,20\">",
"     19,20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H365757209\">",
"    <span class=\"h1\">",
"     USE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of interferon-gamma release assays (IGRAs) is increasing in countries with low or intermediate incidence of disease. More than 25 countries now have at least one guideline statement on the use of IGRAs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/18/37160/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. In these guidelines, a range of approaches are recommended for the use of IGRAs, including replacement of tuberculin skin testing (TST) by IGRA, use of either assay interchangeably, or a two-step approach (TST followed by IGRA) in certain circumstances (",
"    <a class=\"graphic graphic_table graphicRef76107 \" href=\"mobipreview.htm?15/7/15484\">",
"     table 1",
"    </a>",
"    ). Some guidelines favor more than one approach, depending on the risk group tested. The latest guidelines from the United States, Canada, the European Centre for Disease Prevention and Control (ECDC), the United Kingdom, and World Health Organization (WHO) are outlined in the following sections.",
"   </p>",
"   <p>",
"    As with the TST, results of IGRAs should be interpreted with other relevant clinical information, such as age, Bacille Calmette-Gu&eacute;rin (BCG) status, history of contact with active tuberculosis (TB), and risk factors that increase the risk of progression to active disease. An online",
"    <span class=\"nowrap\">",
"     TST/QFT",
"    </span>",
"    algorithm has been developed to facilitate the interpretation of these tests [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/18/37160/abstract/29\">",
"     29",
"    </a>",
"    ]. The algorithm provides information on positive predictive value of a test result, along with predicted risk of progression to disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2194407\">",
"    <span class=\"h2\">",
"     Guidelines",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H365757216\">",
"    <span class=\"h3\">",
"     United States guidelines",
"    </span>",
"    &nbsp;&mdash;&nbsp;The United States Centers for Disease Control and Prevention (CDC) 2010 guidelines addresses both T-SPOT.TB and QFT-GIT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/18/37160/abstract/5\">",
"     5",
"    </a>",
"    ]. The guidelines indicate that IGRAs can be used in place of (but not in addition to) TST in all situations in which CDC recommends TST as an aid in diagnosing Mycobacterium tuberculosis infection. This includes contact investigations, testing during pregnancy, and screening of healthcare workers and others undergoing serial evaluation for M. tuberculosis infection.",
"   </p>",
"   <p>",
"    Populations in which IGRAs are preferred over TST include individuals who have received BCG (either as a vaccine or for cancer therapy) and individuals from groups that historically have poor rates of return for TST reading. TST is preferred over IGRAs for testing children less than five years of age. Despite the preferences noted, use of either TST or IGRA is acceptable in these groups; each institution should evaluate the availability and benefits of IGRAs in prioritizing their use.",
"   </p>",
"   <p>",
"    Routine testing with both TST and IGRA is",
"    <strong>",
"     not",
"    </strong>",
"    recommended. However, results from both tests might be useful in the following situations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      When the initial test (whichever test was used first) is",
"      <strong>",
"       negative",
"      </strong>",
"      and the risk for infection, progression to disease,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      poor outcome is high (eg, HIV-infected individuals or children under five years of age who are exposed to a person with infectious TB).",
"     </li>",
"     <li>",
"      When the initial test is",
"      <strong>",
"       positive",
"      </strong>",
"      and:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Additional evidence of infection would be helpful to encourage adherence to latent tuberculosis infection (LTBI) treatment (for example, in the setting of foreign-born healthcare workers (HCWs) who believe their positive TST is due to BCG).",
"     </li>",
"     <li>",
"      The person has a low risk of infection and progression from infection to TB disease. A positive result from the second test increases the likelihood that the test reflects infection. An alternative is to assume, without additional testing, that the initial result is a false positive or that the risk for disease does not warrant additional evaluation or treatment, regardless of test results.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Repeating an IGRA or performing a TST might be useful when the initial IGRA result is indeterminate and there is a persistent reason for testing. Multiple negative results from any combination of these tests cannot exclude M. tuberculosis infection. Selection of the most suitable test or combination of tests for detection of M. tuberculosis infection should be based on the reasons and the context for testing, test availability, and cost of testing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H365757223\">",
"    <span class=\"h3\">",
"     Canadian guidelines",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Canadian Tuberculosis Committee issued an updated Advisory Committee Statement on IGRAs in 2010 with the following recommendations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/18/37160/abstract/6\">",
"     6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For persons with a positive TST and low pretest probability of recently acquired LTBI, as well as no other risk factors for progression to active disease (",
"      <a class=\"graphic graphic_table graphicRef60941 \" href=\"mobipreview.htm?38/36/39502\">",
"       table 2",
"      </a>",
"      ), IGRAs may be used as a confirmatory test to exclude the possibility of a false positive TST.",
"     </li>",
"     <li>",
"      For persons with high risk of progression to active disease if infected (",
"      <a class=\"graphic graphic_table graphicRef60941 \" href=\"mobipreview.htm?38/36/39502\">",
"       table 2",
"      </a>",
"      ), a TST should be used; if this is positive, the person should be considered to have LTBI. If negative, an IGRA could be done; if positive the person should be considered to have LTBI.",
"     </li>",
"     <li>",
"      In immunocompromised individuals, the TST should be the initial test used to detect LTBI. If the TST is positive, the person should be considered to have LTBI. However, given the rate of false-negative TST results in immunocompromised populations, IGRA testing is appropriate in the setting of negative TST results. If the IGRA result is positive, the person may be considered to have LTBI.",
"     </li>",
"     <li>",
"      In children, IGRAs may be used as a supplementary diagnostic tool, together with clinical specimens for definitive microbiologic diagnosis, TST, and other investigations. However, IGRA should not be a substitute for, or obviate the need for, appropriate microbiologic specimen collection. In addition, IGRAs (and the TST) may fail to detect patients with active TB. A negative IGRA (or TST) does NOT rule out active TB at any age. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?12/53/13143?source=see_link&amp;anchor=H2#H2\">",
"       \"Latent tuberculosis infection in children\", section on 'Diagnosis'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/4/23625?source=see_link&amp;anchor=H9#H9\">",
"       \"Tuberculosis disease in children\", section on 'Diagnosis'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H365757230\">",
"    <span class=\"h3\">",
"     United Kingdom guidelines",
"    </span>",
"    &nbsp;&mdash;&nbsp;The United Kingdom National Institute for Health and Clinical Excellence (NICE) guidelines were published in 2006 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/18/37160/abstract/30\">",
"     30",
"    </a>",
"    ]. In April 2011, the updated NICE guidelines were published [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/18/37160/abstract/31\">",
"     31",
"    </a>",
"    ]. The main recommendations are:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      TST should be used as the first-line test for LTBI in contacts of infectious cases and new entrants from high-incidence countries. Those with positive TST results may be considered for IGRA testing, depending on BCG status and results of the TST.",
"     </li>",
"     <li>",
"      In persons with HIV infection and low CD4 counts (&lt;200), IGRA plus concurrent TST is recommended.",
"     </li>",
"     <li>",
"      In persons with HIV infection and CD4 counts of 200 to 500, IGRA alone or IGRA plus concurrent TST is recommended.",
"     </li>",
"     <li>",
"      In persons with immunocompromising conditions (other than HIV), IGRA alone or IGRA plus concurrent TST is recommended.",
"     </li>",
"     <li>",
"      IGRA testing may be used as the sole test for LTBI in hard-to-reach groups and in an outbreak situation when a large number of people might need to be screened.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2507724\">",
"    <span class=\"h3\">",
"     European guidelines",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ECDC guidelines on IGRAs were published in March, 2011 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/18/37160/abstract/32\">",
"     32",
"    </a>",
"    ]. The main recommendations are:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      IGRAs should not replace the existing standard diagnostic methods for the diagnosis of active TB, and a negative IGRA result does not exclude active TB disease.",
"     </li>",
"     <li>",
"      For LTBI diagnosis, IGRAs may be used as part of the overall risk assessment to identify individuals for preventive treatment (eg, immunocompromised persons, children, close contacts, and recently-exposed individuals).",
"     </li>",
"     <li>",
"      In high-TB incidence countries, there is no added value in using IGRAs to diagnose LTBI, as the focus of prevention and control is to identify and treat active cases. In low-TB incidence countries, given the evidence available, IGRAs could be used in contact tracing algorithms applying the two-step approach (following TST, in TST-positive subjects).",
"     </li>",
"     <li>",
"      In immunocompromised individuals, as it is essential to maximize sensitivity, the simultaneous use of TST and IGRAs could be beneficial in identifying LTBI. However, in immune-compromised individuals, IGRAs should not be used to exclude LTBI",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      active TB.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H365757238\">",
"    <span class=\"h2\">",
"     Children",
"    </span>",
"    &nbsp;&mdash;&nbsp;Available data suggest that TST and IGRAs have similar accuracy for the detection of TB infection or the diagnosis of disease in children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/18/37160/abstract/10,33\">",
"     10,33",
"    </a>",
"    ]. The 2010 CDC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/18/37160/abstract/5\">",
"     5",
"    </a>",
"    ] and Canadian guidelines [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/18/37160/abstract/6\">",
"     6",
"    </a>",
"    ] provide specific guidance for use of IGRAs in children (see previous sections). In addition, the Red Book of the American Academy of Pediatrics (AAP) published recommendations in 2009 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/18/37160/abstract/7\">",
"     7",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For immunocompetent children five years of age and older, IGRAs can be used in place of a TST to confirm cases of LTBI or TB and likely will yield fewer false-positive test results. Data are insufficient to support use of IGRAs for children younger than five years of age or for immunocompromised children of any age.",
"     </li>",
"     <li>",
"      Children with a positive IGRA result should be considered infected with M. tuberculosis complex. A negative IGRA result should not be interpreted to reflect absence of infection.",
"     </li>",
"     <li>",
"      Indeterminate IGRA results do not exclude TB infection and should not be used to make clinical decisions.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H365757254\">",
"    <span class=\"h2\">",
"     Serial testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serial (repeated) testing for TB infection is indicated in specific populations such as HCWs in high risk settings, prison inmates and staff, and close contacts. Interpretation of serial TSTs is challenging due to boosting, conversions, and reversions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/18/37160/abstract/34\">",
"     34",
"    </a>",
"    ]. IGRAs appear to be highly dynamic assays with high frequencies of conversions and reversions in both low and high TB incidence settings [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/18/37160/abstract/8,35-38\">",
"     8,35-38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The use of IGRAs for serial testing is complicated by lack of data on optimal cut-offs for serial testing, and unclear interpretation of conversions and reversions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/18/37160/abstract/3,5,8,35-40\">",
"     3,5,8,35-40",
"    </a>",
"    ]. Existing data suggest that use of simplistic definitions are used for conversions (ie, change from negative to positive result) may result in higher conversion rates than expected based on the known epidemiologic profile of a given population. IGRA reversions are more likely to occur among those with interferon-gamma values (or spot counts) just above the diagnostic threshold, and in those with a discordant profile (TST-negative, but IGRA-positive) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/18/37160/abstract/3,5,8,35-39\">",
"     3,5,8,35-39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are no data to show that IGRAs are superior for identifying incidence of new TB infection than the TST [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/18/37160/abstract/8,39\">",
"     8,39",
"    </a>",
"    ]. Furthermore, although TST conversion is associated with an increased risk for active TB, to date, no studies have reported data on the association between IGRA conversion and subsequent disease risk.",
"   </p>",
"   <p>",
"    For serial testing in populations exposed to TB, data for IGRA are insufficient to provide adequate guidance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/18/37160/abstract/6,35,41\">",
"     6,35,41",
"    </a>",
"    ]. The Canadian guidelines favor use of TST in this setting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/18/37160/abstract/6,41\">",
"     6,41",
"    </a>",
"    ]; the United States guidelines indicate that either TST or IGRA may be used with special considerations regarding conversions and reversions, but acknowledge that criteria for interpreting changes in IGRA results remain uncertain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/18/37160/abstract/5\">",
"     5",
"    </a>",
"    ]. The ECDC guidelines state that there is insufficient evidence on the positive predictive value of IGRAs for the screening of HCWs, although given the available evidence for the use of IGRAs, a two-step approach could increase the specificity depending on the BCG vaccination status [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/18/37160/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19560072\">",
"    <span class=\"h3\">",
"     Reproducibility",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several studies have raised concerns about the reproducibility of IGRA results. There are at least five causes of assay variability:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Factors prior to analysis (ie, sample agitation, time elapsed prior to incubation, duration of incubation). The time elapsed prior to incubation can have an important effect on test results; in one study, delays in incubation of 6 or 12 hours were associated with positive-to-negative reversion rates of 19 and 22 percent, respectively [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/18/37160/abstract/42\">",
"       42",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Test reproducibility within a single laboratory. Substantial variability has been observed when assays are repeated on the samples from the same individual on the same day. In one study including 1086 test results obtained from 543 subjects, the result of the second test was discordant from the first in 8 percent of patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/18/37160/abstract/43\">",
"       43",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Test reproducibility in different laboratories. Results&nbsp;have varied considerably when two samples taken from the same person on the same day are tested in different laboratories [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/18/37160/abstract/44\">",
"       44",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Variability in response of a given individual observed on different samples collected on different days. Among 48 healthcare workers who underwent monthly IGRA testing for a year, conversions or reversions were observed in 52 percent of participants [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/18/37160/abstract/45\">",
"       45",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These issues with reproducibility have led to suggestions that a borderline range for IGRA interpretation be established for quantitative reporting of results, rather than reporting qualitative results only (eg, negative or positive). Thus far a borderline range has not been established for the approved assays, and absolute IFN-gamma values or number of spot-forming cells are not reported routinely [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/18/37160/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Until more definitive evidence and consensus emerges, laboratories should report both quantitative results and qualitative results, and all quantitative IGRA results should be interpreted with caution. For patients with test results that are close to threshold cutoff, a repeat test may be warranted, depending on the clinical context and relevant risk factors. In addition, laboratories should ensure standardization of preanalytical procedures such as tube agitation, time interval between specimen collection and incubation, and duration of incubation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4852034\">",
"    <span class=\"h2\">",
"     Limitations of IGRAs",
"    </span>",
"    &nbsp;&mdash;&nbsp;The reagent costs of IGRAs are substantially higher than costs of TST, and IGRAs require laboratories with adequate equipment and trained personnel to perform the assays (",
"    <a class=\"graphic graphic_table graphicRef76107 \" href=\"mobipreview.htm?15/7/15484\">",
"     table 1",
"    </a>",
"    ). In addition, IGRAs require fresh blood samples, and transportation delays can affect test performance. Blood specimens for the QFT assay must be placed in an incubator as soon as possible and within 16 hours of blood collection. For the standard T-SPOT.TB assay, blood must be processed within eight hours of collection. However, if the T-Cell Xtend reagent is used, whole blood can be stored overnight prior to processing in the T-SPOT.TB assay. Test kits must be transported and stored in optimum conditions to prevent exposure to excessive heat. Strict quality assurance is necessary to detect unusual patterns in results (such as a spike in the number of indeterminate results due to low mitogen response), and it is important to run both positive and negative controls with each assay. Areas for additional research have been identified [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/18/37160/abstract/1,5,47\">",
"     1,5,47",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H82128982\">",
"    <span class=\"h3\">",
"     Indeterminate results",
"    </span>",
"    &nbsp;&mdash;&nbsp;An &ldquo;indeterminate result&rdquo; implies that the test cannot produce a valid result; often this is because of immune suppression which leads to lack of T-cell response to the positive control. The likelihood of indeterminate results increases as CD4 count levels decrease in HIV-infected individuals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/18/37160/abstract/9\">",
"     9",
"    </a>",
"    ]. An indeterminate IGRA result should be repeated to make sure there are no technical or laboratory flaws. If the repeat result is also indeterminate, then the clinician cannot rely on IGRA for clinical decision making, except to assume that the patient is probably anergic [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/18/37160/abstract/48\">",
"     48",
"    </a>",
"    ]. Other tests, risk factors and clinical information must be used instead.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17249216\">",
"    <span class=\"h3\">",
"     Window period",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is limited evidence on timing of IGRA conversions. Available evidence suggests that most IGRA conversions occur within four to seven weeks after TB exposure. However, in some cases conversion may be delayed longer than three months; agreement between TST and IGRA show better concordance after this window period [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/18/37160/abstract/49,50\">",
"     49,50",
"    </a>",
"    ]. These are important considerations for using IGRA to screen contacts of a TB patient. Based on limited evidence, a six- to eight-week period can be used for repeat IGRA screening after last known TB exposure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H82128991\">",
"    <span class=\"h3\">",
"     Monitoring therapeutic response",
"    </span>",
"    &nbsp;&mdash;&nbsp;IGRAs should not be used to monitor response to TB therapy; studies in this area are inconsistent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/18/37160/abstract/51-53\">",
"     51-53",
"    </a>",
"    ]. Some data suggest that a large percentage of active TB patients become IGRA negative by the end of TB therapy, while other studies do not support this. Some data suggest that TB patients can remain IGRA positive, even years after TB treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4852053\">",
"    <span class=\"h2\">",
"     Use in low- and middle-income countries",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ECDC guidelines state that in high-TB incidence countries, there is no added value in using IGRAs to diagnose LTBI, as the focus of prevention and control is to identify and treat active cases. Available evidence suggests that TST and IGRA have similar accuracy and performance in low- and middle-income countries as in developed settings, and there is no evidence that IGRA is superior to TST in these settings [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/18/37160/abstract/2,12,13\">",
"     2,12,13",
"    </a>",
"    ]. In particular, both tests have similar and only modest predictive value in high-burden settings [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/18/37160/abstract/21\">",
"     21",
"    </a>",
"    ]. While either IGRA or TST could be used to diagnose LTBI, the TST might be the most feasible option in low and middle income countries because of its lower cost. Neither IGRA nor TST should be used for diagnosis of active TB diagnosis in high TB burden settings.",
"   </p>",
"   <p>",
"    The WHO advises against the use of both IGRAs and TST for diagnosis of active TB in low and middle income countries. Neither IGRAs nor the TST should be used for the diagnosis of active TB disease; neither test can accurately predict the risk of infected individuals developing active TB disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/18/37160/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4850512\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Interferon gamma release assays (IGRAs) are diagnostic tools for latent tuberculosis infection (LTBI). They are in vitro blood tests of cell-mediated immune response to Mycobacterium tuberculosis and measure T cell release of interferon-gamma (IFN-gamma) following stimulation by antigens specific to M. tuberculosis. (See",
"      <a class=\"local\" href=\"#H365757202\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      IGRAs are not affected by Bacille Calmette-Gu&eacute;rin (BCG) vaccination status. Therefore, they are superior to the",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?15/35/15924?source=see_link\">",
"       tuberculin skin test",
"      </a>",
"      (TST) for evaluation of LTBI in BCG-vaccinated individuals, since TST specificity varies depending on the timing and number of BCG vaccination. (See",
"      <a class=\"local\" href=\"#H4851314\">",
"       'Overview of IGRAs'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are two major IGRAs available: the QuantiFERON-TB Gold In-Tube (QFT-GIT) assay and the T-SPOT.TB assay. QFT-GIT is an ELISA-based whole blood test. T-SPOT.TB is an enzyme-linked immunospot (ELISPOT) performed on separated peripheral blood mononuclear cells (PBMCs). (See",
"      <a class=\"local\" href=\"#H4850561\">",
"       'Types of assays'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      IGRAs have specificity &gt;95 percent for diagnosis of LTBI. IGRAs are preferred for patients with history of BCG vaccination, especially in countries where BCG is given after infancy or repeated. (See",
"      <a class=\"local\" href=\"#H365757209\">",
"       'Use'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The sensitivity for T-SPOT.TB appears to be higher than for QFT-GIT or TST, likely because the testing platform ensures that an adequate number of peripheral blood mononuclear cells are available even in the presence of low lymphocyte cell counts in whole blood. (See",
"      <a class=\"local\" href=\"#H4851487\">",
"       'Sensitivity and specificity'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The United States Centers for Disease Control and Prevention (CDC) 2010 guidelines indicate that IGRAs can be used in place of TST in all situations in which CDC recommends TST as an aid in diagnosing M. tuberculosis infection. IGRAs are preferred for patients with history of BCG vaccination, and for individuals from groups that historically have poor rates of return for TST reading; TST is preferred for testing children under five years of age. (See",
"      <a class=\"local\" href=\"#H365757216\">",
"       'United States guidelines'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The Canadian TB Committee guidelines indicate that use of IGRA as a confirmatory tool may be useful for settings in which false negative or false positive TST results are suspected. (See",
"      <a class=\"local\" href=\"#H365757223\">",
"       'Canadian guidelines'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      IGRAs cannot distinguish between latent infection and active TB disease, and should not be used for diagnosis of active TB in adults. In children, IGRA may be used as a supplementary diagnostic tool for evaluation of active TB disease, although evidence for use of IGRAs in children is limited. A negative IGRA does not rule out active TB at any age. (See",
"      <a class=\"local\" href=\"#H4851314\">",
"       'Overview of IGRAs'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H365757223\">",
"       'Canadian guidelines'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For serial testing in populations exposed to TB, data are insufficient for interpretation of IGRA conversions and reversions. While the Canadian guidelines favor use of TST in this setting, the United States guidelines indicate that either TST or IGRA may be used (",
"      <a class=\"graphic graphic_table graphicRef76107 \" href=\"mobipreview.htm?15/7/15484\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H365757254\">",
"       'Serial testing'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/18/37160/abstract/1\">",
"      Menzies D, Pai M, Comstock G. Meta-analysis: new tests for the diagnosis of latent tuberculosis infection: areas of uncertainty and recommendations for research. Ann Intern Med 2007; 146:340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/18/37160/abstract/2\">",
"      Pai M, Zwerling A, Menzies D. Systematic review: T-cell-based assays for the diagnosis of latent tuberculosis infection: an update. Ann Intern Med 2008; 149:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/18/37160/abstract/3\">",
"      van Zyl-Smit RN, Zwerling A, Dheda K, Pai M. Within-subject variability of interferon-g assay results for tuberculosis and boosting effect of tuberculin skin testing: a systematic review. PLoS One 2009; 4:e8517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/18/37160/abstract/4\">",
"      Chang KC, Leung CC. Systematic review of interferon-gamma release assays in tuberculosis: focus on likelihood ratios. Thorax 2010; 65:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/18/37160/abstract/5\">",
"      Mazurek GH, Jereb J, Vernon A, et al. Updated guidelines for using Interferon Gamma Release Assays to detect Mycobacterium tuberculosis infection - United States, 2010. MMWR Recomm Rep 2010; 59:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/18/37160/abstract/6\">",
"      Canadian Tuberculosis Committee. Recommendations on Interferon Gamma Release Assays for the Diagnosis of Latent Tuberculosis Infection - 2010 Update. Can Commun Dis Rep 2010; 36:1.",
"     </a>",
"    </li>",
"    <li>",
"     Tuberculosis. In: Red Book, American Academy of Pediatrics, 2009. file://aapredbook.aappublications.org/ (Accessed on September 22, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/18/37160/abstract/8\">",
"      Zwerling A, van den Hof S, Scholten J, et al. Interferon-gamma release assays for tuberculosis screening of healthcare workers: a systematic review. Thorax 2012; 67:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/18/37160/abstract/9\">",
"      Cattamanchi A, Smith R, Steingart KR, et al. Interferon-gamma release assays for the diagnosis of latent tuberculosis infection in HIV-infected individuals: a systematic review and meta-analysis. J Acquir Immune Defic Syndr 2011; 56:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/18/37160/abstract/10\">",
"      Machingaidze S, Wiysonge CS, Gonzalez-Angulo Y, et al. The utility of an interferon gamma release assay for diagnosis of latent tuberculosis infection and disease in children: a systematic review and meta-analysis. Pediatr Infect Dis J 2011; 30:694.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/18/37160/abstract/11\">",
"      Smith R, Cattamanchi A, Steingart KR, et al. Interferon-&gamma; release assays for diagnosis of latent tuberculosis infection: evidence in immune-mediated inflammatory disorders. Curr Opin Rheumatol 2011; 23:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/18/37160/abstract/12\">",
"      Metcalfe JZ, Everett CK, Steingart KR, et al. Interferon-&gamma; release assays for active pulmonary tuberculosis diagnosis in adults in low- and middle-income countries: systematic review and meta-analysis. J Infect Dis 2011; 204 Suppl 4:S1120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/18/37160/abstract/13\">",
"      Sester M, Sotgiu G, Lange C, et al. Interferon-&gamma; release assays for the diagnosis of active tuberculosis: a systematic review and meta-analysis. Eur Respir J 2011; 37:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/18/37160/abstract/14\">",
"      Zwerling A, Behr MA, Verma A, et al. The BCG World Atlas: a database of global BCG vaccination policies and practices. PLoS Med 2011; 8:e1001012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/18/37160/abstract/15\">",
"      Adams LV, Waddell RD, Von Reyn CF. T-SPOT.TB Test(R) results in adults with Mycobacterium avium complex pulmonary disease. Scand J Infect Dis 2008; 40:196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/18/37160/abstract/16\">",
"      Andersen P, Munk ME, Pollock JM, Doherty TM. Specific immune-based diagnosis of tuberculosis. Lancet 2000; 356:1099.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/18/37160/abstract/17\">",
"      Arend SM, van Meijgaarden KE, de Boer K, et al. Tuberculin skin testing and in vitro T cell responses to ESAT-6 and culture filtrate protein 10 after infection with Mycobacterium marinum or M. kansasii. J Infect Dis 2002; 186:1797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/18/37160/abstract/18\">",
"      Lewis FM, Marsh BJ, von Reyn CF. Fish tank exposure and cutaneous infections due to Mycobacterium marinum: tuberculin skin testing, treatment, and prevention. Clin Infect Dis 2003; 37:390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/18/37160/abstract/19\">",
"      Wallis RS, Pai M, Menzies D, et al. Biomarkers and diagnostics for tuberculosis: progress, needs, and translation into practice. Lancet 2010; 375:1920.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/18/37160/abstract/20\">",
"      Pai M. Spectrum of latent tuberculosis - existing tests cannot resolve the underlying phenotypes. Nat Rev Microbiol 2010; 8:242; author reply 242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/18/37160/abstract/21\">",
"      Rangaka MX, Wilkinson KA, Glynn JR, et al. Predictive value of interferon-&gamma; release assays for incident active tuberculosis: a systematic review and meta-analysis. Lancet Infect Dis 2012; 12:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/18/37160/abstract/22\">",
"      Bakir M, Millington KA, Soysal A, et al. Prognostic value of a T-cell-based, interferon-gamma biomarker in children with tuberculosis contact. Ann Intern Med 2008; 149:777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/18/37160/abstract/23\">",
"      del Corral H, Par&iacute;s SC, Mar&iacute;n ND, et al. IFNgamma response to Mycobacterium tuberculosis, risk of infection and disease in household contacts of tuberculosis patients in Colombia. PLoS One 2009; 4:e8257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/18/37160/abstract/24\">",
"      Hill PC, Jackson-Sillah DJ, Fox A, et al. Incidence of tuberculosis and the predictive value of ELISPOT and Mantoux tests in Gambian case contacts. PLoS One 2008; 3:e1379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/18/37160/abstract/25\">",
"      Lienhardt C, Fielding K, Hane AA, et al. Evaluation of the prognostic value of IFN-gamma release assay and tuberculin skin test in household contacts of infectious tuberculosis cases in Senegal. PLoS One 2010; 5:e10508.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/18/37160/abstract/26\">",
"      Mahomed H, Hawkridge T, Verver S, et al. The tuberculin skin test versus QuantiFERON TB Gold&reg; in predicting tuberculosis disease in an adolescent cohort study in South Africa. PLoS One 2011; 6:e17984.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/18/37160/abstract/27\">",
"      Pai M, Minion J, Sohn H, et al. Novel and improved technologies for tuberculosis diagnosis: progress and challenges. Clin Chest Med 2009; 30:701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/18/37160/abstract/28\">",
"      Denkinger CM, Dheda K, Pai M. Guidelines on interferon-&gamma; release assays for tuberculosis infection: concordance, discordance or confusion? Clin Microbiol Infect 2011; 17:806.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.tstin3d.com (Accessed on September 01, 2010).",
"    </li>",
"    <li>",
"     National Institute for Health and Clinical Excellence. Clinical Guideline 33. Tuberculosis: clinical diagnosis and management of tuberculosis, and measures for its prevention and control. Vol. 2006. London: NICE, 2006. file://www.nice.org.uk/page.aspx?o=CG033NICEguideline (Accessed on August 16, 2010).",
"    </li>",
"    <li>",
"     National Institute for Health and Clinical Excellence. Clinical guideline 17. Tuberculosis: clinical diagnosis and management of tuberculosis, and measures for its prevention and control. London: NICE, 2011. file://www.nice.org.uk/nicemedia/live/13422/53642/53642.pdf.",
"    </li>",
"    <li>",
"     European Center for Disease Prevention and Control. Use of interferon-gamma release assays in support of TB diagnosis. Stockholm, 2011. file://ecdc.europa.eu/en/publications/Publications/1103_GUI_IGRA.pdf (Accessed on May 16, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/18/37160/abstract/33\">",
"      Mandalakas AM, Detjen AK, Hesseling AC, et al. Interferon-gamma release assays and childhood tuberculosis: systematic review and meta-analysis. Int J Tuberc Lung Dis 2011; 15:1018.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/18/37160/abstract/34\">",
"      Menzies D. Interpretation of repeated tuberculin tests. Boosting, conversion, and reversion. Am J Respir Crit Care Med 1999; 159:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/18/37160/abstract/35\">",
"      Pai M, O'Brien R. Serial testing for tuberculosis: can we make sense of T cell assay conversions and reversions? PLoS Med 2007; 4:e208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/18/37160/abstract/36\">",
"      Fong KS, Tomford JW, Teixeira L, et al. Challenges of interferon-&gamma; release assay conversions in serial testing of health-care workers in a TB control program. Chest 2012; 142:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/18/37160/abstract/37\">",
"      Joshi M, Monson TP, Woods GL. Use of interferon-gamma release assays in a health care worker screening program: experience from a tertiary care centre in the United States. Can Respir J 2012; 19:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/18/37160/abstract/38\">",
"      Pai M, Elwood K. Interferon-gamma release assays for screening of health care workers in low tuberculosis incidence settings: dynamic patterns and interpretational challenges. Can Respir J 2012; 19:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/18/37160/abstract/39\">",
"      Zwerling A, van den Hof S, Scholten J, et al. Interferon-gamma release assays for tuberculosis screening of healthcare workers: a systematic review. Thorax 2012; 67:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/18/37160/abstract/40\">",
"      Loddenkemper R, Diel R, Nienhaus A. To repeat or not to repeat-that is the question!: Serial testing of health-care workers for TB infection. Chest 2012; 142:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/18/37160/abstract/41\">",
"      Canadian Tuberculosis Committee (CTC). Updated recommendations on interferon gamma release assays for latent tuberculosis infection. An Advisory Committee Statement (ACS). Can Commun Dis Rep 2008; 34:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/18/37160/abstract/42\">",
"      Doberne D, Gaur RL, Banaei N. Preanalytical delay reduces sensitivity of QuantiFERON-TB gold in-tube assay for detection of latent tuberculosis infection. J Clin Microbiol 2011; 49:3061.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/18/37160/abstract/43\">",
"      Metcalfe JZ, Cattamanchi A, McCulloch CE, et al. Test variability of the QuantiFERON-TB gold in-tube assay in clinical practice. Am J Respir Crit Care Med 2013; 187:206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/18/37160/abstract/44\">",
"      Whitworth WC, Hamilton LR, Goodwin DJ, et al. Within-subject interlaboratory variability of QuantiFERON-TB gold in-tube tests. PLoS One 2012; 7:e43790.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/18/37160/abstract/45\">",
"      Park JS, Lee JS, Kim MY, et al. Monthly follow-ups of interferon-&gamma; release assays among health-care workers in contact with patients with TB. Chest 2012; 142:1461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/18/37160/abstract/46\">",
"      Pai M. Serial testing with TB interferon-&gamma; release assays: toward a nuanced understanding. Chest 2012; 142:1366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/18/37160/abstract/47\">",
"      Pai M, Dheda K, Cunningham J, et al. T-cell assays for the diagnosis of latent tuberculosis infection: moving the research agenda forward. Lancet Infect Dis 2007; 7:428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/18/37160/abstract/48\">",
"      Pai M, Lewinsohn DM. Interferon-gamma assays for tuberculosis: is anergy the Achilles' heel? Am J Respir Crit Care Med 2005; 172:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/18/37160/abstract/49\">",
"      Anibarro L, Trigo M, Villaverde C, et al. Tuberculin skin test and interferon-&gamma; release assay show better correlation after the tuberculin 'window period' in tuberculosis contacts. Scand J Infect Dis 2011; 43:424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/18/37160/abstract/50\">",
"      Lee SW, Oh DK, Lee SH, et al. Time interval to conversion of interferon-gamma release assay after exposure to tuberculosis. Eur Respir J 2011; 37:1447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/18/37160/abstract/51\">",
"      Adetifa IM, Ota MO, Walther B, et al. Decay kinetics of an interferon gamma release assay with anti-tuberculosis therapy in newly diagnosed tuberculosis cases. PLoS One 2010; 5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/18/37160/abstract/52\">",
"      Bocchino M, Chairadonna P, Matarese A, et al. Limited usefulness of QuantiFERON-TB Gold In-Tube for monitoring anti-tuberculosis therapy. Respir Med 2010; 104:1551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/18/37160/abstract/53\">",
"      Chee CB, KhinMar KW, Gan SH, et al. Tuberculosis treatment effect on T-cell interferon-gamma responses to Mycobacterium tuberculosis-specific antigens. Eur Respir J 2010; 36:355.",
"     </a>",
"    </li>",
"    <li>",
"     World Health Organization. The use of tuberculosis interferon-gamma release assays (IGRAs) in low- and middle-income countries. Policy Statement. Geneva, WHO, 2011 file://www.who.int/tb/features_archive/igra_policy24oct/en/index.html (Accessed on October 19, 2011).",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15352 Version 17.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-202.43.93.2-77D3A94D3A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_18_37160=[""].join("\n");
var outline_f36_18_37160=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H4850512\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H365757202\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4851314\">",
"      OVERVIEW OF IGRAs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4850554\">",
"      Assay antigens",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4850561\">",
"      Types of assays",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4851487\">",
"      Sensitivity and specificity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H454305591\">",
"      Prediction of active disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H365757209\">",
"      USE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2194407\">",
"      Guidelines",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H365757216\">",
"      - United States guidelines",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H365757223\">",
"      - Canadian guidelines",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H365757230\">",
"      - United Kingdom guidelines",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2507724\">",
"      - European guidelines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H365757238\">",
"      Children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H365757254\">",
"      Serial testing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19560072\">",
"      - Reproducibility",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4852034\">",
"      Limitations of IGRAs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H82128982\">",
"      - Indeterminate results",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17249216\">",
"      - Window period",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H82128991\">",
"      - Monitoring therapeutic response",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4852053\">",
"      Use in low- and middle-income countries",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4850512\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/15352\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/15352|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?15/7/15484\" title=\"table 1\">",
"      TST vs IGRA comparison",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?38/36/39502\" title=\"table 2\">",
"      Active TB risk factors",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/46/12009?source=related_link\">",
"      Diagnosis of latent tuberculosis infection in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/10/20648?source=related_link\">",
"      Diagnosis of latent tuberculosis infection in HIV-negative adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/56/9098?source=related_link\">",
"      Diagnosis of pulmonary tuberculosis in HIV-negative patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/53/13143?source=related_link\">",
"      Latent tuberculosis infection in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/4/23625?source=related_link\">",
"      Tuberculosis disease in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_18_37161="Periocular atopic dermatitis";
var content_f36_18_37161=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F75681%7EDERM%2F56815&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F75681%7EDERM%2F56815&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Atopic dermatitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Erythematous plaques with fine scale are present on the periocular skin in this patient with atopic dermatitis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Atopic dermatitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Slightly lichenified dermatitic plaques are present on the face. Erythema is subtle in this dark-skinned patient.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_18_37161=[""].join("\n");
var outline_f36_18_37161=null;
var title_f36_18_37162="Pharmacology of non-nucleoside reverse transcriptase inhibitors";
var content_f36_18_37162=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pharmacology of non-nucleoside reverse transcriptase inhibitors",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/18/37162/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/18/37162/contributors\">",
"     Amy L Graziani, PharmD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/18/37162/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/18/37162/contributors\">",
"     John G Bartlett, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/18/37162/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/18/37162/contributors\">",
"     Allyson Bloom, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?36/18/37162/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 25, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The non-nucleoside reverse transcriptase inhibitors (NNRTIs) are a class of potent oral antiretroviral (ARV) drugs that are very effective in reducing HIV-1 viremia and in improving CD4 counts. They are listed as first line agents for HIV-1-infected, antiretroviral-na&iuml;ve patients in both the Department of Health and Human Services (DHHS) and International Antiviral Society (IAS)-USA HIV treatment guidelines for adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/18/37162/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. They are not active against HIV-2.",
"   </p>",
"   <p>",
"    There are currently three first generation NNRTIs (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/12/18633?source=see_link\">",
"     nevirapine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/10/27816?source=see_link\">",
"     delavirdine",
"    </a>",
"    ) and two second generation, diarylpyrimidine (DAPY) NNRTIs (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/0/13320?source=see_link\">",
"     etravirine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15798?source=see_link\">",
"     rilpivirine",
"    </a>",
"    ) available for use.",
"   </p>",
"   <p>",
"    The pharmacology and side effects of these antiretroviral medications will be discussed here. Information regarding the appropriate use of these drugs in combination therapy and patient counseling and monitoring is available elsewhere. Furthermore, information on drug resistance is also discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/24/36234?source=see_link\">",
"     \"Selecting antiretroviral regimens for the treatment naive HIV-infected patient\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/61/986?source=see_link\">",
"     \"Counseling HIV-infected patients regarding potential side effects of antiretroviral therapy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/17/38167?source=see_link\">",
"     \"Patient monitoring during HIV antiretroviral therapy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/26/34218?source=see_link\">",
"     \"Primer on interpretation of HIV drug resistance testing\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GENERAL PRINCIPLES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following class of drugs are potent inhibitors of HIV-1 replication and are usually administered in combination with at least two other antiretroviral agents (eg, two nucleoside analogs). They are active against HIV-1 but are not active against HIV-2. There are important differences between the various agents that may influence treatment decisions in individual patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Pharmacologic profile",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are differences in absorption, serum half-lives, dosing frequency, and potential adverse events among the different non-nucleoside reverse transcriptase inhibitors (NNRTIs) that are discussed in detail below and also summarized in Appendix B, Table 2 of the",
"    <a class=\"external\" href=\"file://aidsinfo.nih.gov/guidelines\">",
"     DHHS Antiretroviral Guidelines for the Treatment of Adults and Adolescents",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Resistance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Resistance profiles will strongly influence treatment decisions.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/42/29353?source=see_link\">",
"     Efavirenz",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/12/18633?source=see_link\">",
"     nevirapine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/10/27816?source=see_link\">",
"     delavirdine",
"    </a>",
"    share the same major mutational patterns; for example, the presence of K103N would confer broad resistance to any of these agents. However,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/0/13320?source=see_link\">",
"     etravirine",
"    </a>",
"    would still have activity against a viral isolate with this particular mutation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/18/37162/abstract/3\">",
"     3",
"    </a>",
"    ]. In contrast, phenotypic resistance to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15798?source=see_link\">",
"     rilpivirine",
"    </a>",
"    is associated with wide NNRTI cross-resistance, including etravirine. Issues related to drug resistance are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/26/34218?source=see_link\">",
"     \"Primer on interpretation of HIV drug resistance testing\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A specific concern related to the NNRTIs is the potential for rapid development of drug resistance and cross resistance when an NNRTI-containing antiretroviral regimen is discontinued. Due to the long serum half-lives (referred to as \"the tail\"), when an NNRTI-containing antiretroviral combination regimen is discontinued, functional NNRTI monotherapy occurs, increasing the risk of developing NNRTI drug resistance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/18/37162/abstract/4\">",
"     4",
"    </a>",
"    ]. For example, 5 of 18 patients who discontinued a",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/12/18633?source=see_link\">",
"     nevirapine",
"    </a>",
"    -containing regimen had detectable levels of nevirapine for an additional seven days [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/18/37162/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some experts suggest that when stopping a regimen that contains either",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/12/18633?source=see_link\">",
"     nevirapine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    , the concomitant nucleoside backbone should be continued for three to seven days after discontinuation of the NNRTI or that a boosted protease inhibitor be substituted for the NNRTI for one week before discontinuing the nucleoside backbone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/18/37162/abstract/1,6\">",
"     1,6",
"    </a>",
"    ]. These relatively cumbersome stop strategies have not been well studied, and due to the variable serum and intracellular half-lives of both the NRTIs and the NNRTIs, it is difficult to recommend any one approach.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Drug interactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Use of NNRTIs can lead to drug interactions. Before prescribing or discontinuing NNRTIs, a thorough review of the patient's concomitant medications is needed. See below under specific drugs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Side effect profile",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are significant differences among agents in this class in terms of potential adverse events, which may play a role in drug selection. Patient-related issues in general drug selection is also discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/18/3370?source=see_link\">",
"     \"Considerations prior to initiating antiretroviral therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Abbreviations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abbreviations used in this topic are listed below followed by the trade name:",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/42/29353?source=see_link\">",
"     Efavirenz",
"    </a>",
"    EFV; Sustiva",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/12/18633?source=see_link\">",
"     Nevirapine",
"    </a>",
"    NVP; Viramune",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/10/27816?source=see_link\">",
"     Delavirdine",
"    </a>",
"    DLV; Rescriptor",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/0/13320?source=see_link\">",
"     Etravirine",
"    </a>",
"    ETV; Intelence",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15798?source=see_link\">",
"     Rilpivirine",
"    </a>",
"    ; Edurant",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     MECHANISM OF ACTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Non-nucleoside reverse transcriptase inhibitors (NNRTIs) prevent HIV-1 reverse transcriptase from adding new nucleotides to the growing DNA chain. The NNRTIs block viral cDNA elongation at a secondary allosteric site, which is separate from the active site that is targeted by the nucleoside reverse transcriptase inhibitor (NRTIs) class. The specific binding site on reverse transcriptase has been identified; the NNRTIs bind to a hydrophobic pocket in the palm subdomain of p66, approximately 10 angstroms from the polymerase active site [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/18/37162/abstract/7\">",
"     7",
"    </a>",
"    ]. This causes a stereochemical change in the protein, which reduces the ability of naturally occurring nucleosides to bind to the active site pocket. Reverse transcriptase becomes less flexible and DNA polymerization is inhibited. cDNA elongation is reduced, which ultimately leads to a decline in viral replication [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/18/37162/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     EFAVIRENZ (SUSTIVA)",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/42/29353?source=see_link\">",
"     Efavirenz",
"    </a>",
"    (Sustiva) is the most widely used of the non-nucleoside reverse transcriptase inhibitors (NNRTIs) and is one of the preferred agents for use in combination therapy for treatment-naive patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/18/37162/abstract/1\">",
"     1",
"    </a>",
"    ]. It is also available as a coformulation of Atripla, which also includes",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/15/5366?source=see_link\">",
"     emtricitabine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/24/36234?source=see_link\">",
"     \"Selecting antiretroviral regimens for the treatment naive HIV-infected patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Pharmacology/Pharmacokinetics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Like",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/12/18633?source=see_link\">",
"     nevirapine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/0/13320?source=see_link\">",
"     etravirine",
"    </a>",
"    , the serum half-life of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    is extremely long, 40 to 55 hours [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/18/37162/abstract/1\">",
"     1",
"    </a>",
"    ], and variable.",
"   </p>",
"   <p>",
"    Meals high in fat increase the peak plasma levels of the newer tablet formulation by 79 percent. For this reason, and because higher levels may predispose patients to more central nervous system (CNS) side effects, the product labeling states that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    should be taken on an empty stomach. Target total plasma concentrations identified to date for wild-type HIV include a Cmin &gt;1000",
"    <span class=\"nowrap\">",
"     ng/ml",
"    </span>",
"    and a Cmax &lt;4000",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/18/37162/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/42/29353?source=see_link\">",
"     Efavirenz",
"    </a>",
"    is highly protein bound to albumin (99.7 percent). Cerebral spinal fluid levels of efavirenz were demonstrated to be above the half maximal inhibitory concentration (IC50) for wild-type virus in 78 of 80 patients participating in an observational study of the effects of ART on HIV-associated neurological disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/18/37162/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/42/29353?source=see_link\">",
"     Efavirenz",
"    </a>",
"    is metabolized by cytochrome P4503A4 and 2B6 (CYP3A4, 2B6) and induces its own metabolism over the first two weeks of treatment. The glucuronide metabolite is inactive. The metabolites are excreted in the urine (14 to 34 percent) and feces (16 to 62 percent). No dosage adjustment is required in renal failure. The variability in the serum half-life may be due to genetic variations in CYP2B6 metabolism and may explain some of the CNS toxicity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/18/37162/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Side effects'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Pharmacogenetics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Polymorphisms in cytochrome (CYP) 2B6 can lead to increases or decreases in steady-state plasma concentrations of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/18/37162/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. For example, lower plasma efavirenz clearance is associated with a polymorphism of the CYP2B6 gene (ie, 516G--&gt;T), which is more frequent among African American individuals than among European American individuals. Increased serum concentrations of efavirenz can lead to higher rates of adverse events and increased risk of essential monotherapy with efavirenz when combination ART is discontinued. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Side effects'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/42/29353?source=see_link\">",
"     Efavirenz",
"    </a>",
"    is one of the most widely studied antiretroviral agents for the treatment of HIV infection. It is very effective in achieving viral suppression, including in patients with viral loads &gt;100,000",
"    <span class=\"nowrap\">",
"     copies/mL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/18/37162/abstract/15\">",
"     15",
"    </a>",
"    ]. Clinical trials have demonstrated that efavirenz plus two nucleoside analogs were superior virologically to some protease inhibitor-based regimens (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/62/19433?source=see_link\">",
"     nelfinavir",
"    </a>",
"    ) and to triple nucleoside analog regimens [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/18/37162/abstract/16-18\">",
"     16-18",
"    </a>",
"    ]. Finally, in a recent meta-analysis of 17,666 treatment-naive patients who participated in clinical trials, participants on efavirenz-containing regimens had the best overall clinical and virologic outcomes compared to other regimens [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/18/37162/abstract/19\">",
"     19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/4/9287?source=see_link\">",
"     \"Clinical trials of HIV antiretroviral therapy: Non-nucleoside reverse transcriptase inhibitors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Due to its potency, easy dosing (one tablet a day), and relatively favorable side effect profile, it is listed as one of the preferred agents for treatment of patients in both the Department of Health and Human Services (DHHS) and International Antiviral Society (IAS)-USA treatment guidelines [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/18/37162/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/24/36234?source=see_link\">",
"     \"Selecting antiretroviral regimens for the treatment naive HIV-infected patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Side effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/42/29353?source=see_link\">",
"     Efavirenz",
"    </a>",
"    is generally well tolerated, but several potential side effects are important to consider when deciding whether or not to use this agent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Neuropsychiatric side effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/42/29353?source=see_link\">",
"     Efavirenz",
"    </a>",
"    causes unusual CNS side effects in more than half of the patients taking this drug in open label trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/18/37162/abstract/20\">",
"     20",
"    </a>",
"    ]. For example, in one randomized clinical trial involving 303 HIV-infected patients, efavirenz was associated with more neurologic symptoms and sleep disturbances than other regimens that did not contain efavirenz [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/18/37162/abstract/21\">",
"     21",
"    </a>",
"    ]. Patients with sleep disturbance often reported vivid or bizarre dreams. However, no significant changes in mood were noted and most of these side effects resolved by one month of therapy.",
"   </p>",
"   <p>",
"    One of the most common symptoms after initiating",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    includes a \"hung-over\" feeling the following day after the first dose. Less commonly, efavirenz can lead to confusion, agitation, hallucinations, amnesia, euphoria, depression, suicidal ideation, paranoia, mania, aggressive behavior, and depersonalization. One study found that stepped dosing of efavirenz (200",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    stepped up weekly until full dosing achieved after 14 days) was associated with decreased rates of neuropsychiatric side effects compared with full-dose efavirenz [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/18/37162/abstract/22\">",
"     22",
"    </a>",
"    ]. However, the study had too few patients to detect small differences in treatment effectiveness and is not currently a recommended approach.",
"   </p>",
"   <p>",
"    High serum levels are associated with an increased risk for CNS side effects and high-fat meals increase the peak serum levels of the tablet formulation by 79 percent and the area under the curve concentrations (AUC) by 28 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/18/37162/abstract/1,11,23\">",
"     1,11,23",
"    </a>",
"    ]. Thus, an important strategy for minimizing CNS side effects is to take",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    on an empty stomach at least one hour before or two hours after food.",
"   </p>",
"   <p>",
"    Pharmacogenomic studies have identified a genetic predisposition to high",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    plasma levels and CNS side effects. In one study, 456 HIV-infected patients receiving efavirenz had CYP2B6 genotyping performed. Those with a G-to-T polymorphism at position 516G-to-T on the *6 and *26 allele had very high efavirenz levels over 6000",
"    <span class=\"nowrap\">",
"     ng/ml",
"    </span>",
"    (normal range 1000 to 4000",
"    <span class=\"nowrap\">",
"     ng/mL).",
"    </span>",
"    Twenty percent of African Americans have this cytochrome polymorphism. Presence of the CYP p450 2B6 variant reduces the ability to metabolize efavirenz, resulting in higher serum concentrations and increased CNS side effects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/18/37162/abstract/23\">",
"     23",
"    </a>",
"    ]. In contrast, only 3 percent of European-Americans have this variant allele. Future research is focused on identifying a clinical assay, which could give better guidance on dosing in this patient population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/18/37162/abstract/11,24\">",
"     11,24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    To minimize these central nervous system effects,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    should be administered at bedtime, at least two hours after food, particularly when therapy is first started. Because the CNS side effects can be quite dramatic in select patients and is worse after the first few doses, we counsel our patients to start their therapy when they will have a few days off from work",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    from their general life responsibilities. If the patient has children, having a friend or family member available to help with child care during the first few days of therapy can be helpful. Patients can be counseled that side effects typically dissipate slowly over the first two to four weeks of therapy. Bedtime dosing may also be helpful as patients may sleep through some of the CNS effects. Conversely, if patients have bothersome sleep disturbances that do not abate over the first few days, daytime dosing can be attempted.",
"   </p>",
"   <p>",
"    Occasionally, in approximately 2 to 5 percent of patients, the symptoms persist and therapy must be changed. Case reports have suggested that some of these patients may be those with the CYP 2B6 polymorphism resulting in excessively high serum concentrations (see above). If so, checking a trough serum level",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    CYP 2B6 genotype might be helpful [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/18/37162/abstract/24\">",
"     24",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Pharmacogenetics'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Other side effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other side effects include rash (rarely Stevens-Johnson syndrome), gynecomastia, teratogenicity, fat redistribution, and dyslipidemia, although lipid abnormalities are typically less than with PI-based regimens [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/18/37162/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/42/29353?source=see_link\">",
"     Efavirenz",
"    </a>",
"    can also cause hepatotoxicity; in a prospective study of 321 patients, the incidence of efavirenz-related drug injury was approximately 8 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/18/37162/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients who are being monitored for random drug testing need to be advised that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    can cause a false positive screening test for cannabinoid",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    benzodiazepine use [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/18/37162/abstract/27,28\">",
"     27,28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11300390\">",
"    <span class=\"h3\">",
"     Hypovitaminosis D",
"    </span>",
"    &nbsp;&mdash;&nbsp;In observational studies and controlled trials,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    has been associated with an increased risk of vitamin D insufficiency [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/18/37162/abstract/29-31\">",
"     29-31",
"    </a>",
"    ]. However, these studies did not assess the clinical significance of vitamin D insufficiency (eg, low bone mineral density, fracture risk, muscle weakness). One proposed mechanism by which efavirenz may be associated with hypovitaminosis D is its induction of the conversion of 25(OH)D to calcitroic acid via CYP3A4. Polymorphisms in efavirenz pharmacokinetics or vitamin D metabolism may affect susceptibility to these effects. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/35/32313?source=see_link\">",
"     \"Bone and calcium disorders in HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Use in pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/42/29353?source=see_link\">",
"     Efavirenz",
"    </a>",
"    administration results in significant teratogenic effects in animals. In preclinical studies, 3 of 10 cynomolgus monkeys developed serious neural tube defects including anencephaly, microphthalmia, and anophthalmia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/18/37162/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a South African registry of 623 women who were exposed to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    during pregnancy, no increased risk of birth defects was noted; however, only 183 of these women were exposed during the first trimester so the study was underpowered to assess safety of efavirenz in early fetal development [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/18/37162/abstract/32\">",
"     32",
"    </a>",
"    ]. In a meta-analysis of 1132 pregnant women exposed to efavirenz and 7163 women exposed to non-efavirenz containing ART, no increased risk of birth defects was noted, although the limited sample size prevented any firm conclusions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/18/37162/abstract/33\">",
"     33",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    There are at least eight case reports of neural tube abnormalities in babies born to women with first trimester exposure to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/18/37162/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/42/29353?source=see_link\">",
"     Efavirenz",
"    </a>",
"    has been rated as a Category D drug in pregnancy by the US Food and Drug Administration (FDA); it should be avoided in women who are pregnant or are considering pregnancy, and in women who are of child bearing potential and who are not using reliable birth control consistently. Pregnancy should be avoided for at least 12 weeks after efavirenz has been discontinued. The DHHS perinatal guideline committee suggests that efavirenz may be considered after the first trimester if there are no other viable options and the benefits outweigh the risks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/18/37162/abstract/34\">",
"     34",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/44/25290?source=see_link&amp;anchor=H329145#H329145\">",
"     \"Use of antiretroviral medications in pregnant HIV-infected patients and their infants in resource-rich settings\", section on 'Preferred non-nucleoside reverse transcriptase inhibitors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Drug interactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/42/29353?source=see_link\">",
"     Efavirenz",
"    </a>",
"    , like most other NNRTIs and protease inhibitors, has the potential to cause many drug interactions due to CYP p450 enzyme activity. It most often acts as a CYP 3A4 inducer but can also inhibit CYP3A4, 2C9 and 2C19. For detailed information about NNRTI drug interactions, see table 14, 15B, and 16B of the",
"    <a class=\"external\" href=\"file://aidsinfo.nih.gov/guidelines\">",
"     DHHS Antiretroviral Guidelines for the Treatment of Adults and Adolescents",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    For example, its ability to induce CYP 3A4 is the presumed mechanism by which it can lower levels of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    by up to 77 percent; concomitant use is not recommended. It can also reduce serum levels of the following drugs by 35 to 60 percent:",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/63/32760?source=see_link\">",
"     rifabutin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/57/10138?source=see_link\">",
"     clarithromycin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/37/35417?source=see_link\">",
"     atorvastatin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/36/17993?source=see_link\">",
"     simvastatin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/57/36761?source=see_link\">",
"     methadone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/10/25770?source=see_link\">",
"     carbamazepine",
"    </a>",
"    , and other anticonvulsants. Conversely,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    can lead to an increase in ethinyl estradiol levels by 37 percent.",
"   </p>",
"   <p>",
"    Concomitant drugs can also lead to changes in",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    levels. For example,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/48/35594?source=see_link\">",
"     phenytoin",
"    </a>",
"    can reduce efavirenz levels, which could result in rebound viremia and drug resistance, whereas",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    can increase efavirenz levels 44 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/18/37162/abstract/1\">",
"     1",
"    </a>",
"    ]. Before initiation of efavirenz, the clinician should thoroughly scrutinize other concomitant drugs that are being administered. In addition, unrecognized drug interactions should be considered in patients who are discontinuing efavirenz due to side effects.",
"   </p>",
"   <p>",
"    This is only a partial list of drug interactions. Additional information can be found in the product labeling and in other topics. (See",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/42/29353?source=see_link\">",
"     \"Efavirenz: Drug information\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Formulations and dosing",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/42/29353?source=see_link\">",
"     Efavirenz",
"    </a>",
"    was initially approved in 1998 for the treatment of HIV. In July 2006, efavirenz became available in the United States as a coformulated product (Atripla) with two nucleoside reverse transcriptase inhibitors (NRTIs),",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/15/5366?source=see_link\">",
"     emtricitabine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    , combined in one pill. This once-daily coformulation was a remarkable advance for patients, who often had to take 10 to 15 pills per day over three to five dosing intervals during the early 1990s.",
"   </p>",
"   <p>",
"    Atripla is a particularly good choice for patients coinfected with HIV and hepatitis B virus (HBV) since both",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/15/5366?source=see_link\">",
"     emtricitabine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    have dual activity against HIV and HBV. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/51/16185?source=see_link\">",
"     \"Treatment of hepatitis B in the HIV-infected patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Usual adult dosing",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/42/29353?source=see_link\">",
"       Efavirenz",
"      </a>",
"      (Sustiva) 600 mg tablet: one tablet, at bedtime, on an empty stomach.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/42/29353?source=see_link\">",
"       Efavirenz",
"      </a>",
"      600",
"      <span class=\"nowrap\">",
"       mg/",
"       <a class=\"drug drug_general\" href=\"mobipreview.htm?5/15/5366?source=see_link\">",
"        emtricitabine",
"       </a>",
"      </span>",
"      200",
"      <span class=\"nowrap\">",
"       mg/",
"       <a class=\"drug drug_general\" href=\"mobipreview.htm?18/47/19191?source=see_link\">",
"        tenofovir",
"       </a>",
"      </span>",
"      300 mg (Atripla): One tablet, at bedtime, on an empty stomach.",
"     </li>",
"     <li>",
"      Also available:",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/42/29353?source=see_link\">",
"       efavirenz",
"      </a>",
"      50 mg, 100 mg, and 200 mg capsules. No liquid formulation is available yet in the United States.",
"     </li>",
"     <li>",
"      Liquid: No liquid formulation is commercially available in the United States; however, it can be obtained for pediatric use only, via a Pediatric Expanded Access protocol (877-372-7097). A liquid formulation is available commercially in the Netherlands.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In healthy adults who have difficulty swallowing capsules, the contents of three 200 mg",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    capsules sprinkled on top of 2 teaspoons of applesauce, grape jelly, or yogurt was bioequivalent to three 200 mg capsules of efavirenz taken on an empty stomach [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/18/37162/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Renal insufficiency",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      No dosing adjustment is necessary for",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/42/29353?source=see_link\">",
"       efavirenz",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/18/37162/abstract/1,36\">",
"       1,36",
"      </a>",
"      ]. However, the efavirenz-",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?5/15/5366?source=see_link\">",
"       emtricitabine",
"      </a>",
"      -",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?18/47/19191?source=see_link\">",
"       tenofovir",
"      </a>",
"      coformulated product, Atripla, should not be given to patients with CrCl &lt;50",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      because the tenofovir component requires dose reduction in this patient subset.",
"     </li>",
"     <li>",
"      Hemodialysis and CAPD do not significantly affect",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/42/29353?source=see_link\">",
"       efavirenz",
"      </a>",
"      levels [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/18/37162/abstract/37,38\">",
"       37,38",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Hepatic insufficiency",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There are limited reports of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/42/29353?source=see_link\">",
"       efavirenz",
"      </a>",
"      use in patients with liver disease and the data are conflicting. In one pharmacokinetic study, 10 volunteers with chronic liver disease had efavirenz AUCs that were similar to those with normal liver function [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/18/37162/abstract/39\">",
"       39",
"      </a>",
"      ]. In a case report, two patients with hepatic dysfunction had high efavirenz levels and the authors state that dose reduction may be required [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/18/37162/abstract/40\">",
"       40",
"      </a>",
"      ]. In a more recent report, HIV-infected patients with Hepatitis B or C and mild, Child-Pugh 5-6 hepatic dysfunction did not develop elevated efavirenz levels [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/18/37162/abstract/41\">",
"       41",
"      </a>",
"      ]. The product labeling and DHHS guidelines state: \"No data are available; use with caution\" in patients with liver disease [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/18/37162/abstract/1,36\">",
"       1,36",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?12/29/12759?source=see_link\">",
"       \"Dose modification of antiretroviral agents in adults with renal or hepatic dysfunction\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     NEVIRAPINE (VIRAMUNE)",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/12/18633?source=see_link\">",
"     Nevirapine",
"    </a>",
"    (Viramune), like",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    , is a potent agent for the treatment of HIV. In the 2NN trial, nevirapine combined with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/45/43734?source=see_link\">",
"     stavudine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    resulted in similar rates of viral suppression as efavirenz-based combination therapy (66 versus 70 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/18/37162/abstract/42\">",
"     42",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/4/9287?source=see_link\">",
"     \"Clinical trials of HIV antiretroviral therapy: Non-nucleoside reverse transcriptase inhibitors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, due to its toxicity profile, the Department of Health and Human Services (DHHS) has listed",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/12/18633?source=see_link\">",
"     nevirapine",
"    </a>",
"    as an alternative to the preferred non-nucleoside reverse transcriptase inhibitor (NNRTI),",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    , for treatment-na&iuml;ve patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/18/37162/abstract/1\">",
"     1",
"    </a>",
"    ]. Furthermore, the administration of nevirapine is relegated to carefully defined patient subgroups. Specifically, nevirapine should not be given to women with CD4 counts &gt;250 and men with CD4 counts &gt;400",
"    <span class=\"nowrap\">",
"     mL/mm",
"     <sup>",
"      3",
"     </sup>",
"     .",
"    </span>",
"    The rationale for these parameters is discussed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Pharmacology/pharmacokinetics",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/12/18633?source=see_link\">",
"     Nevirapine",
"    </a>",
"    is a dipyridodiazepinone derivative structurally related to the benzodiazepines. It has a long serum half-life of approximately 25 to 30 hours. Meals high in fat do not significantly affect nevirapine plasma levels, and therefore nevirapine may be administered with or without food [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/18/37162/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    After a single 200 mg dose, peak",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/12/18633?source=see_link\">",
"     nevirapine",
"    </a>",
"    levels (at four hours) were approximately 2",
"    <span class=\"nowrap\">",
"     ug/mL",
"    </span>",
"    (7.5 uM). Nevirapine levels increase linearly during repeated dosing such that trough nevirapine concentrations at steady state (400 mg daily) were 4.5",
"    <span class=\"nowrap\">",
"     +/-",
"    </span>",
"    1.9",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    (17 + 7 uM) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/18/37162/abstract/43\">",
"     43",
"    </a>",
"    ]. The IC50 for laboratory and clinical isolates is 10-100 nM [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/18/37162/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/12/18633?source=see_link\">",
"     Nevirapine",
"    </a>",
"    is not as highly protein bound as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/0/13320?source=see_link\">",
"     etravirine",
"    </a>",
"    ; it is only 60 percent bound to plasma proteins. In a small study of six patients, CSF levels were approximately 45 percent of the simultaneous plasma levels and this ratio was similar to the unbound, free fraction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/18/37162/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/12/18633?source=see_link\">",
"     Nevirapine",
"    </a>",
"    is highly metabolized by cytochrome P4503A4 and 2B6 (CYP3A4, 2B6). Like",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    , it induces its own metabolism during the first two to four weeks of treatment. This auto-induction reduces the initial 45-hour single dose half-life down to a 25- to 30-hour terminal half-life. The hydroxylated metabolites are glucuronidated and eliminated renally [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/18/37162/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It has been postulated that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/12/18633?source=see_link\">",
"     nevirapine",
"    </a>",
"    may be able to reach anatomical reservoirs of HIV better than",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    . In a retrospective study of 165 patients taking either nevirapine or efavirenz (both in combination with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/15/5366?source=see_link\">",
"     emtricitabine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    ), a greater proportion of patients on nevirapine were able to achieve a viral load of &lt;1",
"    <span class=\"nowrap\">",
"     copy/mL",
"    </span>",
"    (81 versus 56 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/18/37162/abstract/45\">",
"     45",
"    </a>",
"    ]. Whether tighter control of viremia is associated with other beneficial effects, such as lower levels of immune activation markers, is unknown. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Clinical efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the 2NN trial,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/12/18633?source=see_link\">",
"     nevirapine",
"    </a>",
"    was comparable to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    in terms of viral suppression and immunologic benefit [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/18/37162/abstract/42\">",
"     42",
"    </a>",
"    ]. However, nevirapine has a less favorable toxicity profile. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/4/9287?source=see_link\">",
"     \"Clinical trials of HIV antiretroviral therapy: Non-nucleoside reverse transcriptase inhibitors\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H13\">",
"     'Side effects'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    An extended-release formulation for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/12/18633?source=see_link\">",
"     nevirapine",
"    </a>",
"    became available in 2011 for once daily dosing. Preliminary clinical trial data suggest that the extended-release form of nevirapine given has comparable antiviral efficacy and safety as twice-daily dosing of immediate-release nevirapine at 48 weeks of follow-up [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/18/37162/abstract/46-48\">",
"     46-48",
"    </a>",
"    ]. Virologic suppression was achieved in 80 percent of patients on the new extended release formulation compared with 75 percent on the immediate release formulation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/18/37162/abstract/46,47\">",
"     46,47",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15592376\">",
"    <span class=\"h2\">",
"     Side effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major side effects of concern related to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/12/18633?source=see_link\">",
"     nevirapine",
"    </a>",
"    include hypersensitivity reactions and hepatotoxicity. The lipid profile of nevirapine is one of the most favorable of available antiretroviral medications.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Hypersensitivity reaction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although registration trials of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/12/18633?source=see_link\">",
"     nevirapine",
"    </a>",
"    demonstrated acceptable toxicity profiles, postmarketing reports of severe liver injury led to renewed evaluation of the safety of this agent.",
"   </p>",
"   <p>",
"    In an HIV treatment trial assessing the efficacy and safety of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/15/5366?source=see_link\">",
"     emtricitabine",
"    </a>",
"    , a higher incidence of hepatotoxicity, often in association with rash and fever, was observed in patients assigned to the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/12/18633?source=see_link\">",
"     nevirapine",
"    </a>",
"    arm than in those in the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    arm [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/18/37162/abstract/49\">",
"     49",
"    </a>",
"    ]. This clinical picture was consistent with a hypersensitivity reaction. Women with a body mass index &lt;18.5 and low albumin levels had a markedly increased risk of developing abnormal aminotransferases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/18/37162/abstract/50\">",
"     50",
"    </a>",
"    ]. Another study found a relationship between decreased nevirapine drug clearance and risk of rash among women in sub-Saharan Africa [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/18/37162/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The hypersensitivity syndrome may include rash (50 percent of patients) with or without flu-like symptoms, fever, weight loss, and fatigue and usually occurs within six weeks of treatment initiation.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/12/18633?source=see_link\">",
"     Nevirapine",
"    </a>",
"    should be discontinued in any patient who presents with rash",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    fever to avoid progression to more severe dermatologic complications (eg, Stevens-Johnson syndrome); liver function tests should be checked immediately. Risk factors for rash include a CD4 cell count &gt;250",
"    <span class=\"nowrap\">",
"     cells/mm",
"     <sup>",
"      3",
"     </sup>",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/18/37162/abstract/52,53\">",
"     52,53",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/29/17882?source=see_link\">",
"     \"Stevens-Johnson syndrome and toxic epidermal necrolysis: Clinical manifestations; pathogenesis; and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Warnings against the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/12/18633?source=see_link\">",
"     nevirapine",
"    </a>",
"    for post-exposure prophylaxis after HIV exposure were issued after four individuals developed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/18/37162/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4845324\">",
"    <span class=\"h3\">",
"     Hepatotoxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/12/18633?source=see_link\">",
"     Nevirapine",
"    </a>",
"    has also been associated with hepatotoxicity, which can be asymptomatic or symptomatic, with right upper quadrant pain, nausea, vomiting, or jaundice. Important concepts have evolved regarding risk factors for hepatotoxicity and the timing of its onset.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h4\">",
"     Timing of onset",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/12/18633?source=see_link\">",
"     nevirapine",
"    </a>",
"    -associated hepatotoxicity occurs mainly in the first 18 weeks of drug initiation in an untreated patient, although cases with later onset have occasionally occurred [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/18/37162/abstract/26\">",
"     26",
"    </a>",
"    ]. After two to three months, the risk of hepatotoxicity secondary to nevirapine is similar to the risk of drug-related injury due to other antiretroviral medications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/18/37162/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h4\">",
"     Risk factors for hepatotoxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;A subsequent analysis was performed in 1731 patients who had taken",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/12/18633?source=see_link\">",
"     nevirapine",
"    </a>",
"    in various clinical trials and 1900 control patients to assess risk factors for nevirapine-related toxicity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/18/37162/abstract/55\">",
"     55",
"    </a>",
"    ]. This study and other analyses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/18/37162/abstract/56\">",
"     56",
"    </a>",
"    ] led Boehringer-Ingelheim to issue a warning that the risk of hepatotoxicity was increased in patients with higher CD4 counts, specifically &gt;250",
"    <span class=\"nowrap\">",
"     cells/microL",
"    </span>",
"    in women and &gt;400",
"    <span class=\"nowrap\">",
"     cells/microL",
"    </span>",
"    in men. Women with higher CD4 counts were at a 12 times higher risk of developing this potentially fatal hepatitis compared to controls (11 percent versus 0.9 percent). Similarly, men with higher CD4 counts were also at higher risk than controls (6.3 percent versus 1.2 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/18/37162/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Subsequently, there have been conflicting data about a CD4 threshold as a predictor of rash or hepatotoxicity among women taking",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/12/18633?source=see_link\">",
"     nevirapine",
"    </a>",
"    :",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A United States Centers for Disease Control and Prevention (CDC)-sponsored study in Zambia, Thailand, and Kenya prospectively followed 820 treatment-naive women who initiated",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?18/12/18633?source=see_link\">",
"       nevirapine",
"      </a>",
"      -containing antiretroviral therapy (ART) and found no relationship between a baseline CD4 count of &gt;250 cells with incident rash or hepatotoxicity [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/18/37162/abstract/57\">",
"       57",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A retrospective study of 614 treatment-naive women was performed to evaluate predictors of adverse events related to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?18/12/18633?source=see_link\">",
"       nevirapine",
"      </a>",
"      use in pregnant and nonpregnant women [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/18/37162/abstract/52\">",
"       52",
"      </a>",
"      ]. Nevirapine was administered to 152 women (56 percent of whom were pregnant). Non-nevirapine containing regimens were used in 460 patients; 15 percent of whom were pregnant. A multivariate analysis demonstrated no association between nevirapine and hepatotoxicity, regardless of CD4 cell count, and this was confirmed among the subset of patients who were pregnant; the analysis did confirm an association with hepatitis C virus coinfection. This study did show an association between higher CD4 cell counts and the onset of rash. (See",
"      <a class=\"local\" href=\"#H25\">",
"       'Hypersensitivity reaction'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11300552\">",
"    <span class=\"h3\">",
"     HLA status and risk of adverse events",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several studies have investigated the association between specific HLA genetic status and the incidence of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/12/18633?source=see_link\">",
"     nevirapine",
"    </a>",
"    adverse reactions, although no clear marker has emerged [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/18/37162/abstract/58-60\">",
"     58-60",
"    </a>",
"    ]. Researchers examining the predictive factors for nevirapine-induced skin rash in a genome-wide association study (GWAS) in Thai patients found several potential risk factors, including host genetics, history of drug allergy, pretreatment CD4 count, and whether or not patients received the recommended two-week low-dose lead-in titration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/18/37162/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Since the risk of hypersensitivity is highest during the first few months of therapy, more frequent laboratory monitoring (eg, liver function tests) is prudent Most importantly, patients should be counseled thoroughly about pertinent symptoms, (eg rash, anorexia, weight loss, or fatigue) and when to contact their HIV provider. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/17/38167?source=see_link\">",
"     \"Patient monitoring during HIV antiretroviral therapy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/61/986?source=see_link\">",
"     \"Counseling HIV-infected patients regarding potential side effects of antiretroviral therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Safety of switch strategies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Subsequent retrospective studies have suggested that the incidence of these side effects may be much lower in treated patients who are switched to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/12/18633?source=see_link\">",
"     nevirapine",
"    </a>",
"    , regardless of their CD4 count at the time of the change in medications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/18/37162/abstract/62-64\">",
"     62-64",
"    </a>",
"    ]. The safety of this approach is greatest when HIV viremia is suppressed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/18/37162/abstract/65,66\">",
"     65,66",
"    </a>",
"    ]. This observation appears to hold true in patients taking once-daily or twice-daily dosing of nevirapine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/18/37162/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a retrospective analysis of seven observational cohorts, treatment-experienced patients with high CD4 cell counts and viral suppression had no increased risk of hepatotoxicity when switching to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?18/12/18633?source=see_link\">",
"       nevirapine",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/18/37162/abstract/66\">",
"       66",
"      </a>",
"      ]. In contrast, those patients with detectable viremia had a significant increased risk of drug-induced liver injury (hazard ratio 1.3, 95% CI 1.03-2.03).",
"     </li>",
"     <li>",
"      In the EuroSIDA cohort, 1571 patients who initiated",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?18/12/18633?source=see_link\">",
"       nevirapine",
"      </a>",
"      were studied retrospectively and stratified into four groups based on baseline CD4 T-cell counts and whether they were treatment-experienced or not [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/18/37162/abstract/62\">",
"       62",
"      </a>",
"      ]. The risk of nevirapine discontinuation due to adverse events or",
"      <span class=\"nowrap\">",
"       patient/physician",
"      </span>",
"      choice in the treatment-experienced groups were approximately half that compared to rates in treatment-naive patients. The discontinuation rate for rash with severe hepatotoxicity was 0.8 percent for men and 2.7 percent for women. These rates are low compared to historical control rates of discontinuation in naive patients.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These combined data suggest that using",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/12/18633?source=see_link\">",
"     nevirapine",
"    </a>",
"    in a \"switch strategy\" may be well tolerated, provided there is no detectable viremia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h3\">",
"     Lipid profile",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/12/18633?source=see_link\">",
"     Nevirapine",
"    </a>",
"    is relatively \"lipid friendly\". In the 2NN study, increases in HDL-c were significantly greater in the nevirapine arm than in the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    arm (43 versus 34 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/18/37162/abstract/67\">",
"     67",
"    </a>",
"    ]. In addition, triglyceride increases were significantly less in the nevirapine arm than in the efavirenz arm (20 versus 49 percent). Nevirapine increases apolipoprotein A1 production selectively without increasing HDL catabolism; HDL increases of 20 percent have been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/18/37162/abstract/68,69\">",
"     68,69",
"    </a>",
"    ]. One author postulated that this might be why interruption of NNRTI-based regimens increased cardiovascular risk in the SMART study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/18/37162/abstract/69,70\">",
"     69,70",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/3/49?source=see_link\">",
"     \"Management of dyslipidemia and cardiovascular risk in the HIV-infected patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Use in pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Unlike",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/12/18633?source=see_link\">",
"     nevirapine",
"    </a>",
"    can be used in pregnant women, providing that the baseline CD4 count is less than 250",
"    <span class=\"nowrap\">",
"     cells/mm",
"     <sup>",
"      3",
"     </sup>",
"    </span>",
"    at initiation. Nevirapine is a category C drug for pregnant women, as defined by the FDA.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Prevention of mother-to-child transmission of HIV",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/12/18633?source=see_link\">",
"     Nevirapine",
"    </a>",
"    has been used to prevent maternal-fetal transmission of HIV. For women with no prenatal care or treatment, single doses given intrapartum are effective. However, the risk of developing resistance in the mother",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    infant has been a concern. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/44/25290?source=see_link\">",
"     \"Use of antiretroviral medications in pregnant HIV-infected patients and their infants in resource-rich settings\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/4/15433?source=see_link\">",
"     \"Prenatal evaluation and intrapartum management of the HIV-infected patient in resource-rich settings\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Drug interactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/12/18633?source=see_link\">",
"     Nevirapine",
"    </a>",
"    , like",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    , is a CYP p450 3A4 inducer and substrate. Nevirapine can also induce CYP 2B6 isoenzymes. Therefore, it can reduce the serum concentrations of drugs that are 3A4 or 2B6 substrates including ethinyl estradiol (20 percent),",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/34/33312?source=see_link\">",
"     ketoconazole",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/57/36761?source=see_link\">",
"     methadone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/10/25770?source=see_link\">",
"     carbamazepine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/16/12554?source=see_link\">",
"     diltiazem",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    . For detailed information about NNRTI drug interactions, see tables of the",
"    <a class=\"external\" href=\"file://aidsinfo.nih.gov/guidelines\">",
"     DHHS Antiretroviral Guidelines for the Treatment of Adults and Adolescents",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/31/10746?source=see_link\">",
"     Rifampin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/63/32760?source=see_link\">",
"     rifabutin",
"    </a>",
"    can lower",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/12/18633?source=see_link\">",
"     nevirapine",
"    </a>",
"    levels and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/57/10138?source=see_link\">",
"     clarithromycin",
"    </a>",
"    may increase nevirapine levels. It is preferable to avoid concomitant use of rifamycins when possible. Close monitoring for hepatotoxicity is recommended [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/18/37162/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As with the other drug interaction sections of these topic reviews, this is only a partial list of drug interactions. Additional information can be found in other references, including the product labeling, and in other topics. (See",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/12/18633?source=see_link\">",
"     \"Nevirapine: Drug information\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     Formulations and dosing",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/12/18633?source=see_link\">",
"     Nevirapine",
"    </a>",
"    is only available as a single agent; no coformulations have been developed for use in the United States. The original formulation of nevirapine was an immediate release tablet dosed twice daily; in 2011, an extended release formulation (nevirapine XR) was subsequently approved for single daily dosing.",
"   </p>",
"   <p>",
"    The FDA-approved dosing of the immediate release formulation is 200 mg once daily for two weeks followed by twice daily dosing thereafter. The two-week once-daily lead-in phase reduces the risk of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/12/18633?source=see_link\">",
"     nevirapine",
"    </a>",
"    -related rash.",
"   </p>",
"   <p>",
"    Patients who are interested in single daily dosing with the extended release",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/12/18633?source=see_link\">",
"     nevirapine",
"    </a>",
"    must still begin with the immediate release formulation, 200 mg once daily for two weeks; if tolerated, the patient may switch to the 400 mg extended release tablet. In contrast, patients who have already achieved viral suppression on the immediate release formulation can switch immediately to the 400 mg XR tablets.",
"   </p>",
"   <p>",
"    In May 2012, generic",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/12/18633?source=see_link\">",
"     nevirapine",
"    </a>",
"    tablets became the first FDA-approved generic non-nucleoside reverse transcriptase inhibitor in the United States. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h3\">",
"     Usual adult dosage",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Immediate release formulation, 200 mg tablet: Take 200 mg once daily for 14 days, then 200 mg twice daily with or without food. If treatment is stopped for more than seven days, the initial dosing of 200 mg once daily for 14 days should be repeated [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/18/37162/abstract/43\">",
"       43",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      One study in 289 patients with viral suppression found that once-daily dosing was non-inferior to daily dosing with a comparable safety profile [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/18/37162/abstract/71\">",
"       71",
"      </a>",
"      ].",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?18/12/18633?source=see_link\">",
"       Nevirapine",
"      </a>",
"      plasma levels were evaluated in a subset of 44 patients; trough levels were lower in the once-daily arm compared with the twice-daily arm (3.1 versus 4.1), whereas peak levels were higher in the once-daily arm compared with twice-daily dosing (6.3 versus 5.4).",
"     </li>",
"     <li>",
"      Extended release formulation, 400 mg tablet: Patients initiating",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?18/12/18633?source=see_link\">",
"       nevirapine",
"      </a>",
"      treatment should begin with the 200 mg immediate release tablet, one tablet twice daily for two weeks, then switch to the 400 mg immediate release tablet, taking one tablet once daily. This necessitates two prescriptions and two different vial strengths for the patient to distinguish between.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h3\">",
"     Renal insufficiency",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      No dosage adjustment is required in patients with renal dysfunction who are not receiving dialysis. However, in hemodialysis patients, an additional 200 mg post-dialysis dose is recommended. This is based on a pharmacokinetic study in which the",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?18/12/18633?source=see_link\">",
"       nevirapine",
"      </a>",
"      AUC was reduced by 44 percent and the hydroxylated metabolites accumulated [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/18/37162/abstract/42,43\">",
"       42,43",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?12/29/12759?source=see_link\">",
"       \"Dose modification of antiretroviral agents in adults with renal or hepatic dysfunction\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h3\">",
"     Hepatic insufficiency",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Limited data are available in patients with hepatic dysfunction. The product labeling and DHHS guidelines state that",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?18/12/18633?source=see_link\">",
"       nevirapine",
"      </a>",
"      should be avoided in patients with moderate to severe hepatic dysfunction [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/18/37162/abstract/1,43\">",
"       1,43",
"      </a>",
"      ]. Nevirapine can be hepatotoxic. Please refer to Appendix B Table 7 of the",
"      <a class=\"external\" href=\"file://aidsinfo.nih.gov/guidelines\">",
"       DHHS Antiretroviral Guidelines for the Treatment of Adults and Adolescents",
"      </a>",
"      , which summarizes recommendations from United States guidelines that have been based upon these limited data&nbsp;[",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/18/37162/abstract/1\">",
"       1",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3551627\">",
"    <span class=\"h2\">",
"     Medication error potential",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is potential for mix-ups between the 400 mg XR formulation and the 200 mg immediate release formulation. Prescriptions should be written carefully and patients should be carefully counseled regarding the two different vials of medications. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10929706\">",
"    <span class=\"h1\">",
"     RILPIVIRINE (EDURANT)",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15798?source=see_link\">",
"     Rilpivirine",
"    </a>",
"    (Edurant) was approved by the US Food and Drug Administration (FDA) in May 2011, in combination with other antiretroviral agents, for the treatment-naive HIV-infected patient. Rilpivirine is well tolerated and is associated with minimal lipid changes; however, its use should be limited to patients with baseline levels of viremia &lt;100,000",
"    <span class=\"nowrap\">",
"     copies/mL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/18/37162/abstract/72,73\">",
"     72,73",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Clinicians should also be aware that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15798?source=see_link\">",
"     rilpivirine",
"    </a>",
"    is associated with QT interval prolongation. Clinicians should be aware that drug-drug interactions are significant and should check the full prescribing information before administering rilpivirine.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10929714\">",
"    <span class=\"h2\">",
"     Pharmacokinetics",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15798?source=see_link\">",
"     Rilpivirine",
"    </a>",
"    is better absorbed in the presence of food. In contrast, plasma levels are significantly reduced with coadministration with protein drinks. Hence, it is recommended that rilpivirine be taken with food, but not with, or after, protein drinks.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15798?source=see_link\">",
"     Rilpivirine",
"    </a>",
"    is highly protein bound to albumin (ie, 98 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/18/37162/abstract/74,75\">",
"     74,75",
"    </a>",
"    ]. Like other NNRTIs, the half life of rilpivirine is long (ie, 34 to 55 hours). The drug accumulates when daily dosing is initiated; plasma levels increase from day one to day seven by two- to threefold [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/18/37162/abstract/75\">",
"     75",
"    </a>",
"    ]. Rilpivirine is metabolized hepatically, via P450 CYP3A oxidation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/18/37162/abstract/74,75\">",
"     74,75",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11307128\">",
"    <span class=\"h2\">",
"     Clinical efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two controlled trials (ECHO and THRIVE) compared",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15798?source=see_link\">",
"     rilpivirine",
"    </a>",
"    with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    in treatment-naive patients in combination with two nucleoside reverse transcriptase inhibitors (NRTIs) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/18/37162/abstract/76,77\">",
"     76,77",
"    </a>",
"    ]. The pooled results demonstrated that the proportion of patients with viral suppression at 48 weeks was comparable in the rilpivirine and efavirenz-containing arms (83 percent versus 80 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/18/37162/abstract/78\">",
"     78",
"    </a>",
"    ]. These data are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/4/9287?source=see_link\">",
"     \"Clinical trials of HIV antiretroviral therapy: Non-nucleoside reverse transcriptase inhibitors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The virologic failure rates were comparable in patients with a baseline viral load &lt;100,000",
"    <span class=\"nowrap\">",
"     copies/mL:",
"    </span>",
"    5 percent in both arms. However, for patients with a baseline viral load &gt;100,000",
"    <span class=\"nowrap\">",
"     copies/mL",
"    </span>",
"    to &lt;500,000",
"    <span class=\"nowrap\">",
"     copies/mL,",
"    </span>",
"    the proportion of patients with virologic failure was significantly higher in the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15798?source=see_link\">",
"     rilpivirine",
"    </a>",
"    arm. &nbsp;",
"   </p>",
"   <p>",
"    Patients who had virologic failure on",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15798?source=see_link\">",
"     rilpivirine",
"    </a>",
"    were more likely to develop cross-resistance to other NNRTIs than patients who developed virologic failure on",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/18/37162/abstract/74\">",
"     74",
"    </a>",
"    ]. In addition, compared with patients who received efavirenz, rilpivirine-treated patients were more likely to develop drug resistance to other nucleoside reverse transcriptase inhibitors that were given as part of their combination ART.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10929722\">",
"    <span class=\"h2\">",
"     Side effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15798?source=see_link\">",
"     Rilpivirine",
"    </a>",
"    is generally well tolerated and appears to have fewer central nervous system and psychiatric side effects than",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/18/37162/abstract/78\">",
"     78",
"    </a>",
"    ]. The most common adverse drug reactions to rilpivirine include depression, insomnia, headache and rash. However, rash led to drug discontinuation in less than 1 percent of study participants in the phase 3 clinical trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/18/37162/abstract/76\">",
"     76",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11307272\">",
"    <span class=\"h3\">",
"     Lipid abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15798?source=see_link\">",
"     Rilpivirine",
"    </a>",
"    was associated with minimal changes in total cholesterol, LDL-C and triglyceride levels from baseline through 48 week of treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/18/37162/abstract/77\">",
"     77",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11307187\">",
"    <span class=\"h3\">",
"     QT interval prolongation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Administration of high doses of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15798?source=see_link\">",
"     rilpivirine",
"    </a>",
"    (ie, 75 mg and 300 mg once daily) was associated with QT interval prolongation. For this reason, rilpivirine should be used cautiously or avoided in patients with long QT syndrome or other risks for torsade de pointes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/18/37162/abstract/74\">",
"     74",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10929730\">",
"    <span class=\"h2\">",
"     Teratogenicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies in animals have not demonstrated any teratogenicity associated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15798?source=see_link\">",
"     rilpivirine",
"    </a>",
"    ; however, controlled trials have not been conducted in pregnant women (FDA Pregnancy Category B). Rilpivirine should be used during pregnancy only if the potential benefit outweighs the risk.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10929738\">",
"    <span class=\"h2\">",
"     Drug interactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are many important drug-drug interactions with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15798?source=see_link\">",
"     rilpivirine",
"    </a>",
"    ; most are related to its ability to inhibit CYP 3A and its CYP 3A4 substrate status [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/18/37162/abstract/75,79\">",
"     75,79",
"    </a>",
"    ]. The product labeling and drug interaction references should be consulted for a full review. The important drug interactions include, but are not limited to proton-pump inhibitors, some tuberculosis medications (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/63/32760?source=see_link\">",
"     rifabutin",
"    </a>",
"    ) and certain anti-epileptics (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/48/35594?source=see_link\">",
"     phenytoin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/40/29321?source=see_link\">",
"     phenobarbital",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10929746\">",
"    <span class=\"h2\">",
"     Formulations and dosing",
"    </span>",
"    &nbsp;&mdash;&nbsp;The recommended dose of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15798?source=see_link\">",
"     rilpivirine",
"    </a>",
"    is 25 mg daily taken orally with food. Rilpivirine comes formulated as a 25 mg tablet (Edurant) and is also available as a fixed-dose coformulation (Complera) with 200 mg of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/15/5366?source=see_link\">",
"     emtricitabine",
"    </a>",
"    and 300 mg of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/18/37162/abstract/80\">",
"     80",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pediatric formulations, injectable formulations, and coformulations with other antiretroviral agents are under review [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/18/37162/abstract/81\">",
"     81",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15798?source=see_link\">",
"     Rilpivirine",
"    </a>",
"    tablets are very small, about the size of an",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    tablet, and are therefore an option in patients that have difficulty swallowing large tablets. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10929762\">",
"    <span class=\"h3\">",
"     Renal insufficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;No dosage adjustments are recommended in patients with mild renal insufficiency. There are scant data in patients with moderate to severe renal disease. Although there are no recommendations to decrease the dose,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15798?source=see_link\">",
"     rilpivirine",
"    </a>",
"    should be monitored closely in patients with end stage renal disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10929770\">",
"    <span class=\"h3\">",
"     Hepatic insufficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;No dosage adjustments are recommended for mild to moderate hepatic insufficiency at this time. Published data are lacking in patients with advanced liver disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H46\">",
"    <span class=\"h1\">",
"     ETRAVIRINE (INTELENCE)",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/0/13320?source=see_link\">",
"     Etravirine",
"    </a>",
"    (TMC 125; Intelence) was approved for use by the US Food and Drug Administration (FDA) in January 2008 for the treatment-experienced patient with evidence of viral replication and drug resistance. Etravirine is a diarylpyrimidine, a flexible molecule that can fit into the reverse transcriptase active pocket in several different ways even if non-nucleoside reverse transcriptase inhibitor (NNRTI)-resistant mutations are present. Thus, this second generation NNRTI may be effective in patients who have fewer than three documented NNRTI resistance mutations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H47\">",
"    <span class=\"h2\">",
"     Pharmacokinetics",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/0/13320?source=see_link\">",
"     Etravirine",
"    </a>",
"    , like",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/12/18633?source=see_link\">",
"     nevirapine",
"    </a>",
"    , has a very long serum half-life of 41",
"    <span class=\"nowrap\">",
"     +/-",
"    </span>",
"    20 hours.",
"   </p>",
"   <p>",
"    Food increases",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/0/13320?source=see_link\">",
"     etravirine",
"    </a>",
"    levels of the current, newer formulation twofold. It should be taken with or after a meal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/18/37162/abstract/1,82,83\">",
"     1,82,83",
"    </a>",
"    ]. Peak plasma levels following etravirine dosing at 200 mg BID with food were 959 + 278",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    and trough levels were 469 + 149",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/18/37162/abstract/82\">",
"     82",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/0/13320?source=see_link\">",
"     Etravirine",
"    </a>",
"    is very highly protein bound: 99.9 percent, primarily to albumin and alpha1-acid glycoprotein. Despite a high degree of protein binding, etravirine concentrations in serum and cerebrospinal fluid obtained from 12 HIV-infected patients surpassed the inhibitory concentration (IC50) against HIV in all biologic samples [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/18/37162/abstract/84\">",
"     84",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/0/13320?source=see_link\">",
"     Etravirine",
"    </a>",
"    , like",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/12/18633?source=see_link\">",
"     nevirapine",
"    </a>",
"    , is metabolized by cytochrome P450, but to a lesser extent. Eighty-one to 86 percent of a dose is eliminated unchanged in the feces. It utilizes isozymes 3A4, 2C9, and 2C19 (substrate of) and induces 3A4 and inhibits 2C9 and 2C19.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H48\">",
"    <span class=\"h2\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/0/13320?source=see_link\">",
"     Etravirine",
"    </a>",
"    was found to be a potent agent in highly treatment-experienced patients. In a multinational double-blind, placebo-controlled phase III trial (DUET-1), 612 patients were randomly assigned to optimized background therapy plus either etravirine or placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/18/37162/abstract/3\">",
"     3",
"    </a>",
"    ]. At week 24, a significantly higher proportion of patients in the etravirine arm attained a viral load of &lt;50",
"    <span class=\"nowrap\">",
"     copies/mL",
"    </span>",
"    compared to those receiving placebo (56 versus 39 percent).",
"   </p>",
"   <p>",
"    In patients with a history of virologic failure on NNRTIs,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/0/13320?source=see_link\">",
"     etravirine",
"    </a>",
"    should NOT be administered only in combination with a dual nucleoside analog \"backbone\" since this strategy was proven to be ineffective. Preferred treatment strategies include combining etravirine with another protease inhibitor, such as",
"    <span class=\"nowrap\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?35/39/36473?source=see_link\">",
"      darunavir",
"     </a>",
"     /",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?11/58/12202?source=see_link\">",
"      ritonavir",
"     </a>",
"     .",
"    </span>",
"    Clinical trial data on the use of etravirine is found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/4/9287?source=see_link\">",
"     \"Clinical trials of HIV antiretroviral therapy: Non-nucleoside reverse transcriptase inhibitors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H49\">",
"    <span class=\"h2\">",
"     Side effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/0/13320?source=see_link\">",
"     Etravirine",
"    </a>",
"    is generally well tolerated and is associated with fewer neuropsychiatric side effects than",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/18/37162/abstract/3,85-87\">",
"     3,85-87",
"    </a>",
"    ]. The most common adverse event after etravirine administration is rash, which is generally mild. In clinical trials, rash occurred primarily in the second week of therapy and was infrequent after week four. Rash generally resolved within one to two weeks of continued dosing.",
"   </p>",
"   <p>",
"    Importantly, as with other NNRTIs, severe rashes (including Stevens-Johnson Syndrome, toxic epidermal necrolysis and erythema multiforme) have been reported in the postmarketing experience.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/0/13320?source=see_link\">",
"     Etravirine",
"    </a>",
"    should be immediately discontinued when signs and symptoms of severe skin or hypersensitivity reactions develop. To report suspected adverse events, contact Tibotec Therapeutics at 1-877-732-2488 or the FDA at 1-800-FDA-1088.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H50\">",
"    <span class=\"h2\">",
"     Use in pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/0/13320?source=see_link\">",
"     Etravirine",
"    </a>",
"    is in FDA Pregnancy Category B, indicating that there are not well-controlled studies of this drug in humans, but that animal studies have not shown any teratogenic effects. According to the FDA, etravirine should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Any patient that receives etravirine (or any other ARV) while pregnant should be registered with the National Pregnancy Registry by calling 1-800-258-4263. This will help to provide important tolerability and teratogenicity data for the use of these drugs in HIV-positive women.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H51\">",
"    <span class=\"h2\">",
"     Drug interactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because the drug is metabolized by cytochrome P450 isoenzymes, it cannot be coadministered with a number of other drugs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/18/37162/abstract/86\">",
"     86",
"    </a>",
"    ].",
"    <span class=\"nowrap\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?19/33/19992?source=see_link\">",
"      Tipranavir",
"     </a>",
"     /",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?11/58/12202?source=see_link\">",
"      ritonavir",
"     </a>",
"    </span>",
"    reduce the AUC of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/0/13320?source=see_link\">",
"     etravirine",
"    </a>",
"    by 76 percent and thus should not be coadministered with etravirine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/18/37162/abstract/1,83\">",
"     1,83",
"    </a>",
"    ]. Other drugs that should not be coadministered with etravirine include:",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/11/44217?source=see_link\">",
"     fosamprenavir",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/36/25161?source=see_link\">",
"     indinavir",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/62/19433?source=see_link\">",
"     nelfinavir",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/12/18633?source=see_link\">",
"     nevirapine",
"    </a>",
"    . For detailed information about NNRTI drug interactions, see the Tables of the",
"    <a class=\"external\" href=\"file://aidsinfo.nih.gov/guidelines\">",
"     DHHS Antiretroviral Guidelines for the Treatment of Adults and Adolescents",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    Clinicians should be aware that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/0/13320?source=see_link\">",
"     etravirine",
"    </a>",
"    should",
"    <strong>",
"     NOT",
"    </strong>",
"    be coadministered with other NNRTIs, with unboosted protease inhibitors, or with any of the following drugs due to significant drug interactions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/18/37162/abstract/88\">",
"     88",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <span class=\"nowrap\">",
"       <a class=\"drug drug_general\" href=\"mobipreview.htm?19/33/19992?source=see_link\">",
"        Tipranavir",
"       </a>",
"       /",
"       <a class=\"drug drug_general\" href=\"mobipreview.htm?11/58/12202?source=see_link\">",
"        ritonavir",
"       </a>",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       <a class=\"drug drug_general\" href=\"mobipreview.htm?43/11/44217?source=see_link\">",
"        Fosamprenavir",
"       </a>",
"       /",
"       <a class=\"drug drug_general\" href=\"mobipreview.htm?11/58/12202?source=see_link\">",
"        ritonavir",
"       </a>",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       <a class=\"drug drug_general\" href=\"mobipreview.htm?0/31/506?source=see_link\">",
"        Atazanavir",
"       </a>",
"       /",
"       <a class=\"drug drug_general\" href=\"mobipreview.htm?11/58/12202?source=see_link\">",
"        ritonavir",
"       </a>",
"      </span>",
"     </li>",
"     <li>",
"      Full-dose",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?11/58/12202?source=see_link\">",
"       ritonavir",
"      </a>",
"      (eg, 600 mg twice daily)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Coadministration of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/0/13320?source=see_link\">",
"     etravirine",
"    </a>",
"    with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/57/20378?source=see_link\">",
"     lopinavir-ritonavir",
"    </a>",
"    increases etravirine exposure 17 percent (AUC) to 23 percent (Cmax); the FDA suggests increased caution if concomitant administration is being considered [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/18/37162/abstract/89\">",
"     89",
"    </a>",
"    ]. No dose adjustments are recommended for the following combinations: etravirine plus",
"    <span class=\"nowrap\">",
"     lopinavir/",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?11/58/12202?source=see_link\">",
"      ritonavir",
"     </a>",
"    </span>",
"    or etravirine plus",
"    <span class=\"nowrap\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?35/39/36473?source=see_link\">",
"      darunavir",
"     </a>",
"     /ritonavir.",
"    </span>",
"   </p>",
"   <p>",
"    As with the other drug interaction sections in these topic reviews, this is only a partial list of drug interactions. Additional information can be found in other references including the product labeling, DHHS Guidelines, and in other topics.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H52\">",
"    <span class=\"h2\">",
"     Formulations and dosing",
"    </span>",
"    &nbsp;&mdash;&nbsp;The adult",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/0/13320?source=see_link\">",
"     etravirine",
"    </a>",
"    dose is 200 mg (one 200 mg tablet OR two 100 mg tablets) taken twice daily following a meal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/18/37162/abstract/86\">",
"     86",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pharmacokinetic studies of the commercially available 200 mg tablets in HIV-negative volunteers suggest that once-daily",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/0/13320?source=see_link\">",
"     etravirine",
"    </a>",
"    dosing might be possible, although this has not yet been FDA approved [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/18/37162/abstract/90\">",
"     90",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    No coformulations and no liquids are available. Patients who cannot swallow the large 200 mg size tablets can dissolve the tablets in a glass of water, stirring well until it turns a milky color; patients should be instructed to drink the liquid immediately, rinsing the glass several times and drinking the rinse water to ensure the full dose is ingested. The tablets should not be chewed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/18/37162/abstract/83\">",
"     83",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H53\">",
"    <span class=\"h2\">",
"     Renal insufficiency",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?13/0/13320?source=see_link\">",
"       Etravirine",
"      </a>",
"      dosing has not yet been studied in patients with renal insufficiency. However, it is eliminated primarily in the feces as unchanged drug; little (&lt;1.2 percent) is excreted in the urine and it is highly protein bound. Therefore, it is unlikely to require dose adjustments in patients with renal dysfunction including those on hemo- or peritoneal dialysis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H54\">",
"    <span class=\"h2\">",
"     Hepatic insufficiency",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?13/0/13320?source=see_link\">",
"       Etravirine",
"      </a>",
"      does not require dose adjustment for patients with Child-Pugh Class A or B mild to moderate liver dysfunction; there are no data available for patients with Child-Pugh Class C [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/18/37162/abstract/1,76\">",
"       1,76",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H768086\">",
"    <span class=\"h1\">",
"     DELAVIRDINE (RESCRIPTOR)",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/10/27816?source=see_link\">",
"     Delavirdine",
"    </a>",
"    (Rescriptor) is very rarely used as an antiretroviral (ARV) agent because it is the least potent of the non-nucleoside reverse transcriptase inhibitors (NNRTIs), has a high pill burden (six per day), wide interpatient variability of plasma concentrations, and requires three times daily dosing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H768113\">",
"    <span class=\"h2\">",
"     Pharmacokinetics",
"    </span>",
"    &nbsp;&mdash;&nbsp;The serum half-life of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/10/27816?source=see_link\">",
"     delavirdine",
"    </a>",
"    is shorter than the other NNRTIs at 5.8 hours, and its dosing interval is accordingly shorter, eg, every eight hours.",
"   </p>",
"   <p>",
"    Meals did not change the AUC or Cmin of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/10/27816?source=see_link\">",
"     delavirdine",
"    </a>",
"    , and therefore, it can be administered without regard to meals.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/10/27816?source=see_link\">",
"     Delavirdine",
"    </a>",
"    , like",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/0/13320?source=see_link\">",
"     etravirine",
"    </a>",
"    , is highly protein bound. CSF levels in five patients receiving 600 to 1200",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    were approximately 0.4 percent of concomitant plasma levels or about 20 percent of the unbound fraction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/18/37162/abstract/91\">",
"     91",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/10/27816?source=see_link\">",
"     Delavirdine",
"    </a>",
"    is highly metabolized via CYP3A and, to a lesser extent, via CYP2D6. Forty-four percent of a dose is eliminated in the feces and 51 percent in the urine.",
"   </p>",
"   <p>",
"    Unlike the other three NNRTIs,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/10/27816?source=see_link\">",
"     delavirdine",
"    </a>",
"    does not induce CYP3A, but rather inhibits it. In vitro it also reduces CYP2C9, 2D6, and 2C19 activity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H768120\">",
"    <span class=\"h2\">",
"     Side effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Side effects of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/10/27816?source=see_link\">",
"     delavirdine",
"    </a>",
"    include rash, increased aminotransferases, and headache.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H768127\">",
"    <span class=\"h2\">",
"     Teratogenicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;The US Food and Drug Administration (FDA) has categorized",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/10/27816?source=see_link\">",
"     delavirdine",
"    </a>",
"    as a category C drug.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H768134\">",
"    <span class=\"h2\">",
"     Drug Interactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Unlike",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/0/13320?source=see_link\">",
"     etravirine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/12/18633?source=see_link\">",
"     nevirapine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/10/27816?source=see_link\">",
"     delavirdine",
"    </a>",
"    acts primarily as a CYP 3A4 inhibitor, not an inducer. For this reason, delavirdine is more likely to increase serum levels of CYP3A4 substrates. For detailed information about NNRTI drug interactions, see table 15b of the",
"    <a class=\"external\" href=\"file://aidsinfo.nih.gov/guidelines\">",
"     DHHS Antiretroviral Guidelines for the Treatment of Adults and Adolescents",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    This CYP3A inhibition has been exploited in patients who require \"boosting\" of a protease inhibitor, but cannot tolerate the gastrointestinal side effects of the standard \"booster\",",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/58/12202?source=see_link\">",
"     ritonavir",
"    </a>",
"    . For example,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/25/3482?source=see_link\">",
"     saquinavir",
"    </a>",
"    800 mg three times daily plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/10/27816?source=see_link\">",
"     delavirdine",
"    </a>",
"    400 mg three times daily was used to increase saquinavir (Fortovase formulation) levels 500 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/18/37162/abstract/42\">",
"     42",
"    </a>",
"    ]. Unfortunately, this beneficial interaction is not predictable for all protease inhibitors and in fact, some combinations can result in undesirable pharmacokinetic results. Therefore, it is not a strategy that can be recommended or generically applied to all \"boosting\" situations.",
"   </p>",
"   <p>",
"    Antacids, histamine-2 receptor antagonists, or proton pump inhibitors may reduce the absorption of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/10/27816?source=see_link\">",
"     delavirdine",
"    </a>",
"    . In contrast, delavirdine levels may increase when given concomitantly with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/49/15130?source=see_link\">",
"     fluoxetine",
"    </a>",
"    . (See",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/10/27816?source=see_link\">",
"     \"Delavirdine: Drug information\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As with the other drug interaction sections in these topic reviews, this is only a partial list of drug interactions. Additional information can be found in other references including the product labeling, DHHS Guidelines, and in other topics (see",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/10/27816?source=see_link\">",
"     \"Delavirdine: Drug information\"",
"    </a>",
"    ). Concomitant drugs should be carefully reviewed before patients start or stop",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/10/27816?source=see_link\">",
"     delavirdine",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H768141\">",
"    <span class=\"h2\">",
"     Formulations and dosing",
"    </span>",
"    &nbsp;&mdash;&nbsp;The usual adult dose for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/10/27816?source=see_link\">",
"     delavirdine",
"    </a>",
"    is 400 mg three times a day with or without food. The 100 mg tablet can be dissolved in &gt;3 oz of water but the 200 mg tablets should be swallowed whole.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H768148\">",
"    <span class=\"h3\">",
"     Renal insufficiency",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      No dosage adjustment necessary [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/18/37162/abstract/1\">",
"       1",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H767986\">",
"    <span class=\"h3\">",
"     Hepatic insufficiency",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There are no data on the use of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/10/27816?source=see_link\">",
"       delavirdine",
"      </a>",
"      in patients with advanced liver disease; use with caution [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/18/37162/abstract/1\">",
"       1",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H55\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The non-nucleoside reverse transcriptase inhibitors (NNRTIs) are a class of potent oral antiretroviral (ARV) drugs, which include three first generation agents (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/42/29353?source=see_link\">",
"       efavirenz",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?18/12/18633?source=see_link\">",
"       nevirapine",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/10/27816?source=see_link\">",
"       delavirdine",
"      </a>",
"      ) and two later generation agents (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?13/0/13320?source=see_link\">",
"       etravirine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15798?source=see_link\">",
"       rilpivirine",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The choice of individual NNRTI may be influenced drug resistance patterns, potential side effect profile, and drug interactions. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'General principles'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      NNRTIs prevent HIV reverse transcriptase from adding new nucleotides to the growing DNA chain. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Mechanism of action'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/42/29353?source=see_link\">",
"       Efavirenz",
"      </a>",
"      (Sustiva) is the most widely used of the NNRTIs and is one of the preferred agents for use in combination therapy for treatment-naive patients. It is effective in achieving viral suppression, even in patients with a high HIV RNA level. Although efavirenz is generally well tolerated, it can be associated with neuropsychiatric side effects, rash, and hypovitaminosis D. Efavirenz should be avoided in pregnant women. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Efavirenz (Sustiva)'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?18/12/18633?source=see_link\">",
"       Nevirapine",
"      </a>",
"      is also a potent NNRTI agent in terms of viral suppression; however, its side effect profile, which includes serious hepatotoxicity, has led to use of this agent as an alternative to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/42/29353?source=see_link\">",
"       efavirenz",
"      </a>",
"      for the treatment of treatment-naive patients. Furthermore, nevirapine should not be given to women with CD4 counts &gt;250 and men with CD4 counts &gt;400",
"      <span class=\"nowrap\">",
"       mL/mm",
"       <sup>",
"        3",
"       </sup>",
"      </span>",
"      due to increased risk of toxicity in these patient populations. Unlike efavirenz, nevirapine can be used in pregnant women, providing that the baseline CD4 count is less than 250",
"      <span class=\"nowrap\">",
"       cells/mm",
"       <sup>",
"        3",
"       </sup>",
"      </span>",
"      at initiation. It is also relatively \"lipid friendly\" and can increase ApoA-I and HDLc by 20 percent. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Nevirapine (Viramune)'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15798?source=see_link\">",
"       Rilpivirine",
"      </a>",
"      is a well tolerated second generation once-daily NNRTI option for treatment-naive patients; however, its use should only be considered in treatment-naive patients with a viral load &lt;100,000",
"      <span class=\"nowrap\">",
"       copies/mL.",
"      </span>",
"      Rilpivirine should also not be used in patients who require proton pump inhibitor therapy. It is not well absorbed in patients taking medications that increase gastric pH. A coformulated product with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?1/52/1863?source=see_link\">",
"       tenofovir-emtricitabine",
"      </a>",
"      is available as a one pill once-a-day regimen. (See",
"      <a class=\"local\" href=\"#H10929706\">",
"       'Rilpivirine (Edurant)'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/10/27816?source=see_link\">",
"       Delavirdine",
"      </a>",
"      (Rescriptor) is very rarely used as an ARV agent because it is the least potent of the NNRTIs, has a high pill burden (six per day), wide interpatient variability of plasma concentrations, and requires three times daily dosing. (See",
"      <a class=\"local\" href=\"#H768086\">",
"       'Delavirdine (Rescriptor)'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?13/0/13320?source=see_link\">",
"       Etravirine",
"      </a>",
"      (Intelence) is effective in patients who have documented NNRTI resistance mutations and is thus an effective agent in treatment-experienced patients with drug resistance. However, in treatment-experienced patients, it should be combined with more than just two nucleosides and there are several important protease inhibitor drug interactions to consider. (See",
"      <a class=\"local\" href=\"#H46\">",
"       'Etravirine (Intelence)'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?13/0/13320?source=see_link\">",
"       Etravirine",
"      </a>",
"      's main side effect is mild rash. Animal studies do not suggest teratogenicity although studies in humans have not been performed. (See",
"      <a class=\"local\" href=\"#H46\">",
"       'Etravirine (Intelence)'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     file://aidsinfo.nih.gov/Guidelines/GuidelineDetail.aspx?MenuItem=Guidelines&amp;Search=Off&amp;GuidelineID=7&amp;ClassID=1 (Accessed on February 12, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/18/37162/abstract/2\">",
"      Hammer SM, Saag MS, Schechter M, et al. Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel. JAMA 2006; 296:827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/18/37162/abstract/3\">",
"      Madruga JV, Cahn P, Grinsztejn B, et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet 2007; 370:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/18/37162/abstract/4\">",
"      Hare CB, Mellors J, Krambrink A, et al. Detection of nonnucleoside reverse-transcriptase inhibitor-resistant HIV-1 after discontinuation of virologically suppressive antiretroviral therapy. Clin Infect Dis 2008; 47:421.",
"     </a>",
"    </li>",
"    <li>",
"     Kilkaire B, Walker S, Khoo S, et al. Plasma levels of nevirapine following interruption of ZDV/3Tc/nvp in African adults within the DART trial. Program and abstracts of the XVI International AIDS Conference; August 13-18, 2006; Toronto, Ontario, Canada. Abstract WEAB0201.",
"    </li>",
"    <li>",
"     Bartlett JG, Gallant JE. 2007 Medical Management of HIV Infection, Johns Hopkins Medicine Health Publishing Business Group, Baltimore, MD 2007.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/18/37162/abstract/7\">",
"      Grobler JA, Dornadula G, Rice MR, et al. HIV-1 reverse transcriptase plus-strand initiation exhibits preferential sensitivity to non-nucleoside reverse transcriptase inhibitors in vitro. J Biol Chem 2007; 282:8005.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/18/37162/abstract/8\">",
"      Zdanowicz MM. The pharmacology of HIV drug resistance. Am J Pharm Educ 2006; 70:100.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.hivclinic.ca/main/home.html (Accessed on October 17, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/18/37162/abstract/10\">",
"      Best BM, Koopmans PP, Letendre SL, et al. Efavirenz concentrations in CSF exceed IC50 for wild-type HIV. J Antimicrob Chemother 2011; 66:354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/18/37162/abstract/11\">",
"      Gatanaga H, Hayashida T, Tsuchiya K, et al. Successful efavirenz dose reduction in HIV type 1-infected individuals with cytochrome P450 2B6 *6 and *26. Clin Infect Dis 2007; 45:1230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/18/37162/abstract/12\">",
"      Ribaudo HJ, Liu H, Schwab M, et al. Effect of CYP2B6, ABCB1, and CYP3A5 polymorphisms on efavirenz pharmacokinetics and treatment response: an AIDS Clinical Trials Group study. J Infect Dis 2010; 202:717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/18/37162/abstract/13\">",
"      Ribaudo HJ, Haas DW, Tierney C, et al. Pharmacogenetics of plasma efavirenz exposure after treatment discontinuation: an Adult AIDS Clinical Trials Group Study. Clin Infect Dis 2006; 42:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/18/37162/abstract/14\">",
"      Leger P, Dillingham R, Beauharnais CA, et al. CYP2B6 variants and plasma efavirenz concentrations during antiretroviral therapy in Port-au-Prince, Haiti. J Infect Dis 2009; 200:955.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/18/37162/abstract/15\">",
"      Potard V, Rey D, Mokhtari S, et al. First-line highly active antiretroviral regimens in 2001-2002 in the French Hospital Database on HIV: combination prescribed and biological outcomes. Antivir Ther 2007; 12:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/18/37162/abstract/16\">",
"      Gulick RM, Ribaudo HJ, Shikuma CM, et al. Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. N Engl J Med 2004; 350:1850.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/18/37162/abstract/17\">",
"      Robbins GK, De Gruttola V, Shafer RW, et al. Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection. N Engl J Med 2003; 349:2293.",
"     </a>",
"    </li>",
"    <li>",
"     Riddler SA, Haubrich R, DiRenzo G, et al. A prospective, randomized, Phase III trial of NRTI-, PI-, and NNRTI-sparing regimens for initial treatment of HIV-1 infection - ACTG 5142, XVI International AIDS Conference Aug 13-18, 2006; Toronto, Canada. Abstract THLB0204.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/18/37162/abstract/19\">",
"      Antiretroviral Therapy Cohort Collaboration. Rates of disease progression according to initial highly active antiretroviral therapy regimen: a collaborative analysis of 12 prospective cohort studies. J Infect Dis 2006; 194:612.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/18/37162/abstract/20\">",
"      Staszewski S, Morales-Ramirez J, Tashima KT, et al. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team. N Engl J Med 1999; 341:1865.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/18/37162/abstract/21\">",
"      Clifford DB, Evans S, Yang Y, et al. Impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals. Ann Intern Med 2005; 143:714.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/18/37162/abstract/22\">",
"      Guti&eacute;rrez-Valencia A, Viciana P, Palacios R, et al. Stepped-dose versus full-dose efavirenz for HIV infection and neuropsychiatric adverse events: a randomized trial. Ann Intern Med 2009; 151:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/18/37162/abstract/23\">",
"      Haas DW, Ribaudo HJ, Kim RB, et al. Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study. AIDS 2004; 18:2391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/18/37162/abstract/24\">",
"      Torno MS, Witt MD, Saitoh A, Fletcher CV. Successful use of reduced-dose efavirenz in a patient with human immunodeficiency virus infection: case report and review of the literature. Pharmacotherapy 2008; 28:782.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/18/37162/abstract/25\">",
"      Rahim S, Ortiz O, Maslow M, Holzman R. A case-control study of gynecomastia in HIV-1-infected patients receiving HAART. AIDS Read 2004; 14:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/18/37162/abstract/26\">",
"      Sulkowski MS, Thomas DL, Mehta SH, et al. Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections. Hepatology 2002; 35:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/18/37162/abstract/27\">",
"      R&ouml;der CS, Heinrich T, Gehrig AK, Mikus G. Misleading results of screening for illicit drugs during efavirenz treatment. AIDS 2007; 21:1390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/18/37162/abstract/28\">",
"      Blank A, Hellstern V, Schuster D, et al. Efavirenz treatment and false-positive results in benzodiazepine screening tests. Clin Infect Dis 2009; 48:1787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/18/37162/abstract/29\">",
"      Welz T, Childs K, Ibrahim F, et al. Efavirenz is associated with severe vitamin D deficiency and increased alkaline phosphatase. AIDS 2010; 24:1923.",
"     </a>",
"    </li>",
"    <li>",
"     Brown T, McComsey GA. Association between initiation of antiretroviral therapy with efavirenz and decreases in 25-hydroxyvitamin D. 11th Workshop in Adverse Drug Reactions and Co-morbidities in HIV, Philadelphia, USA, October 2009.",
"    </li>",
"    <li>",
"     Wohl D, et al. Change in vitamin D levels among patients smaller among adults taking TMC 278 compared with efavirenz. 18 Conference on Retroviruses and Opportunistic Infections, February 27- March 2, 2011, Boston, MA.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/18/37162/abstract/32\">",
"      Bera E, McCausland K, Nonkwelo R, et al. Birth defects following exposure to efavirenz-based antiretroviral therapy during pregnancy: a study at a regional South African hospital. AIDS 2010; 24:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/18/37162/abstract/33\">",
"      Ford N, Mofenson L, Kranzer K, et al. Safety of efavirenz in first-trimester of pregnancy: a systematic review and meta-analysis of outcomes from observational cohorts. AIDS 2010; 24:1461.",
"     </a>",
"    </li>",
"    <li>",
"     DHHS Perinatal Guidelines, pg. 16. file://www.aidsinfo.nih.gov/contentfiles/lvguidelines/peri_tables.pdf (Accessed on May 25, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/18/37162/abstract/35\">",
"      Kaul S, Ji P, Lu M, et al. Bioavailability in healthy adults of efavirenz capsule contents mixed with a small amount of food. Am J Health Syst Pharm 2010; 67:217.",
"     </a>",
"    </li>",
"    <li>",
"     Sustiva [package insert]. Princeton, NJ: Bristol-Myers Squibb Company; 2007.",
"    </li>",
"    <li>",
"     Gupta S, Rosenkranz S, Segal Y, et al. The steady-state pharmacokinetics of efavirenz and lopinavir/ritonavir in HIV-infected persons requiring hemodialysis: AIDS Clinical Trials Group Study A5177[abstract 573]. 13th conference on Retroviruses and Opportunistic Infections, Feb 5-8, 2006, Denver, CO.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/18/37162/abstract/38\">",
"      Gill MJ, Ostrop NJ, Fiske WD, Brennan JM. Efavirenz dosing in patients receiving continuous ambulatory peritoneal dialysis. AIDS 2000; 14:1062.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/18/37162/abstract/39\">",
"      Fiske W, Benedek I, Brennan J, et al. Pharmacokinetics of efavirenz in subjects with chronic liver disease. Conf Retroviruses Opportunistic Infect 1999; 1:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/18/37162/abstract/40\">",
"      Maserati R, Villani P, Seminari E, et al. High plasma levels of nelfinavir and efavirenz in two HIV-positive patients with hepatic disease. AIDS 1999; 13:870.",
"     </a>",
"    </li>",
"    <li>",
"     Pereira S, Caixas U, Branco T, et al. Does HCV or HBV infection influence efavirenz plasma concentrations in HIV-infected patients with well-compensated disease? [abstract 3]. 8th International Workshop on Clinical Pharmacology of HIV Therapy. Budapest, Hungary, April 16-18, 2007.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/18/37162/abstract/42\">",
"      van Leth F, Phanuphak P, Ruxrungtham K, et al. Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study. Lancet 2004; 363:1253.",
"     </a>",
"    </li>",
"    <li>",
"     Viramune [package insert]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals; 2007.",
"    </li>",
"    <li>",
"     file://www.hivclinic.ca/main/home.html (Accessed on May 13, 2008).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/18/37162/abstract/45\">",
"      Ha&iuml;m-Boukobza S, Morand-Joubert L, Flandre P, et al. Higher efficacy of nevirapine than efavirenz to achieve HIV-1 plasma viral load below 1 copy/ml. AIDS 2011; 25:341.",
"     </a>",
"    </li>",
"    <li>",
"     Gathe J. ICAAC Boston, MA September 12-15, 2010.",
"    </li>",
"    <li>",
"     Gathe J, et al. Comparison of 48 week efficacy and safety of 400 mg qd nevirapine extended release formulation versus 200 mg BID nevirapine immediate release formulation in combination with emtricitabine/tenofovir in antiretroviral naive HIV infected patients (VERxVE). International AIDS Conference July 18-23, 2010, Vienna, Australia.",
"    </li>",
"    <li>",
"     Product labeling, Viramune XR (nevirapine XR), April 2011",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/18/37162/abstract/49\">",
"      Sanne I. Severe liver toxicity in patients receiving two nucleoside analogs and a non-nucleoside reverse transcriptase inhibitor. AIDS 2000; 14:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/18/37162/abstract/50\">",
"      Sanne I, Mommeja-Marin H, Hinkle J, et al. Severe hepatotoxicity associated with nevirapine use in HIV-infected subjects. J Infect Dis 2005; 191:825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/18/37162/abstract/51\">",
"      Dong BJ, Zheng Y, Hughes MD, et al. Nevirapine pharmacokinetics and risk of rash and hepatitis among HIV-infected sub-Saharan African women. AIDS 2012; 26:833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/18/37162/abstract/52\">",
"      Aaron E, Kempf MC, Criniti S, et al. Adverse events in a cohort of HIV infected pregnant and non-pregnant women treated with nevirapine versus non-nevirapine antiretroviral medication. PLoS One 2010; 5:e12617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/18/37162/abstract/53\">",
"      van Leth F, Andrews S, Grinsztejn B, et al. The effect of baseline CD4 cell count and HIV-1 viral load on the efficacy and safety of nevirapine or efavirenz-based first-line HAART. AIDS 2005; 19:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/18/37162/abstract/54\">",
"      Benn PD, Mercey DE, Brink N, et al. Prophylaxis with a nevirapine-containing triple regimen after exposure to HIV-1. Lancet 2001; 357:687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/18/37162/abstract/55\">",
"      Stern JO, Robinson PA, Love J, et al. A comprehensive hepatic safety analysis of nevirapine in different populations of HIV infected patients. J Acquir Immune Defic Syndr 2003; 34 Suppl 1:S21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/18/37162/abstract/56\">",
"      Leith J, Piliero P, Storfer S, et al. Appropriate use of nevirapine for long-term therapy. J Infect Dis 2005; 192:545.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.retroconference.org/2009/Abstracts/33861.htm (Accessed on September 16, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/18/37162/abstract/58\">",
"      Martin AM, Nolan D, James I, et al. Predisposition to nevirapine hypersensitivity associated with HLA-DRB1*0101 and abrogated by low CD4 T-cell counts. AIDS 2005; 19:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/18/37162/abstract/59\">",
"      Vitezica ZG, Milpied B, Lonjou C, et al. HLA-DRB1*01 associated with cutaneous hypersensitivity induced by nevirapine and efavirenz. AIDS 2008; 22:540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/18/37162/abstract/60\">",
"      Ciccacci C, Borgiani P, Ceffa S, et al. Nevirapine-induced hepatotoxicity and pharmacogenetics: a retrospective study in a population from Mozambique. Pharmacogenomics 2010; 11:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/18/37162/abstract/61\">",
"      Chantarangsu S, Mushiroda T, Mahasirimongkol S, et al. Genome-wide association study identifies variations in 6p21.3 associated with nevirapine-induced rash. Clin Infect Dis 2011; 53:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/18/37162/abstract/62\">",
"      Mocroft A, Staszewski S, Weber R, et al. Risk of discontinuation of nevirapine due to toxicities in antiretroviral-naive and -experienced HIV-infected patients with high and low CD4+ T-cell counts. Antivir Ther 2007; 12:325.",
"     </a>",
"    </li>",
"    <li>",
"     De Roo A, Moerman F, Lynen L, et al. Incidence of rash and severe hepatotoxicitity in patients switching from a PI or efavirenz to nevirapine at relatively high CD4 count levels. Program and anstractos of the XVI International AIDS Conference; August 13-18, 2006; Toronto, Ontario, Canada. Abstract CDB0697.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/18/37162/abstract/64\">",
"      Wit FW, Kesselring AM, Gras L, et al. Discontinuation of nevirapine because of hypersensitivity reactions in patients with prior treatment experience, compared with treatment-naive patients: the ATHENA cohort study. Clin Infect Dis 2008; 46:933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/18/37162/abstract/65\">",
"      Calmy A, Vallier N, Nguyen A, et al. Safety and efficacy of once-daily nevirapine dosing: a multicohort study. Antivir Ther 2009; 14:931.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/18/37162/abstract/66\">",
"      Kesselring AM, Wit FW, Sabin CA, et al. Risk factors for treatment-limiting toxicities in patients starting nevirapine-containing antiretroviral therapy. AIDS 2009; 23:1689.",
"     </a>",
"    </li>",
"    <li>",
"     van Leth F, Hassink E, Phanuphak P, et al. Results of the 2NN study: a randomized comparative trial of first-line antiretroviral therapy with regimens containing either nevirapine alone, efavirenz alone or both drugs combined, together with stavudine and lamivudine. In: Program and abstracts of the 10th Conference on Retroviruses and Opportunistic Infections; February 10-14, 2003, Boston, MA. Abstract 176.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/18/37162/abstract/68\">",
"      Fisac C, Fumero E, Crespo M, et al. Metabolic benefits 24 months after replacing a protease inhibitor with abacavir, efavirenz or nevirapine. AIDS 2005; 19:917.",
"     </a>",
"    </li>",
"    <li>",
"     Reiss P, Sankatsing R, Franssen R, et al. Nevirapine increases high density lipoprotein-cholesterol by stimulation of apolipoprotein AI synthesis. IAS 2007, Sydney, Australia.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/18/37162/abstract/70\">",
"      Strategies for Management of Antiretroviral Therapy (SMART) Study Group, El-Sadr WM, Lundgren J, et al. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med 2006; 355:2283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/18/37162/abstract/71\">",
"      Podzamczer D, Olmo M, Sanz J, et al. Safety of Switching Nevirapine Twice Daily to Nevirapine Once Daily in Virologically Suppressed Patients. J Acquir Immune Defic Syndr 2009; 50:390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/18/37162/abstract/72\">",
"      Cohen CJ, Andrade-Villanueva J, Clotet B, et al. Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial. Lancet 2011; 378:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/18/37162/abstract/73\">",
"      Molina JM, Cahn P, Grinsztejn B, et al. Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial. Lancet 2011; 378:238.",
"     </a>",
"    </li>",
"    <li>",
"     Product labeling, Edurant (rilpivirine), Tibotec, May 2011.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/18/37162/abstract/75\">",
"      Ford N, Lee J, Andrieux-Meyer I, Calmy A. Safety, efficacy, and pharmacokinetics of rilpivirine: systematic review with an emphasis on resource-limited settings. HIV AIDS (Auckl) 2011; 3:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/18/37162/abstract/76\">",
"      Sch&ouml;ller-Gy&uuml;re M, Kakuda TN, De Smedt G, et al. Effects of hepatic impairment on the steady-state pharmacokinetics of etravirine 200 mg BID: an open-label, multiple-dose, controlled Phase I study in adults. Clin Ther 2010; 32:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/18/37162/abstract/77\">",
"      Cohen CJ, Molina JM, Cahn P, et al. Efficacy and safety of rilpivirine (TMC278) versus efavirenz at 48 weeks in treatment-naive HIV-1-infected patients: pooled results from the phase 3 double-blind randomized ECHO and THRIVE Trials. J Acquir Immune Defic Syndr 2012; 60:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/18/37162/abstract/78\">",
"      Pozniak AL, Morales-Ramirez J, Katabira E, et al. Efficacy and safety of TMC278 in antiretroviral-naive HIV-1 patients: week 96 results of a phase IIb randomized trial. AIDS 2010; 24:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/18/37162/abstract/79\">",
"      Crauwels HM, Kakuda TN. Drug interactions with new and investigational antiretrovirals. Clin Pharmacokinet 2010; 49:67.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.fda.gov/ForConsumers/ByAudience/ForPatientAdvocates/HIVandAIDSActivities/ucm267592.htm (Accessed on September 26, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/18/37162/abstract/81\">",
"      van 't Klooster G, Hoeben E, Borghys H, et al. Pharmacokinetics and disposition of rilpivirine (TMC278) nanosuspension as a long-acting injectable antiretroviral formulation. Antimicrob Agents Chemother 2010; 54:2042.",
"     </a>",
"    </li>",
"    <li>",
"     Tseng, A et al. Antiretroviral Agents. file://www.hivclinic.ca (Accessed on March 01, 2008).",
"    </li>",
"    <li>",
"     Intelence [package insert]. Yardley, PA: Tibotec, Inc.; 2008.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/18/37162/abstract/84\">",
"      Tiraboschi JM, Niubo J, Vila A, et al. Etravirine concentrations in CSF in HIV-infected patients. J Antimicrob Chemother 2012; 67:1446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/18/37162/abstract/85\">",
"      Montaner J, Yeni P, Clumeck NN, et al. Safety, tolerability, and preliminary efficacy of 48 weeks of etravirine therapy in a phase IIb dose-ranging study involving treatment-experienced patients with HIV-1 infection. Clin Infect Dis 2008; 47:969.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/18/37162/abstract/86\">",
"      Johnson LB, Saravolatz LD. Etravirine, a next-generation nonnucleoside reverse-transcriptase inhibitor. Clin Infect Dis 2009; 48:1123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/18/37162/abstract/87\">",
"      Nelson M, Stellbrink HJ, Podzamczer D, et al. A comparison of neuropsychiatric adverse events during 12 weeks of treatment with etravirine and efavirenz in a treatment-naive, HIV-1-infected population. AIDS 2011; 25:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/18/37162/abstract/88\">",
"      Etravirine (Intelence) for HIV infection. Treat Guidel Med Lett 2008; 50:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/18/37162/abstract/89\">",
"      Tibotec Intelence not for first-line use, FDA says: is follow-on naive?. Pharmaceutical Approvals Monthly 2008; 13:36.",
"     </a>",
"    </li>",
"    <li>",
"     Scholler-Gyure M, et al. Pharmacokinetics of TMCF 125 in once-daily and twice-daily regimens in HIV-negative volunteers [Abstract A-1427]. 47th International Conference on Antimicrobial Agents and Chemotherapy. September 17-20, 2007 Chicago, Illinois.",
"    </li>",
"    <li>",
"     Rescriptor [package insert]. New York, NY: Pharmacia &amp; Upjohn Company; 2006.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3771 Version 14.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-203.80.222.8-CDD449C725-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_18_37162=[""].join("\n");
var outline_f36_18_37162=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H55\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GENERAL PRINCIPLES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Pharmacologic profile",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Resistance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Drug interactions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Side effect profile",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Abbreviations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      MECHANISM OF ACTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      EFAVIRENZ (SUSTIVA)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Pharmacology/Pharmacokinetics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Pharmacogenetics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Efficacy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Side effects",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Neuropsychiatric side effects",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Other side effects",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11300390\">",
"      - Hypovitaminosis D",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Use in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Drug interactions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Formulations and dosing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Usual adult dosing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Renal insufficiency",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Hepatic insufficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      NEVIRAPINE (VIRAMUNE)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Pharmacology/pharmacokinetics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Clinical efficacy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15592376\">",
"      Side effects",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Hypersensitivity reaction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4845324\">",
"      - Hepatotoxicity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Timing of onset",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Risk factors for hepatotoxicity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11300552\">",
"      - HLA status and risk of adverse events",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Safety of switch strategies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      - Lipid profile",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Use in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Prevention of mother-to-child transmission of HIV",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Drug interactions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Formulations and dosing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      - Usual adult dosage",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      - Renal insufficiency",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      - Hepatic insufficiency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3551627\">",
"      Medication error potential",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10929706\">",
"      RILPIVIRINE (EDURANT)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10929714\">",
"      Pharmacokinetics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11307128\">",
"      Clinical efficacy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10929722\">",
"      Side effects",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11307272\">",
"      - Lipid abnormalities",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11307187\">",
"      - QT interval prolongation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10929730\">",
"      Teratogenicity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10929738\">",
"      Drug interactions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10929746\">",
"      Formulations and dosing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10929762\">",
"      - Renal insufficiency",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10929770\">",
"      - Hepatic insufficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H46\">",
"      ETRAVIRINE (INTELENCE)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H47\">",
"      Pharmacokinetics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H48\">",
"      Efficacy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H49\">",
"      Side effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H50\">",
"      Use in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H51\">",
"      Drug interactions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H52\">",
"      Formulations and dosing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H53\">",
"      Renal insufficiency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H54\">",
"      Hepatic insufficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H768086\">",
"      DELAVIRDINE (RESCRIPTOR)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H768113\">",
"      Pharmacokinetics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H768120\">",
"      Side effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H768127\">",
"      Teratogenicity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H768134\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H768141\">",
"      Formulations and dosing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H768148\">",
"      - Renal insufficiency",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H767986\">",
"      - Hepatic insufficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H55\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/35/32313?source=related_link\">",
"      Bone and calcium disorders in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/4/9287?source=related_link\">",
"      Clinical trials of HIV antiretroviral therapy: Non-nucleoside reverse transcriptase inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/18/3370?source=related_link\">",
"      Considerations prior to initiating antiretroviral therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/61/986?source=related_link\">",
"      Counseling HIV-infected patients regarding potential side effects of antiretroviral therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?27/10/27816?source=related_link\">",
"      Delavirdine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/29/12759?source=related_link\">",
"      Dose modification of antiretroviral agents in adults with renal or hepatic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?28/42/29353?source=related_link\">",
"      Efavirenz: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/3/49?source=related_link\">",
"      Management of dyslipidemia and cardiovascular risk in the HIV-infected patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?18/12/18633?source=related_link\">",
"      Nevirapine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/17/38167?source=related_link\">",
"      Patient monitoring during HIV antiretroviral therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/4/15433?source=related_link\">",
"      Prenatal evaluation and intrapartum management of the HIV-infected patient in resource-rich settings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/26/34218?source=related_link\">",
"      Primer on interpretation of HIV drug resistance testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/24/36234?source=related_link\">",
"      Selecting antiretroviral regimens for the treatment naive HIV-infected patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/29/17882?source=related_link\">",
"      Stevens-Johnson syndrome and toxic epidermal necrolysis: Clinical manifestations; pathogenesis; and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/51/16185?source=related_link\">",
"      Treatment of hepatitis B in the HIV-infected patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/44/25290?source=related_link\">",
"      Use of antiretroviral medications in pregnant HIV-infected patients and their infants in resource-rich settings",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_18_37163="Prolonged fast I";
var content_f36_18_37163=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F58512&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F58512&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Results of a prolonged fast in a patient with suspected insulinoma",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Time, hours",
"       </td>",
"       <td class=\"subtitle1\">",
"        Serum glucose, mg/dL",
"       </td>",
"       <td class=\"subtitle1\">",
"        Serum insulin, &micro;U/mL",
"       </td>",
"       <td class=\"subtitle1\">",
"        Serum C-peptide, pmol/L",
"       </td>",
"       <td class=\"subtitle1\">",
"        Serum proinsulin, pmol/L",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        61",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        48",
"       </td>",
"       <td>",
"        42",
"       </td>",
"       <td>",
"        13",
"       </td>",
"       <td>",
"        510",
"       </td>",
"       <td>",
"        55",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        60",
"       </td>",
"       <td>",
"        40",
"       </td>",
"       <td>",
"        8",
"       </td>",
"       <td>",
"        330",
"       </td>",
"       <td>",
"        37",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        66",
"       </td>",
"       <td>",
"        33",
"       </td>",
"       <td>",
"        13",
"       </td>",
"       <td>",
"        480",
"       </td>",
"       <td>",
"        50",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        68",
"       </td>",
"       <td>",
"        31",
"       </td>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        310",
"       </td>",
"       <td>",
"        34",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        72",
"       </td>",
"       <td>",
"        32",
"       </td>",
"       <td>",
"        11",
"       </td>",
"       <td>",
"        360",
"       </td>",
"       <td>",
"        37",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     To convert serum glucose values to mmol/L multiply by 0.056, and to convert serum insulin values to pmol/L multiply by 6.0.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_18_37163=[""].join("\n");
var outline_f36_18_37163=null;
var title_f36_18_37164="Macules";
var content_f36_18_37164=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F61066&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F61066&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Differential diagnosis of macules",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tbody>",
"      <tr>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Erythematous macules",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Drug eruption",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Viral exanthem",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Secondary syphilis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Rheumatic fever",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Photodistributed macules",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Drugs",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Dermatomyositis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Lupus erythematosus",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Porphyria cutanea tarda",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Polymorphous light eruption",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Hypopigmented macules",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Postinflammatory",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Tinea versicolor",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Vitiligo",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Halo nevus",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Sarcoidosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Tuberous sclerosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Cutaneous T cell lymphoma",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Leprosy",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Hyperpigmented macules",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Nevi",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Fixed drug eruption",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Postinflammatory",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Ephelis (freckle)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Lentigo",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Schamberg's purpura",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Nevus",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Mongolian spot",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Purpura",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Stasis dermatitis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Melasma",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Melanoma",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Ochronosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Mastocytosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Caf&eacute; au lait spot",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_18_37164=[""].join("\n");
var outline_f36_18_37164=null;
var title_f36_18_37165="Gold plus hydroxychloroquine RA";
var content_f36_18_37165=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F82675&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F82675&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 540px\">",
"   <div class=\"ttl\">",
"    J* gold plus hydroxychloroquine in RA",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 520px; height: 274px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Results of a prospective, placebo controlled study in which 101 patients with rheumatoid arthritis were randomized to therapy with a combination of parenteral gold plus hydroxychloroquine (HCQ, red curve) or gold plus placebo (blue curve). Patients receiving gold plus hydroxychloroquine showed more rapid improvement and better overall reduction of disease activity.",
"    <div class=\"footnotes\">",
"     * p&lt;0.05.",
"    </div>",
"    <div class=\"reference\">",
"     Data from Scott, DL, Dawes, PT, Tunn, E, et al, Br J Rheumatol 1989; 28:128.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_18_37165=[""].join("\n");
var outline_f36_18_37165=null;
var title_f36_18_37166="Contents: Pediatric toxicology";
var content_f36_18_37166=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"mobipreview.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"mobipreview.htm?10/42/10926\">",
"       Adult and Pediatric Emergency Medicine",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Pediatric toxicology",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"mobipreview.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Pediatric toxicology",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?24/43/25274\">",
"           Acetaminophen (paracetamol) poisoning in adults: Pathophysiology, presentation, and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?2/57/2970\">",
"           Acute iron poisoning",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?35/57/36759\">",
"           Amanita smithiana mushroom poisoning",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?10/28/10698\">",
"           Amatoxin-containing mushroom poisoning including ingestion of Amanita phalloides",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?21/60/22474\">",
"           Approach to the child with occult toxic exposure",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?24/16/24839\">",
"           Approach to the patient with a suspected spider bite: An overview",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?8/33/8730\">",
"           Arsenic exposure and poisoning",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?23/43/24248\">",
"           Bites of recluse spiders",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?14/62/15337\">",
"           Button and cylindrical battery ingestion",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?21/17/21783\">",
"           Cannabis use disorders: Clinical features and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?1/3/1079\">",
"           Cannabis use disorders: Epidemiology, comorbidity, and pathogenesis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?4/28/4554\">",
"           Cannabis use disorders: Treatment, prognosis, and long-term medical effects",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?11/19/11577\">",
"           Carbamazepine poisoning",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?10/6/10345\">",
"           Carbon monoxide poisoning",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?4/23/4473\">",
"           Caustic esophageal injury in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?0/24/394\">",
"           Childhood lead poisoning: Clinical manifestations and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?10/47/11001\">",
"           Childhood lead poisoning: Exposure and prevention",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?21/5/21594\">",
"           Childhood lead poisoning: Management",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?40/8/41096\">",
"           Ciguatera fish poisoning",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?21/42/22186\">",
"           Clinical manifestations and diagnosis of acetaminophen (paracetamol) poisoning in children and adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?1/47/1786\">",
"           Clinical manifestations and evaluation of mushroom poisoning",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?29/10/29865\">",
"           Clinical manifestations and evaluation of potentially toxic plant ingestions in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?21/50/22313\">",
"           Clonidine and related imidazoline poisoning",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?22/30/23018\">",
"           Cocaine: Acute intoxication",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?7/18/7466\">",
"           Cyanide poisoning",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?37/1/37913\">",
"           Decontamination of poisoned children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?1/47/1784\">",
"           Designer drugs of abuse",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?16/60/17353\">",
"           Dextromethorphan poisoning: Epidemiology, pharmacology and clinical features",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?2/35/2615\">",
"           Dextromethorphan poisoning: Treatment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?25/13/25817\">",
"           Digitalis (cardiac glycoside) poisoning",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?22/32/23043\">",
"           Dosing regimen for digoxin-specific antibody (Fab) fragments in patients with digoxin toxicity",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?26/4/26695\">",
"           Enhanced elimination of poisons",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?2/5/2137\">",
"           Ethanol intoxication in children: Clinical features, evaluation, and management",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?23/5/23639\">",
"           Ethanol intoxication in children: Epidemiology, estimation of toxicity, and toxic effects",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?16/2/16426\">",
"           Food poisoning in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?27/5/27736\">",
"           Hydrocarbon poisoning",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?32/61/33753\">",
"           Inhalant abuse in children and adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?7/1/7191\">",
"           Isoniazid (INH) poisoning",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?19/60/20423\">",
"           Isopropyl alcohol poisoning",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?39/62/40935\">",
"           Ketamine poisoning",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?12/51/13114\">",
"           Management of acetaminophen (paracetamol) poisoning in children and adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?42/60/43974\">",
"           Management of ibuprofen poisoning in children and adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?41/39/42615\">",
"           Management of mushroom poisoning",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?39/18/40233\">",
"           Management of toxic plant ingestions in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?24/31/25081\">",
"           Bites of widow spiders",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?21/3/21560\">",
"           MDMA (ecstasy) intoxication",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?0/29/474\">",
"           Methamphetamine intoxication",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?4/3/4154\">",
"           Methanol and ethylene glycol poisoning",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?22/21/22874\">",
"           Opioid intoxication in children and adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?19/40/20103\">",
"           Opioid withdrawal in adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?11/45/11991\">",
"           Paraquat poisoning",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?0/35/570\">",
"           Phencyclidine (PCP) intoxication in children and adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?40/56/41863\">",
"           Phenytoin poisoning",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?18/41/19098\">",
"           Salicylate poisoning in children and adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?31/22/32104\">",
"           Scorpion stings in the United States and Mexico",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?42/19/43320\">",
"           Second generation (atypical) antipsychotic medication poisoning",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?15/63/16376\">",
"           Serotonin syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?39/5/40022\">",
"           Strychnine poisoning",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?13/16/13578\">",
"           Theophylline poisoning",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0605-95.154.198.148-26D41D3616-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f36_18_37166=[""].join("\n");
var outline_f36_18_37166=null;
var title_f36_18_37167="Normal eyelid position";
var content_f36_18_37167=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F78269&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F78269&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Normal eyelid position",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 324px; height: 212px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The upper lid covers 1 to 2 mm of the upper limbus. The lower lid covers the lower limbus minimully. The central light reflex can be seen within the pupil. The margin reflex distance is measured from this reflex to the upper eyelid margin.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Michael S Lee, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_18_37167=[""].join("\n");
var outline_f36_18_37167=null;
